OA16551A - Fluoro-pyridinone derivatives useful as antibacterial agents. - Google Patents
Fluoro-pyridinone derivatives useful as antibacterial agents. Download PDFInfo
- Publication number
- OA16551A OA16551A OA1201300364 OA16551A OA 16551 A OA16551 A OA 16551A OA 1201300364 OA1201300364 OA 1201300364 OA 16551 A OA16551 A OA 16551A
- Authority
- OA
- OAPI
- Prior art keywords
- fluoro
- butanamide
- methyl
- methylsulfonyl
- mmol
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title description 4
- CISUDJRBCKKAGX-UHFFFAOYSA-N 3-fluoro-1H-pyridin-2-one Chemical class OC1=NC=CC=C1F CISUDJRBCKKAGX-UHFFFAOYSA-N 0.000 title 1
- 206010060945 Bacterial infection Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 253
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 2
- LKEPPVHFBXHFGX-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound FC1=CC(OC)=CC=C1C1=CC(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C1F LKEPPVHFBXHFGX-GOSISDBHSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 6
- DNSISZSEWVHGLH-UHFFFAOYSA-N Butyramide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 201
- 239000007787 solid Substances 0.000 description 143
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 129
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 122
- 238000000034 method Methods 0.000 description 104
- 238000006243 chemical reaction Methods 0.000 description 96
- 238000005160 1H NMR spectroscopy Methods 0.000 description 95
- 235000019439 ethyl acetate Nutrition 0.000 description 61
- 239000000203 mixture Substances 0.000 description 59
- 239000000243 solution Substances 0.000 description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- -1 methoxy, ethoxy, n-propoxy, isopropoxy Chemical group 0.000 description 48
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000003480 eluent Substances 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- HVHKMDCJPVXKPB-BZSJEYESSA-N (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1-yl)-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN1C=C(F)C(I)=CC1=O HVHKMDCJPVXKPB-BZSJEYESSA-N 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 20
- 239000008079 hexane Substances 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- DGZBXZNCTGJNGE-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C1=C(F)C(OC)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 DGZBXZNCTGJNGE-JFGZAKSSSA-N 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 19
- 238000001914 filtration Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reduced Effects 0.000 description 19
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 18
- 235000020127 ayran Nutrition 0.000 description 18
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 15
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 201000009910 diseases by infectious agent Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 230000035492 administration Effects 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000004432 carbon atoms Chemical group C* 0.000 description 11
- WFCTXFNOSNPPJX-CYBMUJFWSA-N ethyl (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1-yl)-2-methyl-2-methylsulfonylbutanoate Chemical compound CCOC(=O)[C@](C)(S(C)(=O)=O)CCN1C=C(F)C(I)=CC1=O WFCTXFNOSNPPJX-CYBMUJFWSA-N 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- GPIQOFWTZXXOOV-UHFFFAOYSA-N 2-chloro-4,6-dimethoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(OC)=N1 GPIQOFWTZXXOOV-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 150000005299 pyridinones Chemical group 0.000 description 9
- 229910052717 sulfur Chemical group 0.000 description 9
- 230000002194 synthesizing Effects 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 125000004434 sulfur atoms Chemical group 0.000 description 8
- 235000019798 tripotassium phosphate Nutrition 0.000 description 8
- OTNFNNBDWPZFES-LJQANCHMSA-N (2R)-4-[5-fluoro-2-oxo-4-[4-(triazol-2-yl)phenyl]pyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)N2N=CC=N2)=C1 OTNFNNBDWPZFES-LJQANCHMSA-N 0.000 description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 7
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 108020004256 beta-Lactamases Proteins 0.000 description 7
- 102000006635 beta-Lactamases Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 125000004430 oxygen atoms Chemical group O* 0.000 description 7
- 235000011056 potassium acetate Nutrition 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrugs Drugs 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- HETFMHWOVYDLCZ-JFGZAKSSSA-N (2R)-4-[5-fluoro-2-oxo-4-[4-(tetrazol-2-yl)phenyl]pyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C(C=C1)=CC=C1N1N=CN=N1 HETFMHWOVYDLCZ-JFGZAKSSSA-N 0.000 description 6
- LPMLXBQJYQBVPF-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]triazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2N=CC=N2)C=C1 LPMLXBQJYQBVPF-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000001184 potassium carbonate Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 6
- BRBWTINHVJRGQL-HJMRYINQSA-N (2R)-4-[5-fluoro-4-[4-[(4-hydroxycyclohexyl)methoxy]phenyl]-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(OCC3CCC(O)CC3)=CC=2)=C1 BRBWTINHVJRGQL-HJMRYINQSA-N 0.000 description 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 5
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- IMYXVWYWLDZXRZ-HXUWFJFHSA-N (2R)-4-[5-fluoro-4-[4-(1,2-oxazol-3-yl)phenyl]-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)C2=NOC=C2)=C1 IMYXVWYWLDZXRZ-HXUWFJFHSA-N 0.000 description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- DRSDBVZXZAWGDF-UHFFFAOYSA-N 2-methylsulfonylbutanamide Chemical compound CCC(C(N)=O)S(C)(=O)=O DRSDBVZXZAWGDF-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-Borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 4
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 241000400611 Eucalyptus deanei Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000007126 N-alkylation reaction Methods 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N Pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-J lipid A(4-) Chemical compound O1[C@H](CO)[C@@H](OP([O-])([O-])=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP([O-])([O-])=O)O1 GZQKNULLWNGMCW-PWQABINMSA-J 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- NQHVICYTIZPXEM-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)triazole Chemical compound FC1=CC(Br)=CC=C1N1N=CC=N1 NQHVICYTIZPXEM-UHFFFAOYSA-N 0.000 description 3
- YWRPAKATXRUAAF-UHFFFAOYSA-N 2-methyl-2-methylsulfonylbutanamide Chemical compound CCC(C)(C(N)=O)S(C)(=O)=O YWRPAKATXRUAAF-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229940023064 Escherichia coli Drugs 0.000 description 3
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 3
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 206010061229 Lung infection Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- NLXXVSKHVGDQAT-UHFFFAOYSA-N O-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 3
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004429 atoms Chemical group 0.000 description 3
- 239000003781 beta lactamase inhibitor Substances 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- DRDIKYRQXJWIIX-MRVPVSSYSA-N ethyl (2R)-4-bromo-2-methyl-2-methylsulfonylbutanoate Chemical compound CCOC(=O)[C@](C)(S(C)(=O)=O)CCBr DRDIKYRQXJWIIX-MRVPVSSYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- OJAGJIIQAMWZJL-QGZVFWFLSA-N (2R)-4-(3,5-difluoro-2-oxo-4-phenylpyridin-1-yl)-2-methyl-2-methylsulfonylbutanoic acid Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=CC=CC=2)=C1F OJAGJIIQAMWZJL-QGZVFWFLSA-N 0.000 description 2
- GQAJBDFCUAIZJQ-GOSISDBHSA-N (2R)-4-(5-fluoro-3-methoxy-2-oxo-4-phenylpyridin-1-yl)-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound FC1=CN(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C(=O)C(OC)=C1C1=CC=CC=C1 GQAJBDFCUAIZJQ-GOSISDBHSA-N 0.000 description 2
- KPVMQWIDGUDYRC-GOSISDBHSA-N (2R)-4-[5-fluoro-2-oxo-4-[4-(tetrazol-2-yl)phenyl]pyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)N2N=NC=N2)=C1 KPVMQWIDGUDYRC-GOSISDBHSA-N 0.000 description 2
- AFAJKBBZJTYCKS-SYIFMXBLSA-N (2R)-4-[5-fluoro-2-oxo-4-[4-(triazol-2-yl)phenyl]pyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C(C=C1)=CC=C1N1N=CC=N1 AFAJKBBZJTYCKS-SYIFMXBLSA-N 0.000 description 2
- GEADSIWBGUGSSK-BXCZEONSSA-N (2R)-4-[5-fluoro-4-[4-[[4-(oxan-2-yloxy)cyclohexyl]methoxy]phenyl]-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C(C=C1)=CC=C1OCC(CC1)CCC1OC1CCCCO1 GEADSIWBGUGSSK-BXCZEONSSA-N 0.000 description 2
- YBNDRTRLXPEWKQ-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1F YBNDRTRLXPEWKQ-UHFFFAOYSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- RJKNZUCBQAJCOL-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C=2N=CC=CN=2)C=C1 RJKNZUCBQAJCOL-UHFFFAOYSA-N 0.000 description 2
- PCERIAQKQOBORR-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]tetrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2N=NC=N2)C=C1 PCERIAQKQOBORR-UHFFFAOYSA-N 0.000 description 2
- LHTYOLUEPPFRBV-UHFFFAOYSA-N 2-methyl-2-methylsulfonylbutanoic acid Chemical compound CCC(C)(C(O)=O)S(C)(=O)=O LHTYOLUEPPFRBV-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- BIEAFGQFWBQNMT-UHFFFAOYSA-N 3,5-difluoro-4-iodo-1H-pyridin-2-one Chemical compound FC1=CNC(=O)C(F)=C1I BIEAFGQFWBQNMT-UHFFFAOYSA-N 0.000 description 2
- KTHYKLLJTJDHER-UHFFFAOYSA-N 3-(4-bromophenoxy)oxetane Chemical compound C1=CC(Br)=CC=C1OC1COC1 KTHYKLLJTJDHER-UHFFFAOYSA-N 0.000 description 2
- RHIGTXHZAUKKGI-UHFFFAOYSA-N 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-oxazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2=NOC=C2)C=C1 RHIGTXHZAUKKGI-UHFFFAOYSA-N 0.000 description 2
- HJESFCFIRQMICX-FDWQPRGYSA-N 4-bromo-N-[(Z)-[(2Z)-2-[(4-bromo-2-fluorophenyl)hydrazinylidene]ethylidene]amino]-2-fluoroaniline Chemical compound FC1=CC(Br)=CC=C1N\N=C/C=N\NC1=CC=C(Br)C=C1F HJESFCFIRQMICX-FDWQPRGYSA-N 0.000 description 2
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 2
- MFEDNNMGKYTJLJ-UHFFFAOYSA-N 5-fluoro-4-iodo-1H-pyridin-2-one Chemical compound FC1=CNC(=O)C=C1I MFEDNNMGKYTJLJ-UHFFFAOYSA-N 0.000 description 2
- 206010056519 Abdominal infection Diseases 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 206010003997 Bacteraemia Diseases 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940041011 Carbapenems Drugs 0.000 description 2
- 206010061036 Central nervous system infection Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 206010060803 Diabetic foot infection Diseases 0.000 description 2
- 206010014665 Endocarditis Diseases 0.000 description 2
- 229940092559 Enterobacter aerogenes Drugs 0.000 description 2
- 229940119563 Enterobacter cloacae Drugs 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000588749 Klebsiella oxytoca Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229960003194 Meglumine Drugs 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- JEOHWCXKNZJFPF-UHFFFAOYSA-N N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound CCC(C)(S(C)(=O)=O)C(=O)NO JEOHWCXKNZJFPF-UHFFFAOYSA-N 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229960003975 Potassium Drugs 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 229940098362 Serratia marcescens Drugs 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010040872 Skin infection Diseases 0.000 description 2
- 229940083542 Sodium Drugs 0.000 description 2
- 229940091252 Sodium supplements Drugs 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 206010046577 Urinary tract infection Diseases 0.000 description 2
- PLSOSXKCTNDWGK-UHFFFAOYSA-M [O-]C(=O)C(S(C)(=O)=O)(C)CCBr Chemical compound [O-]C(=O)C(S(C)(=O)=O)(C)CCBr PLSOSXKCTNDWGK-UHFFFAOYSA-M 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000001851 biosynthetic Effects 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 101710028876 carB4 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical class S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- GLNCRZANCPUHBS-LJQANCHMSA-N ethyl (2R)-4-(3,5-difluoro-2-oxo-4-phenylpyridin-1-yl)-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC=CC=2)=C1F GLNCRZANCPUHBS-LJQANCHMSA-N 0.000 description 2
- CUJDUBIEJRVYNO-OAQYLSRUSA-N ethyl (2R)-4-[5-fluoro-2-oxo-4-[4-(triazol-2-yl)phenyl]pyridin-1-yl]-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)N2N=CC=N2)=C1 CUJDUBIEJRVYNO-OAQYLSRUSA-N 0.000 description 2
- NQYMQSDDBGMFAQ-HXUWFJFHSA-N ethyl (2R)-4-[5-fluoro-4-(4-methylsulfanylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(SC)=CC=2)=C1 NQYMQSDDBGMFAQ-HXUWFJFHSA-N 0.000 description 2
- HRPMUNZTLAAQLK-HYVQGWRZSA-N ethyl (2R)-4-[5-fluoro-4-[4-[[4-(oxan-2-yloxy)cyclohexyl]methoxy]phenyl]-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(OCC3CCC(CC3)OC3OCCCC3)=CC=2)=C1 HRPMUNZTLAAQLK-HYVQGWRZSA-N 0.000 description 2
- DRDIKYRQXJWIIX-UHFFFAOYSA-N ethyl 4-bromo-2-methyl-2-methylsulfonylbutanoate Chemical compound CCOC(=O)C(C)(S(C)(=O)=O)CCBr DRDIKYRQXJWIIX-UHFFFAOYSA-N 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- XYMVZPOXZCDCNP-UHFFFAOYSA-N sulfamoyl cyanide Chemical group NS(=O)(=O)C#N XYMVZPOXZCDCNP-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JCKZNMSBFBPDPM-UHFFFAOYSA-N (2-fluoro-3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1F JCKZNMSBFBPDPM-UHFFFAOYSA-N 0.000 description 1
- VEHQHYJZLSODOU-UHFFFAOYSA-N (2-fluoro-3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1F VEHQHYJZLSODOU-UHFFFAOYSA-N 0.000 description 1
- ULUIXJDBPYBAHS-UHFFFAOYSA-N (2-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(F)=C1 ULUIXJDBPYBAHS-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- YRSHFSFXUIYNEM-IVAFLUGOSA-N (2R)-4-(3,5-difluoro-2-oxo-4-phenylpyridin-1-yl)-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1F)=O)C=C(F)C=1C1=CC=CC=C1 YRSHFSFXUIYNEM-IVAFLUGOSA-N 0.000 description 1
- FVSBZBJBIHJYTG-GOSISDBHSA-N (2R)-4-(5-fluoro-3-methoxy-2-oxo-4-phenylpyridin-1-yl)-2-methyl-2-methylsulfonylbutanoic acid Chemical compound FC1=CN(CC[C@](C)(C(O)=O)S(C)(=O)=O)C(=O)C(OC)=C1C1=CC=CC=C1 FVSBZBJBIHJYTG-GOSISDBHSA-N 0.000 description 1
- WQHBVODMBAECOL-LLVKDONJSA-N (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1-yl)-2-methyl-2-methylsulfonylbutanoic acid Chemical compound OC(=O)[C@@](S(C)(=O)=O)(C)CCN1C=C(F)C(I)=CC1=O WQHBVODMBAECOL-LLVKDONJSA-N 0.000 description 1
- PWPFKMQOVMELAY-LJQANCHMSA-N (2R)-4-[4-(2,3-dihydro-1-benzofuran-5-yl)-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=C3CCOC3=CC=2)=C1 PWPFKMQOVMELAY-LJQANCHMSA-N 0.000 description 1
- FQIVPTZIBLWLGL-LWMIZPGFSA-N (2R)-4-[4-(4-chloro-2-fluorophenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C1=CC=C(Cl)C=C1F FQIVPTZIBLWLGL-LWMIZPGFSA-N 0.000 description 1
- DISWOJOVYDHNNG-QGZVFWFLSA-N (2R)-4-[4-(4-chloro-2-fluorophenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C(=CC(Cl)=CC=2)F)=C1 DISWOJOVYDHNNG-QGZVFWFLSA-N 0.000 description 1
- AAWHDZDZXPNPCJ-LWMIZPGFSA-N (2R)-4-[4-(4-chlorophenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C1=CC=C(Cl)C=C1 AAWHDZDZXPNPCJ-LWMIZPGFSA-N 0.000 description 1
- LACMXESAJCYYMD-QGZVFWFLSA-N (2R)-4-[4-(4-chlorophenyl)-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(Cl)=CC=2)=C1 LACMXESAJCYYMD-QGZVFWFLSA-N 0.000 description 1
- ZFCFTHFMUSPSJR-SYIFMXBLSA-N (2R)-4-[4-(4-ethoxyphenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C1=CC(OCC)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 ZFCFTHFMUSPSJR-SYIFMXBLSA-N 0.000 description 1
- NIXAKIMMVXCMBY-LJQANCHMSA-N (2R)-4-[4-(4-ethoxyphenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound C1=CC(OCC)=CC=C1C1=CC(=O)N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C1F NIXAKIMMVXCMBY-LJQANCHMSA-N 0.000 description 1
- JWKXZUXJLYZTEK-GWQXNCQPSA-N (2R)-4-[4-[4-(difluoromethoxy)-3-fluorophenyl]-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C1=CC=C(OC(F)F)C(F)=C1 JWKXZUXJLYZTEK-GWQXNCQPSA-N 0.000 description 1
- BNHSPDGPNFOQBF-GOSISDBHSA-N (2R)-4-[4-[4-(difluoromethoxy)-3-fluorophenyl]-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=C(F)C(OC(F)F)=CC=2)=C1 BNHSPDGPNFOQBF-GOSISDBHSA-N 0.000 description 1
- HYQPXXFPJZTVAS-XSWBTSGESA-N (2R)-4-[5-fluoro-2-oxo-4-(4-propylphenyl)pyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C1=CC(CCC)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 HYQPXXFPJZTVAS-XSWBTSGESA-N 0.000 description 1
- FSBOOBGKKWMJDG-OAQYLSRUSA-N (2R)-4-[5-fluoro-2-oxo-4-(4-pyrimidin-2-ylphenyl)pyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)C=2N=CC=CN=2)=C1 FSBOOBGKKWMJDG-OAQYLSRUSA-N 0.000 description 1
- GQPFOARPTXKDHU-NRWPOFLRSA-N (2R)-4-[5-fluoro-2-oxo-4-[3-(1,3-thiazol-2-yloxy)phenyl]pyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C(C=1)=CC=CC=1OC1=NC=CS1 GQPFOARPTXKDHU-NRWPOFLRSA-N 0.000 description 1
- MWGYVTKCPBDDDL-HXUWFJFHSA-N (2R)-4-[5-fluoro-2-oxo-4-[3-(1,3-thiazol-2-yloxy)phenyl]pyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=C(OC=3SC=CN=3)C=CC=2)=C1 MWGYVTKCPBDDDL-HXUWFJFHSA-N 0.000 description 1
- ZFFGXQKBKMCUHL-GOSISDBHSA-N (2R)-4-[5-fluoro-2-oxo-4-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(OCC(F)(F)F)=CC=2)=C1 ZFFGXQKBKMCUHL-GOSISDBHSA-N 0.000 description 1
- JPVHWBLUFNYTIL-GWQXNCQPSA-N (2R)-4-[5-fluoro-4-(2-fluoro-3-methoxyphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound COC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NOC3OCCCC3)S(C)(=O)=O)C(=O)C=2)F)=C1F JPVHWBLUFNYTIL-GWQXNCQPSA-N 0.000 description 1
- TZLPSYJOTYYPON-GWQXNCQPSA-N (2R)-4-[5-fluoro-4-(2-fluoro-3-methylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound CC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NOC3OCCCC3)S(C)(=O)=O)C(=O)C=2)F)=C1F TZLPSYJOTYYPON-GWQXNCQPSA-N 0.000 description 1
- YEJUXDVDONNDIS-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(2-fluoro-3-methylphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound CC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)=C1F YEJUXDVDONNDIS-GOSISDBHSA-N 0.000 description 1
- BFRHGIBSZOUJJB-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound FC1=CC(OC)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 BFRHGIBSZOUJJB-JFGZAKSSSA-N 0.000 description 1
- ROMKPNKIEWCWRQ-LWMIZPGFSA-N (2R)-4-[5-fluoro-4-(2-fluorophenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C1=CC=CC=C1F ROMKPNKIEWCWRQ-LWMIZPGFSA-N 0.000 description 1
- FVWQQCSZWPQPAR-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(3-methoxyphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound COC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NOC3OCCCC3)S(C)(=O)=O)C(=O)C=2)F)=C1 FVWQQCSZWPQPAR-JFGZAKSSSA-N 0.000 description 1
- DSZRNYJOAXWMCZ-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(3-methylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound CC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NOC3OCCCC3)S(C)(=O)=O)C(=O)C=2)F)=C1 DSZRNYJOAXWMCZ-JFGZAKSSSA-N 0.000 description 1
- JVXLIWKTSPIRPE-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(3-methylphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound CC1=CC=CC(C=2C(=CN(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)=C1 JVXLIWKTSPIRPE-GOSISDBHSA-N 0.000 description 1
- CNNISRAIKTVRMR-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-fluoro-3-methylphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=C(F)C(C)=CC(C=2C(=CN(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)=C1 CNNISRAIKTVRMR-GOSISDBHSA-N 0.000 description 1
- CNJLSMXFSSGUOI-LWMIZPGFSA-N (2R)-4-[5-fluoro-4-(4-fluorophenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C1=CC=C(F)C=C1 CNJLSMXFSSGUOI-LWMIZPGFSA-N 0.000 description 1
- JEFDQIGURWTOGB-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-methoxyphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C1F JEFDQIGURWTOGB-GOSISDBHSA-N 0.000 description 1
- GREJJMMJXCUVDY-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(4-methylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C1=CC(C)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 GREJJMMJXCUVDY-JFGZAKSSSA-N 0.000 description 1
- ZEWDUBXJVWNHNC-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-methylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound C1=CC(C)=CC=C1C1=CC(=O)N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C1F ZEWDUBXJVWNHNC-GOSISDBHSA-N 0.000 description 1
- BYPXMDMFORFJBQ-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-methylphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=CC(C)=CC=C1C1=CC(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C1F BYPXMDMFORFJBQ-GOSISDBHSA-N 0.000 description 1
- VMSLVXAQUFCANI-JFGZAKSSSA-N (2R)-4-[5-fluoro-4-(4-methylsulfanylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C1=CC(SC)=CC=C1C(C(=C1)F)=CC(=O)N1CC[C@@](C)(S(C)(=O)=O)C(=O)NOC1OCCCC1 VMSLVXAQUFCANI-JFGZAKSSSA-N 0.000 description 1
- AJDXPTPMQHQKBI-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-methylsulfanylphenyl)-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound C1=CC(SC)=CC=C1C1=CC(=O)N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C1F AJDXPTPMQHQKBI-GOSISDBHSA-N 0.000 description 1
- DSIGLWBKACIAAN-GOSISDBHSA-N (2R)-4-[5-fluoro-4-(4-methylsulfanylphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=CC(SC)=CC=C1C1=CC(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C=C1F DSIGLWBKACIAAN-GOSISDBHSA-N 0.000 description 1
- XWUMCRLVJUVCSA-XSWBTSGESA-N (2R)-4-[5-fluoro-4-[4-(1,2-oxazol-3-yl)phenyl]-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound C([C@](C)(C(=O)NOC1OCCCC1)S(C)(=O)=O)CN(C(C=1)=O)C=C(F)C=1C(C=C1)=CC=C1C=1C=CON=1 XWUMCRLVJUVCSA-XSWBTSGESA-N 0.000 description 1
- FXZBCVSROFYQOR-HSZRJFAPSA-N (2R)-4-[5-fluoro-4-[4-(6-methoxypyridin-3-yl)phenyl]-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=NC(OC)=CC=C1C1=CC=C(C=2C(=CN(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)C=C1 FXZBCVSROFYQOR-HSZRJFAPSA-N 0.000 description 1
- UQTTWFZHDFYXRV-BUHVNGGQSA-N (2R)-4-[5-fluoro-4-[4-[[4-(oxan-2-yloxy)cyclohexyl]methoxy]phenyl]-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=CC(OCC3CCC(CC3)OC3OCCCC3)=CC=2)=C1 UQTTWFZHDFYXRV-BUHVNGGQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- OSNSWKAZFASRNG-BMZZJELJSA-N (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-BMZZJELJSA-N 0.000 description 1
- DXQUZPNVVNHBRF-UHFFFAOYSA-N (4-bromo-2-methylphenyl)hydrazine;hydrochloride Chemical compound Cl.CC1=CC(Br)=CC=C1NN DXQUZPNVVNHBRF-UHFFFAOYSA-N 0.000 description 1
- XIFXALMOWDDZMO-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)hydrazine;hydrochloride Chemical compound Cl.NNC1=CC=C(Br)C(F)=C1 XIFXALMOWDDZMO-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- WRQNDLDUNQMTCL-UHFFFAOYSA-N (4-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-UHFFFAOYSA-N 0.000 description 1
- JCIJCHSRVPSOML-UHFFFAOYSA-N (4-fluoro-3-methylphenyl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=C1F JCIJCHSRVPSOML-UHFFFAOYSA-N 0.000 description 1
- PXVDQGVAZBTFIB-UHFFFAOYSA-N (4-methoxy-3-methylphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1C PXVDQGVAZBTFIB-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical compound CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- QEASJVYPHMYPJM-UHFFFAOYSA-N 1,2-dihydrotriazol-5-one Chemical compound OC1=CNN=N1 QEASJVYPHMYPJM-UHFFFAOYSA-N 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- WYXQQAYIAJRORT-UHFFFAOYSA-N 1-benzofuran-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OC=CC2=C1 WYXQQAYIAJRORT-UHFFFAOYSA-N 0.000 description 1
- FOCLRODNGKLAOT-UHFFFAOYSA-N 1-bromo-4-cyclopropyloxybenzene Chemical compound C1=CC(Br)=CC=C1OC1CC1 FOCLRODNGKLAOT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OBVRKNZQNKGNTQ-UHFFFAOYSA-N 2,5-difluoro-4-iodopyridine Chemical compound FC1=CC(I)=C(F)C=N1 OBVRKNZQNKGNTQ-UHFFFAOYSA-N 0.000 description 1
- NOFYKRVJTGRFAQ-UHFFFAOYSA-N 2-(3-iodophenoxy)-1,3-thiazole Chemical compound IC1=CC=CC(OC=2SC=CN=2)=C1 NOFYKRVJTGRFAQ-UHFFFAOYSA-N 0.000 description 1
- DKQIBRDDOQDZCM-UHFFFAOYSA-N 2-(4-bromo-2-methylphenyl)triazole Chemical compound CC1=CC(Br)=CC=C1N1N=CC=N1 DKQIBRDDOQDZCM-UHFFFAOYSA-N 0.000 description 1
- XXKBPRVKBJKNDE-UHFFFAOYSA-N 2-(4-bromophenyl)-4-methoxytriazole Chemical compound N1=C(OC)C=NN1C1=CC=C(Br)C=C1 XXKBPRVKBJKNDE-UHFFFAOYSA-N 0.000 description 1
- BTXPJEJHYCPZGD-UHFFFAOYSA-N 2-(4-bromophenyl)-4-methyltriazole Chemical compound N1=C(C)C=NN1C1=CC=C(Br)C=C1 BTXPJEJHYCPZGD-UHFFFAOYSA-N 0.000 description 1
- NMZGXHGKHYWJFI-UHFFFAOYSA-N 2-(4-bromophenyl)tetrazole Chemical compound C1=CC(Br)=CC=C1N1N=NC=N1 NMZGXHGKHYWJFI-UHFFFAOYSA-N 0.000 description 1
- OGSNAIXWIZRZLF-UHFFFAOYSA-N 2-(4-cyclopropyloxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OC1CC1 OGSNAIXWIZRZLF-UHFFFAOYSA-N 0.000 description 1
- BJNRAXNXFISPNV-UHFFFAOYSA-N 2-(4-iodophenyl)-1,3-oxazole Chemical compound C1=CC(I)=CC=C1C1=NC=CO1 BJNRAXNXFISPNV-UHFFFAOYSA-N 0.000 description 1
- FWXKOKDJKYCPHX-UHFFFAOYSA-N 2-[2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]triazole Chemical compound CC1=CC(B2OC(C)(C)C(C)(C)O2)=CC=C1N1N=CC=N1 FWXKOKDJKYCPHX-UHFFFAOYSA-N 0.000 description 1
- XJFMDBNXMORLIC-UHFFFAOYSA-N 2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-1,3-thiazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(OC=2SC=CN=2)=C1 XJFMDBNXMORLIC-UHFFFAOYSA-N 0.000 description 1
- BPBJCLGGUPENKL-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C=2OC=CN=2)C=C1 BPBJCLGGUPENKL-UHFFFAOYSA-N 0.000 description 1
- NYRSHQCHDLSCNW-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(OC(F)F)C(F)=C1 NYRSHQCHDLSCNW-UHFFFAOYSA-N 0.000 description 1
- BPFSJXBWEVRJFH-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(OC(F)F)C=C1 BPFSJXBWEVRJFH-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- RSUBGBZOMBTDTI-UHFFFAOYSA-N 2-chloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1 RSUBGBZOMBTDTI-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- OJQSEIZNSYEBHE-UHFFFAOYSA-N 2-methoxy-5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyridine Chemical compound C1=NC(OC)=CC=C1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 OJQSEIZNSYEBHE-UHFFFAOYSA-N 0.000 description 1
- KCWBUWJACHDHHQ-UHFFFAOYSA-N 2-methyl-2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound CCC(C)(S(C)(=O)=O)C(=O)NOC1CCCCO1 KCWBUWJACHDHHQ-UHFFFAOYSA-N 0.000 description 1
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
- ZCRBXBJNDRDFCW-UHFFFAOYSA-N 2-methylsulfonyl-N-(oxan-2-yloxy)butanamide Chemical compound CCC(S(C)(=O)=O)C(=O)NOC1CCCCO1 ZCRBXBJNDRDFCW-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-M 2-naphthoate Chemical class C1=CC=CC2=CC(C(=O)[O-])=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-M 0.000 description 1
- RIBOTMNSYSYOHG-UHFFFAOYSA-N 3,4-dihydro-2H-chromen-6-ylboronic acid Chemical compound O1CCCC2=CC(B(O)O)=CC=C21 RIBOTMNSYSYOHG-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- BZZNOXIJKCPQNF-UHFFFAOYSA-N 3-(4-bromophenyl)-1,2-oxazole Chemical compound C1=CC(Br)=CC=C1C1=NOC=C1 BZZNOXIJKCPQNF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- FXTKWBZFNQHAAO-UHFFFAOYSA-N 3-iodophenol Chemical compound OC1=CC=CC(I)=C1 FXTKWBZFNQHAAO-UHFFFAOYSA-N 0.000 description 1
- BWOZXCATOLMOAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[4-(oxetan-3-yloxy)phenyl]-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OC1COC1 BWOZXCATOLMOAH-UHFFFAOYSA-N 0.000 description 1
- BICZJRAGTCRORZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1 BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- WJROSMZTIWEXRO-UHFFFAOYSA-N 4-[4-(2-cyanophenyl)-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C(=CC=CC=2)C#N)=C1 WJROSMZTIWEXRO-UHFFFAOYSA-N 0.000 description 1
- LACMXESAJCYYMD-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=CC(Cl)=CC=2)=C1 LACMXESAJCYYMD-UHFFFAOYSA-N 0.000 description 1
- UBYDLNWNTLCSQQ-UHFFFAOYSA-N 4-[4-(4-cyano-3-methoxyphenyl)-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=C(C#N)C(OC)=CC(C=2C(=CN(CCC(C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)=C1 UBYDLNWNTLCSQQ-UHFFFAOYSA-N 0.000 description 1
- CRPLDKPDOYAQFO-UHFFFAOYSA-N 4-[4-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C1=CC(CN(C)C)=CC=C1C1=CC(=O)N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C1F CRPLDKPDOYAQFO-UHFFFAOYSA-N 0.000 description 1
- BWVSDOAKKXROLE-UHFFFAOYSA-N 4-[5-fluoro-2-oxo-4-(3-oxo-1,2-dihydroisoindol-5-yl)pyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C=C3C(=O)NCC3=CC=2)=C1 BWVSDOAKKXROLE-UHFFFAOYSA-N 0.000 description 1
- YBWUBRQHOMOGCD-UHFFFAOYSA-N 4-[5-fluoro-4-(2-fluoro-3-methoxyphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound COC1=CC=CC(C=2C(=CN(CCC(C)(C(=O)NO)S(C)(=O)=O)C(=O)C=2)F)=C1F YBWUBRQHOMOGCD-UHFFFAOYSA-N 0.000 description 1
- UXWMVGQJOWVWOR-UHFFFAOYSA-N 4-[5-fluoro-4-(2-fluorophenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C(=CC=CC=2)F)=C1 UXWMVGQJOWVWOR-UHFFFAOYSA-N 0.000 description 1
- KZTUVBNARWZEHP-UHFFFAOYSA-N 4-[5-fluoro-4-(3-fluoropyridin-4-yl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound O=C1N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C(F)C(C=2C(=CN=CC=2)F)=C1 KZTUVBNARWZEHP-UHFFFAOYSA-N 0.000 description 1
- UOUFYOXGCMMWJU-UHFFFAOYSA-N 4-[5-fluoro-4-(3-methylimidazo[4,5-b]pyridin-6-yl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide Chemical compound C=1N=C2N(C)C=NC2=CC=1C1=CC(=O)N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C1F UOUFYOXGCMMWJU-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- VYPPIAHUQSPSIH-UHFFFAOYSA-N 4-methoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]triazole Chemical compound N1=C(OC)C=NN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 VYPPIAHUQSPSIH-UHFFFAOYSA-N 0.000 description 1
- KGRKRKBNOQPPEQ-UHFFFAOYSA-N 4-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]triazole Chemical compound N1=C(C)C=NN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 KGRKRKBNOQPPEQ-UHFFFAOYSA-N 0.000 description 1
- ILEXFMLAYIITBO-UHFFFAOYSA-N 5-(4-bromophenyl)-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1C1=CC=C(Br)C=C1 ILEXFMLAYIITBO-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- QMNJBPBGFLZAPU-UHFFFAOYSA-N 5-methoxy-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine Chemical compound N1=CC(OC)=CN=C1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 QMNJBPBGFLZAPU-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N 504-70-1 Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- ZYWICCYXTGRUNM-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N=CC=N2)C2=C1 ZYWICCYXTGRUNM-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241001148231 Acinetobacter haemolyticus Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N Azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N Azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- ZDAORPMLULKKCQ-UHFFFAOYSA-N C(C)C(C(=O)N)(CC)S(=O)(=O)C Chemical compound C(C)C(C(=O)N)(CC)S(=O)(=O)C ZDAORPMLULKKCQ-UHFFFAOYSA-N 0.000 description 1
- YEKQEOIRDYIQHI-UHFFFAOYSA-N COCC1=CC=CC=C1C1=CC(=O)N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C1F Chemical compound COCC1=CC=CC=C1C1=CC(=O)N(CCC(C)(C(=O)NO)S(C)(=O)=O)C=C1F YEKQEOIRDYIQHI-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L Copper(II) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229950010286 Diolamine Drugs 0.000 description 1
- 108010003026 EC 3.5.1.108 Proteins 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 210000000883 Ear, External Anatomy 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 229940047650 Haemophilus influenzae Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229960002182 IMIPENEM Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N IPA isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101700013844 LOXL4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 229940076266 Morganella morganii Drugs 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YJDYQFYKYAYBMU-UHFFFAOYSA-N N-(oxan-2-yloxy)butanamide Chemical compound CCCC(=O)NOC1CCCCO1 YJDYQFYKYAYBMU-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- IYSSFVYKJBJHHQ-HSZRJFAPSA-N O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)C=2N=CC=CN=2)=C1 Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(=CC=2)C=2N=CC=CN=2)=C1 IYSSFVYKJBJHHQ-HSZRJFAPSA-N 0.000 description 1
- KLMHHPKZUPALDD-HXUWFJFHSA-N O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(C)=CC=2)=C1 Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(C)=CC=2)=C1 KLMHHPKZUPALDD-HXUWFJFHSA-N 0.000 description 1
- UQTTWFZHDFYXRV-NXWNVOEXSA-N O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=CC(OC[C@@H]3CC[C@H](CC3)OC3OCCCC3)=CC=2)=C1 Chemical compound O=C1N(CC[C@](C)(C(O)=O)S(C)(=O)=O)C=C(F)C(C=2C=CC(OC[C@@H]3CC[C@H](CC3)OC3OCCCC3)=CC=2)=C1 UQTTWFZHDFYXRV-NXWNVOEXSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229950004864 Olamine Drugs 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N Oleyl alcohol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 241000658540 Ora Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Phenylacetylene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 229940055033 Proteus mirabilis Drugs 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 229940007042 Proteus vulgaris Drugs 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 102100015763 USHBP1 Human genes 0.000 description 1
- 101710012452 USHBP1 Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- WRQNDLDUNQMTCL-ZBJDZAJPSA-N [4-(1,1,2,2,2-pentadeuterioethoxy)phenyl]boronic acid Chemical compound [2H]C([2H])([2H])C([2H])([2H])OC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-ZBJDZAJPSA-N 0.000 description 1
- DWRAMTYYMNLVBD-UHFFFAOYSA-N [4-(2,2,2-trifluoroethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OCC(F)(F)F)C=C1 DWRAMTYYMNLVBD-UHFFFAOYSA-N 0.000 description 1
- KFVPDYTZZTZGFJ-UHFFFAOYSA-N [4-(oxan-2-yloxy)cyclohexyl]methanol Chemical compound C1CC(CO)CCC1OC1OCCCC1 KFVPDYTZZTZGFJ-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-FIBGUPNXSA-N [4-(trideuteriomethoxy)phenyl]boronic acid Chemical compound [2H]C([2H])([2H])OC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-FIBGUPNXSA-N 0.000 description 1
- BIWQNIMLAISTBV-FIBGUPNXSA-N [4-(trideuteriomethyl)phenyl]boronic acid Chemical compound [2H]C([2H])([2H])C1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-FIBGUPNXSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 101710023077 blaNDM-1 Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- CRRYCJOJLZQAFR-UHFFFAOYSA-N cyclohexane;pentane Chemical compound CCCCC.C1CCCCC1 CRRYCJOJLZQAFR-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IIJREXIVDSIOFR-UHFFFAOYSA-N dichloromethane;heptane Chemical compound ClCCl.CCCCCCC IIJREXIVDSIOFR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- VDAHNHLFDPWDQN-CYBMUJFWSA-N ethyl (2R)-4-(3,5-difluoro-4-iodo-2-oxopyridin-1-yl)-2-methyl-2-methylsulfonylbutanoate Chemical compound CCOC(=O)[C@](C)(S(C)(=O)=O)CCN1C=C(F)C(I)=C(F)C1=O VDAHNHLFDPWDQN-CYBMUJFWSA-N 0.000 description 1
- QGMMGJFVXUZTMA-OAQYLSRUSA-N ethyl (2R)-4-[4-(4-ethoxyphenyl)-5-fluoro-2-oxopyridin-1-yl]-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C=2C=CC(OCC)=CC=2)=C1 QGMMGJFVXUZTMA-OAQYLSRUSA-N 0.000 description 1
- MQVVSTNQJBQZFO-OAQYLSRUSA-N ethyl (2R)-4-[5-fluoro-2-oxo-4-(2-phenylethynyl)pyridin-1-yl]-2-methyl-2-methylsulfonylbutanoate Chemical compound O=C1N(CC[C@](C)(C(=O)OCC)S(C)(=O)=O)C=C(F)C(C#CC=2C=CC=CC=2)=C1 MQVVSTNQJBQZFO-OAQYLSRUSA-N 0.000 description 1
- JEAVBVKAYUCPAQ-UHFFFAOYSA-N ethyl 2-chloropropanoate Chemical compound CCOC(=O)C(C)Cl JEAVBVKAYUCPAQ-UHFFFAOYSA-N 0.000 description 1
- KVYLGLYBQFEJAK-UHFFFAOYSA-N ethyl 2-methylsulfonylpropanoate Chemical compound CCOC(=O)C(C)S(C)(=O)=O KVYLGLYBQFEJAK-UHFFFAOYSA-N 0.000 description 1
- WFCTXFNOSNPPJX-UHFFFAOYSA-N ethyl 4-(5-fluoro-4-iodo-2-oxopyridin-1-yl)-2-methyl-2-methylsulfonylbutanoate Chemical compound CCOC(=O)C(C)(S(C)(=O)=O)CCN1C=C(F)C(I)=CC1=O WFCTXFNOSNPPJX-UHFFFAOYSA-N 0.000 description 1
- BNWFSNDPHHMKNO-UHFFFAOYSA-N ethyl 4-(oxan-2-yloxy)cyclohexane-1-carboxylate Chemical compound C1CC(C(=O)OCC)CCC1OC1OCCCC1 BNWFSNDPHHMKNO-UHFFFAOYSA-N 0.000 description 1
- BZKQJSLASWRDNE-UHFFFAOYSA-N ethyl 4-hydroxycyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCC(O)CC1 BZKQJSLASWRDNE-UHFFFAOYSA-N 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 229940005931 ophthalmologic Fluoroquinolone antiinfectives Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- UMFWNFVHKAJOSE-UHFFFAOYSA-N oxetan-3-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1COC1 UMFWNFVHKAJOSE-UHFFFAOYSA-N 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000000432 peptic ulcer disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940041075 systemic Fluoroquinolone antibacterials Drugs 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- JIRRJTAAVDYFBH-ZWBIQZHISA-J tetrasodium;(7Z)-7-[[4-[4-[(2Z)-2-(6-anilino-1-oxo-3-sulfonatonaphthalen-2-ylidene)hydrazinyl]-3-hydroxyphenyl]-2-hydroxyphenyl]hydrazinylidene]-8-oxonaphthalene-1,3,6-trisulfonate;copper Chemical compound [Na+].[Na+].[Na+].[Na+].[Cu].[Cu].OC1=CC(C=2C=C(O)C(N\N=C\3C(=CC4=C(C(=CC(=C4)S([O-])(=O)=O)S([O-])(=O)=O)C/3=O)S([O-])(=O)=O)=CC=2)=CC=C1N\N=C(C(=CC1=C2)S([O-])(=O)=O)\C(=O)C1=CC=C2NC1=CC=CC=C1 JIRRJTAAVDYFBH-ZWBIQZHISA-J 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
Description
This invention relates to novel hydroxamic acid dérivatives. The invention also relates to methods of using such compounds in the treatment of bacterial infections (especially Gram-negative infections) and to pharmaceutical compositions containing such compounds.
Backqround of the Invention
Infection by Gram-negative bacteria such as Pseudomonas aeruginosa, Extended Spectrum β-lactamase producing (ESBL) Entgerobacteriaceae, and Acinetobacter baumannii is a major health problem, especially in the case of hospitalacquired infections. In addition, there is an increasing level of résistance to current antibiotic thérapies, which severely limits treatment options. For example, in 2002, 33% of Pseudomonas aeruginosa infections from intensive care units were résistant to fluoroquinolones, while résistance to imipenem was 22% (CID 42: 657-68, 2006). In addition, multi-drug résistant (MDR) infections are also increasing; in the case of Pseudomonas aeruginosa, MDR increased from 4% in 1992 to 14% in 2002 (Biochem Pharm 71: 991, 2006).
Gram-negative bacteria are unique in that their outer membrane contains lipopolysaccharide (LPS), which is crucial for maintaining membrane integrity, and is essential for bacterial viability (reviewed in Ann. Rev. Biochem 76: 295-329, 2007). The major lipid component of LPS is Lipid A, and inhibition of Lipid A biosynthesis is léthal to bacteria. Lipid A is synthesized on the cytoplasmic surface of the bacterial inner membrane via a pathway that consists of nine different enzymes. These enzymes are highly conserved in most Gram-negative bacteria. LpxC [UDP-3-O-(R-3hydroxymyristoyl)- N-acetylglucosamine deacetylase] is the enzyme that catalyzes the first committed step in the Lipid A biosynthetic pathway, the removal of the N-acetyl group of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine. LpxC is a Zn2+ dépendent enzyme that has no mammalian homologue, making it a good target for the development of novel antibiotics. Several inhibitors of LpxC with low nM affinity hâve been reported (Biochemistry 45: 7940-48, 2006).
Summary of the Invention
A new class of LpxC inhibitors has been discovered. These compounds, or their pharmaceutically acceptable salts, can be represented by Formula I below:
E-----D'
in which:
R1 is represented by C1-C3 alkyl;
R2 is represented by hydrogen or C1-C3 alkyl;
R3 is represented by hydrogen, halogen, hydroxy, cyano, C^C^Ikyl, C^Cgalkoxy, trifluoromethyl or trifluoromethoxy;
T is represented by ethynyl, optionally substituted (C6-C10)aryl or optionally substituted heteroaryl;
D is absent, or is represented by -(CH2)r. -(CH2)n-O-(CH2)p-, or a bond;
r is represented by the integer 1,2, or 3;
n and p are each independently represented by the integer 0,1, or 2;
E is absent, or is represented by a substituent selected from the group consisting of:
i) (C3_C10)cycloalkyl, optionally substituted;
ii) (C6-C10)aryl optionally substituted;
iii) heteroaryl, optionally substituted; and iv) heterocyclic, optionally substituted;
with the proviso that:
) if E is absent, then D is also absent;
2) T is not represented by unsubstituted phenyl; when E and D both are absent, R3 is hydrogen and R1 and R2 are each methyl.
The compounds of Formula I exhibit antibacterial activity, especially against Gram-negative organisms. They may be used to treat bacterial infections in mammals,
especially humans. The compounds may also be used for veterinary applications, such as treating infections in livestock and companion animais.
The compounds of Formula I are useful for treating a variety of infections; especially Gram-negative infections including nosocomial pneumonie, urinary tract infections, systemic infections (bacteremia and sepsis), skin and soft tissue infections, surgical infections, intraabdominal infections, lung infections (including those in patients with cystic fibrosis), Hélicobacter pylori (and relief of associated gastric complications such as peptic ulcer disease, gastric carcinogenesis, etc.), endocarditis, diabeticfoot infections, osteomyelitis, and central nervous system infections.
In order to simplify administration, the compounds will typically be admixed with at least one excipient and formulated into a pharmaceutical dosage form. Examples of such dosage forms include tablets, capsules, solutions/suspensions for injection, aérosols for inhalation, cream/ointments for topical, otic or ophthalmic use, and solutions/suspensions for oral ingestion.
Detailed Description of the Invention
The headings within this document are only being utilized to expedite its review by the reader. They should not be construed as limiting the invention or claims in any manner.
Définitions and Exemplification
As used throughout this application, including the claims, the following terms have the meanings defined below, unless specifically indicated otherwise. The plural and singular should be treated as interchangeable, other than the indication of number:
a. “C-i - C3 alkyl” refers to a branched or straight chained alkyl group containing from 1 to 3 carbon atoms, such as methyl, ethyl, n-propyl, or isopropyl, etc.
b. “C^ C3 alkoxy refers to a straight or branched chain alkoxy group containing from 1 to 3 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, etc.
c. halogen” refers to a chlorine, fluorine, iodine, or bromine atom.
d. “C,. C6 alkyl refers to a branched or straight chained alkyl group containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, pentyl, etc.
e. “C^ C6 alkyl, optionally substituted refers to a branched or straight chained alkyl group containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, pentyl, etc. Such an alkyl group may be optionally substituted, in which up to 3 hydrogen atoms are replaced by a substituent selected from the group consisting of halogen, cyano, sulfonamide, imino, OR4,
-SR4, and -NR4R5 in which R4 and R5 are each independently represented by hydrogen or C1-C3 alkyl.
f. “C^ C6 alkoxy refers to a straight or branched chain alkoxy group containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, nbutoxy, isobutoxy, pentoxy, etc.
g. “C^ C6 alkoxy, optionally substituted” refers to a straight or branched chain alkoxy group containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, npropoxy, isopropoxy, n-butoxy, isobutoxy, pentoxy, etc. Such an alkoxy group may be optionally substituted, in which up to 3 hydrogen atoms are replaced by a substituent selected from the group consisting of halogen, cyano, sulfonamide, imino, -OR4, -SR4, and -NR4R5 in which R4 and R5 are each independently represented by hydrogen or C1-C3 alkyl.
h. “(C6-C10)aryr means a cyclic, aromatic hydrocarbon containing from 6 to 10 carbon atoms. Examples of such aryl groups include phenyl, naphthyl, etc.
i. “(C6-C10)aryl optionally substituted means a cyclic, aromatic hydrocarbon as defined above. Such an aryl moiety may be optionally substituted with up to 4 non-hydrogen substituents, each substituent is independently selected from the group consisting of halogen, cyano, nitro, hydroxy, (C^-C6)alkyl optionally substituted, (C^Cgjalkoxy optionally substituted, trifluoromethyl, trifluromethoxy, phosphate, -SO2NR4R5, -(CH2)m-NR5-C(O)-R4, -(CH2)m-C(O)-N-R4R5, -C(O)-R4,C(O)-O-R4, -SR4, -SO2R4 and -NR4R5, in which m, R4 and R5 are as defined above and each M independently represents an integer from 0-4. These substituents may be the same or different and may be located at any position of the ring, that is chemically permissible. Phenyl optionally substituted refers to a phenyl ring substituted as described above.
j. “heteroaryl” refers to an aromatic ring having one, or more, heteroatoms selected from oxygen, nitrogen and sulfur. More specifically, it refers to a 5- or 6membered ring containing 1,2,3, or 4 nitrogen atoms; 1 oxygen atom; 1 sulfur atom; 1 nitrogen and 1 sulfur atom; 1 nitrogen and 1 oxygen atom; 2 nitrogen atoms and 1 oxygen atom; or 2 nitrogen atoms and 1 sulfur atom. The 5-membered ring has 2 double bonds and the 6- membered ring has 3 double bonds (hereinafter a “5- to 6-membered heteroaryl”). The term “heteroaryl” also
includes bicyclic groups in which the heteroaryl ring is fused to a benzene ring, heterocyclic ring, a cycloalkyl ring, or another heteroaryl ring. Examples of such heteroaryl ring Systems include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazoîyl, oxazolyl, indolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, benzofuran, tetrazole, isoquinolinyl, oxadiazolyl, thiadiazolyl, isothiazolyl, isoxazolyl, triazolyl, benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 7-benzimidazolyl, or benzothiazolyl.
k. “heteroaryl, optionally substituted,” refers to a heteroaryl moiety as defined immediately above, in which up to 4 carbon atoms of the heteroaryl moiety may be substituted with a substituent, each substituent is independently selected from the group consisting of halogen, cyano, nitro, hydroxy, (C1-Ce)alkyl optionally substituted, (C^C^alkoxy optionally substituted, trifluoromethyl, trifluromethoxy, phosphate, -SO2NR4R5, -(CH2)m-N-C(O)-R4, -(CH2)m-C(O)-N-R4R5,
-C(O)-R4, -C(O)-O-R4, -SR4, -SO2R4 and -NR4R5, in which m, R4 and R5 are as defined above. These substituents may be the same or different and may be located at any position of the ring, that is chemically permissible.
Any reference to an optionally substituted 5- to 6- membered heteroaryl refers to 5- to 6-membered heteroaryl ring as described in définition j, having the substitution pattern described immediately above.
l. “(C3-C10) cycloalkyl” refers to a saturated or partially saturated monocyclic, bicyclic, bridged bicyclic or tricyclic alkyl radical wherein each cyclic moiety has 3 to 10 carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and the like.
m. “(C3-C10) cycloalkyl” optionally substituted refers to a (C3-C10) cycloalkyl moiety as described above. Such a cycloalkyl group may be optionally substituted, in which up to 4 hydrogen atoms are replaced by a substituent selected from the group consisting of halogen, cyano, nitro, hydroxy, (C^C^alkyl optionally substituted, (C^C^alkoxy optionally substituted, trifluoromethyl, trifluromethoxy, phosphate, oxo, -SO2NR4R5, -(CH2)m-NR5-C(O)-R4, -(CH2)m-C(O)-N-R4R5, C(O)-R4, -C(O)-O-R4, -SR4, -SO2R4 and -NR4R5, in which M, R4 and R5 are as defined above. These substituents may be the same or different and may be located at any position of the ring, that is chemically permissible.
n. '‘(C3-Ce) cycloalkyl refers to a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl moiety, any of which may be optionally substituted as described above, if chemically permissible.
o. “heterocycle or “heterocyclic ring” refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur; or a 5-, 6-, 7-, 8-, 9-, or 10- membered ring containing 1,2, or 3 nitrogen atoms; 1 oxygen atom;
sulfur atom; 1 nitrogen and 1 sulfur atom; 1 nitrogen and 1 oxygen atom;
oxygen atoms in non-adjacent positions; 1 oxygen and 1 sulfur atom in nonadjacent positions; or 2 sulfur atoms in non-adjacent positions. The 5-membered ring has 0 to 1 double bonds, the 6- and 7-membered rings hâve 0 to 2 double bonds, and the 8, 9, or 10 membered rings may hâve 0,1,2, or 3 double bonds. The term “heterocyclic also includes bicyclic groups in which any of the above heterocyclic rings is fused to a benzene ring, a cyclohexane or cyclopentane ring or another heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, dihydrobenzofuryl or benzothienyl and the like). Heterocyclics include: pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, piperazinyl, azepane, azocane, morpholinyl, isochromyl, quinolinyl, tetrahydrotriazine, tetrahydropyrazole, dihydro-oxathiol-4-yl, dihydro-1Hisoindole, tetrahydro-oxazolyl, tetrahydro-oxazinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl.
p. heterocyclic, optionally substituted refers to a heterocyclic moiety as defined immediately above, in which up to 4 carbon atoms of the heterocycle moiety may be substituted with a substituent, each substituent is independently selected from the group consisting of halogen, cyano, nitro, hydroxy, (C^CgJalkyl optionally substituted, (C^Cgjalkoxy optionally substituted, trifluoromethyl, trifluromethoxy, pentafluoro sulfonyl, phosphate, oxo, SO2NR4R5, -(CH2)m-N-C(O)-R4, -(CH2)mC(O)-N-R4R5, -C(O)-R4, -C(O)-O-R4, -SR4, -SO2R4 and -NR4R5, in which m, R4 and R are as defined above. These substituents may be the same or different and may be located at any position of the ring that is chemically permissible. Any nitrogen atom within such a heterocyclic ring may optionally be substituted with (Ci-C6) alkyl, or any other substituent listed above, if such a substitution is chemically permissible. Any sulfur atom in the ring may be further substituted with 1 or 2 oxygen atoms (if such a substitution is chemically permissible).
V
q. therapeutically effective amount refers to an amount of a compound of Formula I that, when administered to a patient, provides the desired effect; i.e., lessening in the severity of the symptoms associated with a bacterial infection, decreasing the number of bacteria in the affected tissue, and/or preventing bacteria in the affected tissue from increasing in number( localized or systemic).
r. “patient refers to warm blooded animais such as for example, livestock, guinea pigs, mice, rats, gerbils, cats, rabbits, dogs, monkeys, chimpanzees, and humans.
s. treat” refers to the ability of the compounds to relieve, alleviate or slow the progression of the patients bacterial infection (or condition) or any tissue damage associated with the disease.
t. pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingrédients comprising a formulation, and/or the mammal being treated therewith.
u. “isomer'’ means “stereoisomer and “géométrie isomer” as defined below.
v. “stereoisomer” means compounds that possess one or more chiral centers and each center may exist in the R or S configuration. Stereoisomers include ail diastereomeric, enantiomeric and epimeric forms as well as racemates and mixtures thereof.
w. “géométrie isomer’’ means compounds that may exist in cis, trans, anti, entgegen (E), and zusammen (Z) forms as well as mixtures thereof.
x. Compounds of “Formula I”, “formula I, formula (I)’’ and “compounds of the invention” are being used interchangeably throughout the application and should be treated as synonyms.
y. The terms pyridone and “pyridinone hâve been used interchangeably within this application. No différence or distinction is meant, unless otherwise noted. One skilled in the art will readily understand this.
The phrase “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be présent in the compounds of the présent invention. The compounds of the présent invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to préparé pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts,
i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate,
îsonrcotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e·, 1,r-methylene-bis-(2-hydroxy-
3-naphthoate)] salts. The compounds of the présent invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
The invention also relates to base addition salts of the compounds of the invention. The chemical bases that may be used as reagents to préparé these pharmaceutically acceptable base salts are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali métal cations (e.g., potassium and sodium) and alkaline earth métal cations (e.g., calcium and magnésium), ammonium or water-soluble amine addition salts such as Nmethylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
Suitable base salts are formed from bases which form non-toxic salts. Non limiting examples of suitable base salts include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnésium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds of the invention are known to one of skill in the art.
Certain of the compounds of the formula (I) may exist as géométrie isomers. The compounds of the formula (I) may possess one or more asymmetric centers, thus existing as two or more stereoisomeric forms. The présent invention includes ail the individual stereoisomers and géométrie isomers of the compounds of formula (I) and mixtures thereof. Individual enantiomers can be obtained by chiral séparation or using the relevant enantiomer in the synthesis.
In addition, the compounds of the présent invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, éthanol and the like. In general, the solvated forms are considered équivalent to the unsolvated forms for the purposes of the présent invention. The compounds may also
exist in one or more crystalline states, i.e. polymorphe, or they may exist as amorphous solids. Ail such forms are encompassed by the ciaims.
The invention also relates to prodrugs of the compounds of the invention. Thus certain dérivatives of compounds of the invention which may hâve little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of the invention having the desired activity, for example, by hydrolytic cleavage. Such dérivatives are referred to as “'prodrugs”. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug
Design, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical
Association).
This invention also encompasses compounds of the invention containing protective groups. One skilled in the art will also appreciate that compounds of the invention can also be prepared with certain protecting groups that are useful for purification or storage and can be removed before administration to a patient. The protection and deprotection of functional groups is described in “Protective Groups in Organic Chemistry”, edited by J.W.F. McOmie, Plénum Press (1973) and Protective Groups in Organic Synthesis”, 3rd édition, T.W. Greene and P.G.M. Wuts, WileyInterscience (1999).
The présent invention also includes isotopically-labeled compounds, which are identical to those recited in formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to, 2H, 3H, 13C, 14C, 1SN, 170,180,31P, 32P, 35S, 18F, and 36CI, respectively. Compounds of the présent invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopicallylabeled compounds of the présent invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or
reduced dosage requirements and, hence, may be preferred in some circumstances.
Isotopicaily-labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the
Examples below, by substituting a readily available isotopicaily-labeled reagent for a non-isotopically-labeled reagent.
Ail of the compounds of Formula I contain a sulfonyl moiety as depicted below:
SO2-R1 H
This sulfonyl moiety will always be substituted with a lower alkyl moiety. Typically it will be methyl. The carbon atom adjacent to the sulfonyl may optionally be substituted, as represented by R2. Typically both R1 and R2 will be methyl.
As is readily apparent to one skilled in the art, the carbon adjacent to the sulfonyl moiety is a chiral center. Therefore, the compounds can exist as the racemate, as the S-enantiomer, or as the R-enantiomer. In a further embodiment, the compounds may be prepared and administered as the R-enantiomer, as depicted below:
As is readily apparent to one skilled in the art, the compounds as synthesized will rarely be présent exclusively as a single enantiomer. The opposite enantiomer (i.e the Senantiomer) may be présent in minor amounts (i.e. “substantially pure”). This minor amount can be up to 10 w/w%, more typically no greater than 5 w/w%, in a further embodiment no greater than 1 w/w%, or more specifically, no greater than 0.5 w/w%.
Ali of the compounds of Formula I contain a pyridinone moiety as depicted below:
xZ
This pyridinone ring will be connected to the rest of the molécule via the 1 - and 4positions as depicted above. Position 3 will always be substituted with a fluoro moiety as depicted above. The pyridinone moiety may be optionally substituted, as depicted by the R3 moiety. R3 may represent one non-hydrogen substituent, as defined above. This non-hydrogen substituent may be located at either position 2 or 5 of the pyridinone ring. Typically R3 will represent hydrogen.
T will always be présent in the molécule. It will be represented by ethynyl, aryl or heteroaryl (either ring system may be substituted as defined above.) Typically, T will be represented by phenyl, which may be optionally substituted. When T is heteroaryl, it will be linked to the pyridinone via a carbon-carbon bond (i.e. the heteroatom(s) will not be bonded to the pyridinone). If E is présent, and D represents a bond, then it may represent any chemically permissible bond, i.e carbon-carbon, carbon-nitrogen, etc.
The presence of D and E are optional. If présent, D will typically be a bond and E will be represented by either a 5- to 6-membered heteroaryl or a (C3-C6) cycloalkyl, either of which may be optionally substituted as defined above.
More spécifie embodiments of the invention include compounds of Formula I in which:
a) R1 is methyl;
b) R2 is methyl;
c) R3 is hydrogen;
d) the compound is présent as the R-enantiomer (i.e. substantially pure);
e) T is phenyl, which may be optionally substituted and D and E are both absent; and
f) T is phenyl, D is a bond and E is either C3-C6 cycloalkyl or a 5- to 6membered heteroaryl, either of which may be optionally substituted.
A further embodiment of the invention is directed to compounds of Formula I, substantially pure in which:
a) R1 and R2 are each methyl, R3 is hydrogen, and T, D and E are as defined;
•y
b) R1 and R2 are each methyl, R3 is hydrogen, T is optionally substituted phenyl and both E and D are absent;
c) R1 and R2 are each methyl, R3 is hydrogen, T is optionally substituted phenyl, D is a bond and E is a 5- to 6-membered heteroaryl, which may be optionally substituted; and
d) R1 and R2 are each methyl, R3 is hydrogen, T is optionally substituted phenyl, D is a bond and E is Ca-Ce cycloalkyl, which may be optionally substituted.
In a further embodiment, the invention is directed to a subgenus represented by formula la below, in which the molécule is présent as the R-enantiomer (i.e. the Senantiomer may optionally be présent in minor amounts). As depicted below, R1 and R2 are methyl, R3 is hydrogen, both E and D are absent and T is substituted phenyl. More specifically Ra is represented by one or more substituents selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, fluorine, chlorine, hydroxy, trifluoromethyl and trifluoromethoxy.
In a further embodiment, the invention is directed to a subgenus represented by formula lb below, in which the molécule is présent as the R-enantiomer (i.e. the Senantiomer may optionally be présent as a minor impurity). As depicted below, R1 and R2 are methyl, R3 is hydrogen, T is phenyl, D is a bond and E is a 5- to 6-membered heteroaryl, which may be optionally substituted.
In a more spécifie embodiment of the invention, the LpxC inhibitor is the following compound, or its pharmaceutically acceptable sait:
In a more spécifie embodiment of the invention, the LpxC inhibitor is the following compound, or its pharmaceutically acceptable sait:
Synthesis
The compounds of Formula I can be prepared by a variety of methods that are analogously known in the art. The reaction schemes presented below illustrate two alternative methods for preparing these compounds. Others, including modifications thereof, will be readily apparent to one skilled in the art.
The synthesis of the compounds of Formula I is depicted below in Scheme A.
The first step is to carry out the N-alkylation depicted in Step A. The pyridinone of structure 1 is reacted with the sulfonyl dérivative of structure 2 generating the intermediate of structure 3. Structure 3 can be further derivatized to generate the compounds of Formula I. Two alternative synthèses are depicted (Option A or B), but the reader will readily note they are variations of the same synthesis. The only différence is the order in which the steps are carried out.
Initially in Option A, the halide, depicted by X, at the 4-position of the pyridinone of structure 3 is displaced by the desired terminal moiety E-D-T-M1, in which M1 is a métal species, such as a boron dérivative suitable for undergoing a typical crosscoupling such as a Suzuki-Miyaura reaction. Hydrolysis, or removal, of the ethyl protecting group (or other suitable protecting groups) in Step C affords the compound of structure 5. The terminal carboxylic acid of structure 5 is then converted to the protected hydroxamic acid dérivative as depicted by structure 8. Deprotection of the protected hydroxamic acid dérivative of structure 8, as depicted in Step H, affords the final product of Formula I. While these reactions are well known to one skilled in the art, they are discussed in greater detail below.
Initially, in Option B of Scheme A, the ethyl protecting group (or other conventional protecting groups) is removed from the pyridinone of structure 3 generating the compound of structure 6 as depicted in Step E. In Step F, the terminal carboxylic acid of structure 6 is converted to the protected hydroxamic acid dérivative of structure 7 via amidation conditions. In Step G, the halide function at the 4-position on the pyridinone moiety is then directly displaced by the desired terminal moiety, E-D-TM1, via a coupling reaction to afford the protected hydroxamic acid dérivatives of structure 8. As before, deprotection of the protected hydroxamic acid dérivatives, as depicted in Step H, affords the compounds of Formula I.
The N-alkylation depicted above in Step A can be carried out using techniques well known to one skilled in the art. One of the starting materials is the 2-pyridinone dérivative of structure 1. In this pyridinone, X will represented by a halide and R3 will be represented by the same moiety as is desired in the final product. Many of these pyridinone dérivatives are known in the art and the remainder can be produced using synthetic techniques analogously known in the art. The reader’s attention is directed to Tet. Lett. (2005) Vol 46, 7917, for a description of such techniques. Préparation 2 infra, also illustrâtes their préparation.
The other reactant in the N-alkylation depicted in Step A is the protected alkyl sulfonate of structure 2, in which R1 and R2 are represented by the same moiety as is desired in the final product. An ethyl protecting group is portrayed, but any standard protecting group may be substituted. These alkyl sulfonates are also known in the art. The reader’s attention is directed to Journal of Organic Chemistry, (1980) Vol 45, 8, 1486-1489 for a description of their préparation. Préparation 1 infra, also illustrâtes their préparation
The N-alkylation can be carried out as is known in the art. Typically, équivalent amounts of the compounds of structure 1 and 2 are contacted in a mixture of aprotic and protic solvents, such as tetrahydrofuran and f-butanol, in the presence of a base such as potassium carbonate, césium carbonate, sodium carbonate, sodium hydride, etc. A transfer agent, such as tetrabutyl ammonium bromide, can be utilized, if desired. The reactants are typically heated and the reaction is allowed to proceed to completion. The desired product of structure 3 can be isolated by methods known in the art. If desired, the product of structure 3 can be purified, or alternatively the crude can be used in the next step of the reaction. Préparation 2 infra, illustrâtes such an Nalkylation.
Scheme A illustrâtes how to incorporate the hydroxamic acid moiety into the molécules. Initially, the protecting group is removed from the carboxylic acid, thereby generating the intermediate of structure 5 and 6, as depicted in Step C (Option A) and Step E (Option B) respectively. The manner in which this is accomplished will vary with the identity of the actual protecting group and is well known to those skilled in the art. The reader’s attention is directed to McOmie or Greene supra, for a discussion of potential protecting groups and methods for their removal. Préparation 2 infra describes how to remove an ethyl moiety as depicted in Scheme A.
In Steps F and D, the hydroxamic acid moiety as depicted, is incorporated into the molécule. A protected hydroxylamine source may be used followed by a subséquent deprotection reaction (alternatively, hydroxylamine may be directly incorporated to eliminate the deprotection steps). In either case the hydroxamic acid is
Y
incorporated into the molécule using standard amidation reactions. For example, the compound of structure 5 (Option A) or 6 (Option B) may be contacted with an excess of oxalyl chloride, in an aprotic solvent such as dichloromethane for a sufficient period of time to allow the formation of the corresponding acid chloride, followed by the addition of an excess of either hydroxylamine or protected hydroxylamine. The reaction is then allowed to proceed to completion and the protected intermediates of structure 7 (Option B) or 8 (Option A) is isolated from the reaction medium and purified as is known in the art. As mentioned above, any deprotection may be carried out as is known in the art (See Greene or McOmie supra). Alternatively, the amide can be formed using the amide coupling reagent, 1,T-carbonyldiimidazole (CDI), 2-chloro-4,6-dimethoxy-1,3,5triazine (CDMT), or 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), as is known in the art.
Scheme A also depicts how to incorporate the terminal moiety, E-D-T, into the molécule. Regardless of whether Option A or Option B is chosen, a coupling reaction is ultimately carried out to attach the terminal moiety, E-D-T, to the 4-position of the pyridinone intermediate. In Scheme A, the co-reactant is depicted as E-D-T-M1, where E-D-T-M1 represents the same moiety as desired in the final product, except that it will be substituted with a métal (or metalloid) such as magnésium, copper, boronic ester/acid, etc. at the desired point of attachment to the pyridinone intermediate of structure 3 or 7 (i.e. the other reactant). The terminal groups encompassed by Formula I, i.e E-D-T, are either known in the art or can be prepared by methods analogously known in the art.
The coupling reaction can be carried out by a variety of techniques. The SuzukiMiyaura strategy can be used to form the carbon-carbon bond. In such a reaction M1 will be represented by a boronic acid/ester. Equivalent molar amounts of the reactants will be contacted in a solvent such as tetrahydrofuran, 2-methyltetrahydrofuran, 1,4dioxane, water, toluene, or a mixture thereof in the presence of a transition métal catalyst such as a free or resin bound palladium or nickel species, together with a base such as sodium carbonate, potassium carbonate, césium fluoride, césium carbonate, etc. The reaction mixture can be heated by microwave or by other conventional techniques until adéquate conversion is achieved. Once complété, the desired product may be isolated and recovered from the reaction and further purified as is known in the art. Analogously, the Castro-Stevens or Sonogashira-Hagihara strategy can be employed; the T moiety will be a suitable terminal acetylene species reacted in the presence of copper sait such as copper iodide. In such a reaction M1 can be
represented by the in situ generated cuprate species. Equivalent molar amounts of the reactants will be contacted in a solvent such as tetrahydrofuran, 2methyltetrahydrofuran, dimethylformamide or a mixture thereof in the presence of a transition métal catalyst such as free or resin bound palladium or nickel, together with an appropriate base such as a suitable organic base for example N,Ndiisopropylethylamine. The reaction mixture can be heated by microwave or by other conventional techniques until adéquate conversion is achieved. Once complété, the desired product may be isolated and recovered from the reaction and further purified as is known in the art.
The reaction schemes depicted above for producîng the compound of Formula I, are merely illustrative. As is readily apparent to one skilled in the art, they may be modified depending upon the spécifie compound, availability of reagents, etc.
Medical and Veterinary Uses
The compounds may be used for the treatment or prévention of infectious disorders, especially those caused by susceptible and multi-drug résistant (MDR) Gramnegative bacteria. Examples of such Gram-negative bacteria include Acinetobacter baumannii, Acinetobacter spp., Achromobacter spp., Aeromonas spp., Bacteroides fragilis, Bordetella spp., Borrelia spp,, Brucella spp., Campylobacter spp., Citrobacter diversus (koseri), Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Francisella tularensis, Fusobacterium spp., Haemophilus influenzae (βlactamase positive and négative), Hélicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae (including those encoding extended-spectrum β-lactamases (hereinafter ESBLs), Légionella pneumophila, Moraxella catarrhalis (β-lactamase positive and négative), Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Proteus vulgaris, Porphyromonas spp., Prevotella spp., Mannheimia haemolyticus, Pasteurella spp., Proteus mirabilis, Providencia spp., Pseudomonas aeruginosa, Pseudomonas spp., Salmonella spp., Shigella spp., Serratia marcescens, Treponema spp., Burkholderia cepacia, Vibrio spp., Yersinia spp., and Stenotrophomonas mulophilia. Examples of other gram négative organisms include members of the Enterobacteriaceae that express ESBLs; KPCs, CTX-M, metallo-p-lactamases (such as NDM-1, for example), and AmpC-type beta-lactamases that confer résistance to currently available cephalosporins, cephamycins, carbapenems, and beta-lactam/betalactamase inhibitor combinations.
In a more spécifie embodiment, the Gram-negative bacteria are selected from the group consisting of Acinetobacter baumannii, Acinetobacter spp.,Citrobacter spp., Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Serratia marcescens, Stenotrophomonas maltophilia, Pseudomonas aeruginosa and members of the Enterobacteriaceae and Pseudomonas that express ESBLs, KPCs, CTX-M, metallo-p-lactamases, and AmpC-type betalactamases that confer résistance to currently available cephalosporins, cephamycins, carbapenems, and beta-lactam/beta-lactamase inhibitor combinations.
Examples of infections that may be treated with the compounds of Formula I include nosocomial pneumonia, urinary tract infections, systemic infections (bacteremia and sepsis), skin and soft tissue infections, surgical infections, intraabdominal infections, lung infections in patients with cystic fibrosis, patients suffering from lung infections, endocarditis, diabetic foot infections, osteomyelitis, and central nervous system infections.
In addition, the compounds can be used to treat Hélicobacter pylori infections in the Gl tract of humans (and other mammals). Elimination of these bacteria is associated with improved health outcomes including fewer dyspeptic symptoms, reduced peptic ulcer récurrence and rebleeding, reduced risk of gastric cancer, etc. A more detailed discussion of eradicating H. pylori and its impact on gastrointestinal illness may be found at: www.informahealthcare.com. Expert Opin. Drug Saf. (2008) 7(3).
In order to exhibit this anti-infective activity, the compounds need to be administered in a therapeutically effective amount. A therapeutically effective amount is meant to describe a sufficient quantity of the compound to treat the infection, at a reasonable benefit/risk ratio applicable to any such medical treatment. It will be understood, however, that the attending physician, within the scope of sound medical judgment, will décidé the total daily dosage of the compound. The spécifie therapeutically effective dose level for any particular patient will dépend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the spécifie compound employed; the spécifie composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excrétion of the spécifie compound employed; the duration of the treatment; drugs used in combination or coincidental with the spécifie compound employed; and like factors well known in the medical arts. As a general guideline however, the total daily dose will typically range from about 0.1mg/kg/day to about
5000mg/kg/day in single or in divided doses. Typically, dosages for humans will range from about 10 mg to about 3000 mg per day, in a single or multiple doses.
Any route typically used to treat infectious illnesses, including oral, parentéral, topical, rectal, transmucosal, and intestinal, can be used to administer the compounds. Parentéral administrations include injections to generate a systemic effect or injections directly into to the afflicted area. Examples of parentéral administrations are subcutaneous, intravenous, intramuscular, intradermal, intrathecal, and intraocular, intranasal, intravetricular injections or infusions techniques. Topical administrations include the treatment of areas readily accessible by local application, such as, for example, eyes, ears including external and middle ear infections, vaginal, open wound, skin including the surface skin and the underneath dermal structures, or lower intestinal tract. Transmucosal administration includes nasal aérosol or inhalation applications. Formulations
Compounds of the invention can be formulated for administration in any way for use in human or veterinary medicine, by analogy with other bioactive agents such as antibiotics. Such methods are known in the art and are summarized below.
The composition can be formulated for administration by any route known in the art, such as subdermal, by-inhalation, oral, topical or parentéral. The compositions may be in any form known in the art, including but not limited to tablets, capsules, powders, granules, lozenges, creams or liquid préparations, such as oral or stérile parentéral solutions or suspensions.
The topical formulations of the présent invention can be presented as, for instance, ointments, creams or lotions, ophthalmic ointments/drops and otic drops, impregnated dressings and aérosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug pénétration and émollients, etc. Such topical formulations may also contain conventional carriers, such as cream or ointment bases and éthanol or oleyl alcohol for lotions. Such carriers may be présent, for example, from about 1% up to about 98% of the formulation.
Tablets and capsules for oral administration may be in unit dose présentation form, and may contain conventional excipients such as binding agents, for example acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnésium stéarate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid préparations may be in the form of, for example, aqueous or oily suspensions, solutions, émulsions, syrups or élixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid préparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stéarate gel or hydrogenated edible fats, emulsifyîng agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerin, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.
For parentéral administration, fluid unit dosage forms are prepared utilizing the compound and a stérile vehicle, water being typical. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle or other suitable solvent. In preparing solutions, the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parentéral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the stérile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The compositions may contain, for example, from about 0.1 % by weight, to about 100% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will contain, for example, from about 0.5-1000 mg of the active ingrédient. The dosage as employed for adult human treatment will range, for example, from about 10 to 3000 mg per day, depending on the route and frequency of administration.
If desired, the compounds of the invention may be administered in combination with one or more additional antibacterial agents (“the additional active agent”). Such use of compounds of the invention in combination with an additional active agent may be for simultaneous, separate or sequential use.
The Examples and préparations provided below further illustrate and exemplify the compounds of the présent invention and methods of preparing such compounds. It is to be understood that the scope of the présent invention is not limited in any way by the scope of the following Examples and préparations. In the following Examples molécules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molécules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
EXAMPLES
Experimental Procedures
Experiments were generally carried out under an inert atmosphère (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate (generally Sure-Seal™ products from the Aldrich Chemical Company, Milwaukee, Wisconsin). Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS) or atmospheric pressure chemical ionization (APCI). Chemical shifts for nuclear magnetic résonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed. Melting points are uncorrected. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989®, utilizing chemical ionization (ammonium), ora Fisons (or Micro Mass) Atmospheric Pressure Chemical Ionization (APCI) platform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient température refers to 20-25°C.
For synthèses referencing procedures in other Examples, reaction conditions (length of reaction and température) may vary. In general, reactions were followed by thin layer chromatography or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluents/gradients were chosen to provide appropriate R(s or rétention times.
In the discussion above and in the Examples below, the foliowing abbreviations hâve the foliowing meanings. If an abbreviation is not defined, it has its generally accepted meaning.
Ac | = | acetate | |
5 | ACN | = | acetonitrile |
AC3O | acetic anhydride | ||
APCI | = | atmospheric pressure chemîcal ionization | |
Aq. | = | aqueous | |
9-BBN | = | 9-Borabicyclo[3.3.1]nonane | |
10 | bd | = | broad doublet |
bm | = | broad multiplet | |
bs | = | broad singlet | |
BOC | = | tert-butoxycarbonyl | |
°C | = | degrees celsius | |
15 | CBZ | = | benzyloxycarbonyl |
CDI | = | 1,1 ’-carbonyldiimidazole | |
CDMT | = | 2-chloro-4,6-dimethoxy-1,3,5-triazine | |
cm | = | centimeter | |
d | = | doublet | |
20 | DCC | = | 1,3-dicyclohexylcarbodiimide |
DCM | = | dichloromethane | |
dd | = | doublet of doublets | |
ddd | = | doublet of doublets of doublets | |
DIAD | = | diisopropyl azodicarboxylate | |
25 | DME | = | dimethyl ether |
DMF | = | dimethylformamide | |
DMA | = | dimethylacetamîde | |
DMAP | = | 4-dimethylaminopyridine | |
DMSO | = | dimethyl sulfoxide | |
30 | dq | = | doublet of quartets |
dt | = | doublet of triplets | |
EDCI | = | 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide | |
eq. | = | équivalents | |
EtO | = | ethoxy | |
35 | Et2O | = | diethyl ether |
16551 24 | |
EtOAc | ethyl acetate |
g GCMS | grams gas chromatography mass spectromety |
h 1H | hours proton |
HATU | (2-(7-aza-1 H-benzotriazole-1 -yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) |
HCl | hydrochloric acid |
H2N-OTHP = HOBT | 0-tetrahydro-2H-pyran-2-yl-hydroxylamine Hydroxybenzotriazole |
HPLC | high pressure liquid chromatography |
Hz = | hertz |
IPA | isopropanol |
J | coupling constant |
KOAc | potassium acetate |
K3PO4 | potassium phosphate |
L | liter |
LCMS | liquid chromatography mass spectrometry |
LDA | lithium diisopropylamide |
LG | leaving group |
LiHMDS | lithium hexamethyldisilazide/ lithium bis(trimethylsilyl)amide |
m = | multiplet |
M | molar |
M% | mole percent |
max = | maximum |
mCPBA | meta-chloroperbenzoic acid |
MeOH | methanol |
meq = MeTHF | milliequivalent 2-methyltetrahydrofuran |
mg MgSO4 MHz | milligram magnésium sulfate mégahertz |
min | minutes |
mL | milliliter |
mm = | millimeter |
mmol | = | millimole |
MS | = | mass spectrometry |
MTBE | = | methyl tert-butyl ether |
m/z | = | mass to charge ratio |
N | = | normality |
NaHCO3 | = | sodium bicarbonate |
Na2SC>4 | = | sodium sulfate |
NH4CI | = | ammonium chloride |
NMM | = | A/-methylmorpholine |
NMP | = | 1 -methyl-2-pyrrolidinone |
NMR | = | nuclear magnetic résonance |
Pd | = | palladium |
Pd EnCat™ | = | palladium acetate and BINAP, microencapsulated in polyurea matrix 0.39mmol/g Pd loading BINAP 0.25, Pd 1.0 |
Pd(dppf)CI2 | = | bis(diphenylphosphino)ferrocenepalladium(ll) chloride Pd(dppf)CI2 dichloromethane complex |
Pd(PPh3)4 | = | tetrakîs(triphenylphosphine)palladium(0) |
ppt | = | precipitate |
p-TLC | = | préparative thin layer chromatography |
PyBop | — | benzotriazole-l-yl-oxy-trispyrrolidinophosphonium hexafluorophosphate |
q | - | quartet |
Rf | = | rétention factor |
rt | = | room température |
s | = | singlet |
sat. | = | saturated |
tor tr | triplet | |
TBAB | = | tetrabutylammoinum bromide |
TBS | s | tert-butyldimethylsilyl |
TFA | = | trifluoroacetic acid |
THF | = | tetrahydrofuran |
THP | = | tetrahyropyranyl |
TLC | = | thin layer chromatography |
TMS | = | trimethylsilyl |
TPP | = | triphenylphosphine |
ΤΡΡΟ pL triphenylphosphine oxide microliter
PREPARATION OF STARTING MATERIALS
Préparation 1
Synthesis ofTemplate 1 (Tl): Ethvl 4-bromo-2-methvl-2-(methvlsulfonvl)butanoate and individual enantiomers (R) and (S).
MeOzS,
Step A)
Ethyl 2-(methylsuifonvl)Dropanoate
Sodium methanesulfinate (103 g, 937 mmol) was combined with ethyl 2chloropropionate (109 g, 892 mmol) in éthanol (350 mL) in a 500 mL one neck round bottom flask. The reaction was heated to 77 °C for 20 h, and then allowed to cool to room température. The solids were removed by filtration through celite, and the filter pad was washed with éthanol. The combined filtrâtes were concentrated in vacuo. The crude product was suspended in diethyl ether (250 mL), and solids were removed by filtration. The filtrate was concentrated in vacuo to afford the title compound as a pale yellow oil (51 g, 73%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.32 (t, J=7.05 Hz, 3 H) 1.67 (d, J=7.47 Hz, 3 H) 3.05 (s, 3 H) 3.83 - 3.92 (m, 1 H) 4.18 - 4.37 (m, 2 H).
Step B) Ethyl 4-bromo-2-methvl-2-(methvlsulfonvl) butanoate
Sodium hydride (60% dispersion in minerai oil, 2.33 g, 58.3 mmol) was washed with hexanes (2x10 mL) in a 100 mLtwo neck round bottom flask under nitrogen then suspended in DMF (30 mL). The suspension was treated dropwise with ethyl 2(methylsulfonyl)propanoate (10.0 g, 55.49 mmol) in DMF (10 mL). The mixture was stirred 30 min at RT, cooled to 0 °C, and treated drop-wise with 1,2-dibromoethane (5.17 mL, 58.8). The mixture was allowed to warm to room température while stirring overnight. The mixture was quenched with saturated aq ammonium chloride (100 mL) and extracted with diethyl ether (4x50 mL). Combined organics were washed with 50% saturated sodium chloride (4x50 mL), dried (MgSO4), and concentrated in vacuo. Crude material was purified via silica chromatography (350 g, 230-400 mesh) and an eluent of EtOAc in hexanes (10-20%) to afford the title compound as a pale yellow oil
(7.9 g, 50%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.33 (t, J=7.05 Hz, 3 H)
1.64 (s, 3 H) 2.49 - 2.59 (m, 1 H) 2.78 (ddd, J=13.89, 10.16, 6.64 Hz, 1 H) 3.05 (s, 3 H)
3.33 - 3.41 (m, 1 H) 3.46 - 3.54 (m, 1 H) 4.22 - 4.37 (m, 2 H).
Step C) Chiral séparation of Ethvl 4-bromo-2-methyl-2-(methvlsulfonvl)butanoate Crude ethyl 4-bromo-2-methyl-2-(methylsulfonyl)butanoate (1.82 kg) was purified via flash chromatography using an LP-600 column and toluene as the eluent to afford pure ethyl 4-bromo-2-methyl-2-(methylsulfonyl)butanoate (1.63 kg). The purified material was dissolved in éthanol (75 g/L) and resolved via chiral column chromatography (conditions listed in Table 1) on MCC-2 to afford enantiomer #1 (738.4 g, rt = 4.719 min, [a]58920 - +14.1°) at 99% ee and enantiomer #2 (763.8 g, rt = 4.040 min) at 95% ee. Purity of the enantiomers was determined via chiral HPLC, 4.6x250 mm Chiralpak AD, 10μ column, 215 nm wavelength, mobile phase: éthanol, isocratic elution at 1 mL/min at ambient température.
Table 1
Stationary Phase | ChiralPak AD, 20μ |
Column Dimension/Temp | 5x10cm/30 °C |
Mobile Phase | 100% éthanol |
Feed Concentration | 75 g/L in mobile phase |
Feed Rate | 4.0 mL/min |
Eluent Rate | 90.5 mL/min |
Raffinate Rate | 35.6 mL/min |
Extract Rate | 58.9 mL/min |
Recycling Rate | 262 mL/min |
Period Time | 1.0 min |
Enantiomer #1 was determined to be ethyl (2R)-4-bromo-2-methyl-2(methylsulfonyl)butanoate, Template 1 (T1).
Préparation 2
Scheme B illustrâtes the préparation of ethyl (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (T2) and (2R)-4-(5-fluoro-4iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methyisulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide (T3) and the corresponding racemic and diastereomeric mixtures ethyl 4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate
(T4) and 4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (T5).
il
III
T2
Synthesis ofTemplate 3 (T3): (2R)-4-i5-Fluoro-4-iodo-2-oxopyridin-1(2H)-vlÎ-2methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-Dvran-2-yloxv)butanamide
Step A) Compound III: 5-Fluoro-4-iodopyridin-2(1H)-one
Concentrated HCl (50 mL) was added to a mixture of 2,5-difluoro-4-iodopyridine (2.0 g, 8.3 mmol) in 1,4-dioxane (350 mL) and water (100 mL). The mixture was heated to reflux and stirred at this température overnight. The reaction was concentrated to dryness and the residue was triturated in water (20 ml_).The solids were collected via filtration and washed with water (2x30 mL) and hexanes (3x30 mL). The solid was dried under vacuum to afford the title compound as a yellow solid (1.0 g, 50%). MS (LCMS) m/z 240.0 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 7.02 (d, J=5.07 Hz, 1 H) 7.68 (d, J=2.34 Hz, 1 H) 11.50 (br. s., 1 H).
Step B) Template 2 (T2): Ethyl (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-vl)-2methvl-2- (methylsu If onyl) butanoate
Césium carbonate (1.77 g, 5.44 mmol) was added to a suspension of 5-fluoro-4iodopyridin-2(1 H)-one (1.00 g, 4.2 mmol) and ethyl (2R)-4-bromo-2-methyl-2(methylsulfonyl)butanoate (1.56 g, 5.44 mmol) in anhydrous THF (45 mL). The reaction was heated to 70 °C and stirred at this température overnight. The reaction was quenched with water (100 mL) and extracted with EtOAc (2x100 mL). The combined organics were washed with brine (100 mL), dried (MgSO4), filtered, and concentrated. The crude product was purified via flash chromatography using a Varian SF15-24g column and an eluent of EtOAc in n-heptane (30-80%) to afford the title compound as a yellow residue (691 mg, 37%). MS (LCMS) m/z 446.0 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36 (t, 3 H) 1.75 (s, 3 H) 2.37 - 2.57 (m, 2 H) 3.10 (s, 3 H) 3.83 - 4.02 (m, 1 H) 4.16 - 4.37 (m, 3 H) 7.15 (d, 1 H) 7.20 (d, J=3.32 Hz, 1 H).
Step C) Compound IV: (2R)-4-(5-Fluoro-4-iodo-2-oxoDvridin-1 (2H)-vl)-2-methyl-2(methylsulfonyl)butanoic acid
Potassium hydroxide (669 mg, 7.7 mmol) was added to a solution of ethyl (2R)-4-(5fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (691 mg, 1.55 mmol) in 2-methyltetrahydrofuran:water (2:1 22.5 mL) and the solution was stirred at 70°C for 2 h. The reaction was diluted with 1 N aq NaOH (50 mL). The organics were separated and the aqueous layer was washed with EtOAc (2x50 mL), and acidified to a pH of 3 using 3 M aqueous HCl. The aqueous layer was extracted with EtOAc (3x60 mL), dried (MgSO4), filtered and concentrated to afford a yellow-white solid (290 mg, 44.8%). MS (LCMS) m/z 418.0. 1H NMR (400 MHz, DMSO-cf6) δ ppm 1.53 (s, 3 H) 2.08 - 2.20 (m, 1 H) 2.36 - 2.48 (m, 1 H) 3.13 (s, 3 H) 3.79 - 4.02 (m, 2 H) 7.03 (d, J=6.05 Hz, 1 H) 7.96 (d, J=4.29 Hz, 1 H) 13.82 (br. s„ 1 H).
Step D) Template 3 (T3): (2R)-4-(5-Fluoro-4-iodo-2-oxoDvridin-1 (2H)-vl)-2-methyl· 2-(methvlsulfonyl)-N-(tetrahvdro-2H-pyran-2-vloxy)butanamide
N-Methylmorpholine (120 uL, 1.1 mmol) was added to a solution of CDMT (178 mg,
1.01 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2(methylsulfonyl)butanoic acid (280 mg, 0.762 mmol) in 2-methyltetrahydrofuran (7.60 mL) and the reaction was stirred at rt for 1 h. THP-hydroxylamine (117 mg, 1.00 mmol) was added to the reaction and the reaction was stirred overnight at rt. The reaction was quenched with water (50 mL) and the aqueous layer was extracted with EtOAc (3x50 mL). The combined organics were washed with brine (50 mL), dried (MgSO4), filtered,
X
and concentrated to afford the title compound as an off-white solid (399.8 mg) MS (LCMS) 515.0 (M-1).
Example 1 (2R)-4-f5-Fluoro-2-oxo-4-r4-(2H-tetrazol-2-yl)phenvllDvridin-1(2H)-yl}-2-methyl-2(methvlsulfonvl)-N-(tetrahvdro-2H-pyran-2-vloxv)butanamide
NHOH
Step A) 2-r4-(4,4.5,5-Tetramethvl-1,3.2-dioxaborolan-2-vl)Dhenyl1-2H-tetrazole Pd(dppf)CI2 (70.2 mg, 0.10 mmol) was added to a suspension of 4,4,4^,5,5,5^5octamethyl-2,2'-bi-1,3,2-dioxaborolane (291 mg, 1.15 mmol), 2-(4-bromophenyl)-2Htetrazole (215 mg, 0.96 mmol), and potassium acetate (191 mg, 1.91 mmol) in 1,4dioxane (4.78 mL). The resulting suspension was heated to 80 °C and stirred at this température overnight. The reaction was allowed to cool, filtered through celite, and concentrated in vacuo. The crude product was purified via flash chromatography using a 40g silica gel Redisep column and an eluent of EtOAc in n-heptane (0-50%) to afford the title compound as a light yellow solid (258 mg, 99%). MS (LCMS) m/z 273.2 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36 (s, 12 H) 7.66 - 7.73 (m, 2 H) 7.96 8.02 (m, 2 H) 9.01 (s, 1 H).
Step B) (2R)-445-Fluoro-2-oxo-444-(2H-Îetrazol-2-vl)phenvllpyridin-1(2H)-vl}-2methvl“2-(methylsulfonyl)-N-itetrahydro-2H-pyran-2-vloxv)butanamide
Pd EnCat™ (317 mg, 0.10 mmol) was added to a mixture of potassium carbonate (393 mg, 2.84 mmol), 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-tetrazole (258.4 mg, 0.95 mmol), and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (490 mg, 0.95 mmol), T3, in 1,4-dioxane:water (4:1,10 mL). The réaction was heated to 80 °C and stirred at this température overnight. The reaction was filtered through celite, and the filter pad was washed with methanol (250 mL). The combined filtrâtes were concentrated under reduced pressure, and the resulting crude material was purified via flash chromatography using an eluent of EtOAc in n-heptane (20-100%) and methanol in y
EtOAc (0-10%) to afford the title compound as a light tan solid (500 mg, 98%). MS (LCMS) m/z 534.4 (M-1).O
Step C) (2R)-4-f5-Fluoro-2-oxo-4-r4-(2H-tetrazol-2-vl)ohenyl1ovridin-1(2H)-vl}-Nhydroxy-2-methvl-2-(methvlsulfonvl)butanamide
Hydrochloric acid (4.0 M in 1,4-dioxane, 1.7 mL, 6.63 mmol) was added to a solution of (2Fi)-4-{5-flijoro-2-oxo-4-[4-(2H-Îetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (500 mg, 0.94 mmol) in dichloromethane'.methanol (5:1,6 mL) at room température. The reaction was stirred for 1 h then was concentrated under reduced pressure affording a residue, which was triturated in diethyl ether:pentane (1:1) overnight. The solid was collected via filtration and dried under reduced pressure to afford the title compound as a solid (340 mg, 76%). MS (LCMS) m/z 451.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.56 (s, 3 H) 2.09 - 2.21 (m, 1 H) 2.42 - 2.45 (m, 1 H) 3.09 (s, 3 H) 3.78 (m, J=11.80, 11.80, 5.20 Hz, 1 H) 3.97 - 4.10 (m, 1 H) 6.63 (d, J=7.61 Hz, 1 H) 7.84 (dd, J=8.68, 1.66 Hz, 2 H) 8.00-8.15 (m, 3 H) 10.16 (s, 1 H) 11.08 (br. s., 1 H).
Example 2
2R)-4-[5-Fluoro-4-(2-fluoro-3-methvlphenvl)-2-oxopvridin-1(2H)-vll-N-hydroxv-2-methvl2-(methvlsulfonvl)butanamide
NHOH
Step A) (2R)-4-f5-Fluoro-4-(2“fluoro-3-methylphenvn-2-oxopyridin-1(2H)-vn-2methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2-vloxy)butanamide
The title compound (470 mg, 48.7%) was obtained as a solid from (2-fluoro-3methylphenyl)boronic acid (388 mg, 2.52 mmol) using a procedure analogous to thaï described for (2R)-4-(5-Îluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 499 (M + 1 ). 1H NMR (400 MHz, METHANOL-t/4) δ ppm 1.49 -1.57 (m, 3 H) 1.59 (d, J = 3.71 Hz, 3 H) 1.64 - 1.74 (m, 3 H) 2.16 - 2.26 (m, 1 H) 2.27 - 2.31 (m, 3 H) 3.10 (d, J = 5.66 Hz, 3 H) 3.31 (s, 1 H) 3.47 - 3.55 (m, 1 H) 3.72 - 3.88 (m, 1 H)
3.90 (s, 1 H) 3.99 - 4.15 (m, 2 H) 4.94 - 4.99 (m, 1 H) 6.47 (d, J = 7.22 Hz, 1 H) 7.20 7.26 (m, 1 H) 7.26 - 7.32 (m, 1 H) 7.40 - 7.47 (m, 1 H) 8.01 (dd, J = 11.90, 5.85 Hz, 1 H)
11.52 (d, J = 3.51 Hz, 1 H).
Step B) (2R)-4-r5-Fluoro-4-(2-fluoro-3-methvlDhenvD-2-oxODyridin-1(2H)-vll-Nhvdroxy-2-methvl-2-(methvlsulfonyl)butanamide
The title compound (185 mg, 46.6%) was obtained as a solid from (2R)-4-[5-fluoro-4-(2fluoro-3-methylphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide (477 mg, 0.957 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}~ N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 1, Step C. MS (LCMS) m/z 415 (M + 1) 1H NMR (400 MHz, DMSO-de) δ ppm 1.54 (s, 3 H) 2.13 (ddd, J = 13.03, 11.07, 4.78 Hz, 1 H) 2.40 - 2.45 (m, 1 H) 3.08 (s, 3 H) 3.76 (td, J = 11.81,5.07 Hz, 1 H) 4.02 (td, J = 11.85, 5.17 Hz, 1 H) 6.53 (d, J = 7.61 Hz, 1 H) 7.45 - 7.64 (m, 4 H) 8.02 (d, J = 6.63 Hz, 1 H) 9.11 9.26 (m, 1 H) 11.00 - 11.13 (m, 1 H).
Example 3 (2R)-4-r4-(4-Chlorophenvl)-5-fluoro-2-oxopvridin-1(2H)-vll-N-hvdroxv-2-methyl-2(methvlsulfonvl)butanamide ci
Step A) (2R)-4-r4-(4-Chlorophenvl)-5-fluoro-2-oxopyridin-1 (2H)-vll-2-methvl-2(methvlsuifonvl)-N-(tetrahvdro-2H-pvran-2-vloxv)butanamide
The title compound (870 mg, 59.8%) was obtained as a solid from (4chlorophenyl)boronic acid (610 mg, 4.36 mmol) using a procedure analogous to that described for (2R)-445'fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 502 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 1.17 -1.28 (m, 2 H) 1.45 -1.53 (m, 3 H) 1.56 (d, J = 3.71 Hz, 3 H) 1.60 -1.72 (m, 3 H) 2.08 - 2.23 (m, 1 H)3.07 (d, J = 6.44 Hz, 3 H) 3.48 (d, J = 11.12 Hz, 1 H) 3.67 - 3.85 (m, 1 H) 3.96 - 4.12 (m, 2 H) 4.88 - 4.97 (m, 1 H) 6.53 (d, J = 7.61 Hz, 1 H) 7.50 - 7.62 (m, 3 H) 8.00 (dd, 7=13.07, 6.63 Hz, 1 H) 11.50 (s, 1 H).
x/
Step B) (2R)-4-[4-(4-Chloroohenvl)-5-fluoro-2-oxopyridin-1(2H)-vn-N-hydroxv-2methvl-2-(methylsulfonyl)butanamide
The title compound (340 mg, 47.0%) was obtained as a solid from (2R)-4-[4-(4chlorophenyl)-5-fluoro-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide (870 mg, 1.74 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 1, Step C. MS (LCMS) m/z 417 (M + 1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.54 (s, 3 H) 2.13 (ddd, J = 13.12, 11.27, 5.07 Hz, 1 H) 2.37 - 2.45 (m, 1 H) 3.08 (s, 3 H) 3.76 (td, J = 11.90, 5.07 Hz, 1 H) 3.93 - 4.12 (m, 1 H) 6.53 (d, J = 7.61 Hz, 1 H) 7.49 - 7.66 (m, 4 H) 8.02 (d, J = 6.63 Hz, 1 H) 9.21 (s, 1 H) 10.95-11.17 (m, 1 H).
Example 4 (2R)-4-r5-Fluoro-4-(2-fluorophenyl)-2-oxopyridin-1(2H)-vH-N-hvdroxv-2-methvl-2(methylsulfonvl)butanamide
Step A) (2R)-4-f5-Fluoro-4-(2-fluoroohenvl)-2-oxoovridin-1 (2H)-yll-2-methyl-2(methylsulfonvO-N-(tetrahvdro-2H-pvran-2-vloxy)butanamide
The title compound (230 mg, 81.7%) was obtained as a solid from (2fluorophenyl)boronic acid (122 mg, 0.871 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 485 (M+1). 1H NMR (400 MHz, DMS0-d6) δ ppm 1.21-1.28 (m, 2 H) 1.48 -1.56 (m, 3 H) 1.58 (d, J = 3.71 Hz, 3 H) 1.63 -1.74 (m, 3 H) 2.15 - 2.26 (m, 1 H) 3.10 (d, J = 5.66 Hz, 3 H) 3.34 (br. s., 1 H) 3.51 (d, J = 10.73 Hz, 1 H) 3.71 - 3.88 (m, 1 H) 3.99 - 4.15 (m, 2 H) 4.94 - 4.99 (m, 1 H) 6.50 (d, J = 7.02 Hz, 1 H) 7.31 - 7.40 (m, 2 H) 7.46 - 7.53 (m, 1 H) 7.56 (m, J=7.76, 7.76, 5.56, 1.76 Hz, 1 H) 8.01 (dd, J = 11.90, 5.85 Hz, 1 H) 11.51 (d, J = 3.32 Hz, 1 H).
Step B) (2R)-4-[5-Fluoro-4-(2-fluorophenvl)-2-oxopvridin-1(2H)-vll-N-hvdroxy-2methyl-2-(methylsulfonyl)butanamide
The title compound (68 mg, 36.0%) was obtained as a solid from (2R)-4-[5-fluoro-4-(2fluorophenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (230 mg, 0.475 mmol) using a procedure analogous to that described for (2R)-4-[5-Îluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide,-Example 1, Step C. MS (LCMS) m/z 401 (M+1). 1H NMR (400 MHz, DMSO-d6) Ô ppm 1.58 (s, 3 H) 2.18 (td, J = 12.15, 4.98 Hz, 1 H) 2.47 (m, 1 H) 3.12 (s, 3 H) 3.79 (td, J = 11.85, 5.17 Hz, 1 H) 4.07 (td, J = 11.81, 4.68 Hz, 1 H) 6.50 (d, J = 7.02 Hz, 1 H) 7.30 - 7.44 (m, 2 H) 7.46 - 7.64 (m, 2 H) 8.04 (d, J = 6.05 Hz, 1 H) 9.20 - 9.32 (m, 1 H) 10.99 -11.17 (m, 1 H).
Example 5 (2R)-4-r4-(2.3-Dihvdro-1-benzofuran-5-yl)-5-fluoro-2-oxopyridin-1(2H)-vll-N-hvdroxv-2methvl-2-(methvlsulfonvl)butanamide
ΝΗΟΗ
Step A) (2R)-4-f4-(2,3-Dihvdro-1-benzofuran-5-vl)-5-fluoro-2-oxopyridin-1 (2H)-vl12-methvl-2-(methylsulfonyl)-N-(tetrahvdro-2H-pyran-2-vloxy)butanamide
The title compound (198 mg, 61.0%) was obtained as a solid from 2,3-dihydro-l benzofuran-5-ylboronic acid (153 mg, 0.871 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide,-Example 1, Step B. MS (LCMS) m/z 509 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.46 -1.56 (m, 2 H) 1.58 (d, J = 4.10 Hz, 3 H) 1.63-1.76 (m, 3 H) 2.12-2.27 (m, 1 H) 2.40-2.48 (m, 1 H) 3.10 (d, J = 6.05 Hz, 3 H) 3.23 (t, J=8.78 Hz, 2 H) 3.35 (br. s, 1 H) 3.51 (d, J = 12.10 Hz, 1 H) 3.67 - 3.88 (m, 1 H) 3.98 - 4.15 (m, 2 H) 4.59 (t, J = 8.78 Hz, 2 H) 4.96 (d, J = 2.73 Hz, 1 H) 6.46 (d, J = 7.81 Hz, 1 H) 6.81 - 6.92 (m, 1 H) 7.28 - 7.39 (m, 1 H) 7.47 (s, 1 H) 7.96 (dd, J=12.78, 6.73 Hz, 1 H) 11.55 (s, 1 H).
Step B) (2R)-4-r4-(2.3-Dihvdro-1-benzofuran-5-vl)-5-fluoro-2-oxopvridin-1 (2H)-vl1N-hvdroxv-2-methvl-2-(methvlsulfonvl)butanamide
The title compound (165 mg, 53.0%) was obtained as a solid from (2R)-4-[4-(2,3dihydro-1-benzofuran-5-yl)-5-fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)16551
N-(tetrahydro-2H-pyran-2-yloxy)butanamide (198 mg, 0.389 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2yl)phenyl]pyridin-1 (2H)-ylJ-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,-Example 1, Step C. MS (LCMS) m/z 425 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 1.57 (s, 3 H) 2.16 (dd, J = 5.56, 1.07 Hz, 1 H) 2.36 - 2.49 (m, 1 H) 3.11 (s, 3 H) 3.23 (t, J = 8.59 Hz, 2 H) 3.66 - 3.86 (m, 1 H) 4.04 (dd, J = 6.15, 0.88 Hz, 1 H) 4.59 (t, J = 8.78 Hz, 2 H)
6.45 (d, J = 7.81 Hz, 1 H) 6.87 (d, J = 8.39 Hz, 1 H) 7.34 (dd, J = 8.20, 1.95 Hz, 1 H)
7.46 (s, 1 H) 7.98 (d, J = 6.83 Hz, 1 H) 9.15 - 9.31 (m, 1 H) 11.01 -11.19 (m, 1 H).
Example 6 (2R)-4-r4-(3,4-DifluoroDhenvl)-5-fluoro-2-oxoDyridin-1 (2H)-vll-N-hydroxy-2-methyl-2(methylsulfonvl)butanamide
NHOH
Step A) (2R)-4-r4-(3.4-DifluoroDhenvlÎ-5-fluoro-2-oxoDvridin-1(2H)-vll-2methyl-2(methvlsulfonyl)-N-(tetrahydro-2H-Dyran-2-vloxv)butanamide
The title compound (760 mg, 52.1%) was obtained as a solid from (3,4difluorophenyl)boronic acid (596 mg, 3.78 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 503 (M+1).
Step B) (2R)-4-r4~(3,4-Difluorophenyl)-5-fluoro-2-oxoDvridin-1(2H)-yri-N-hvdroxy-2methvl-2-(methvlsulfonyl)butanamide
The title compound (350 mg, 55.0%) was obtained as a solid from (2R)-4-[4-(3,4difluorophenyl)-5-fluoro-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (760 mg, 1.51 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 1, Step C. MS (LCMS) m/z 419 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 1.57 (s, 3 H) 2.06 - 2.25 (m, 1 H) 2.38 - 2.48 (m, 1 H) 3.11 (s, 3 H) 3.68 - 3.87 (m, 1 H) 3.96 16551
4.18 (m, 1 H) 6.60 (d, J = 7.61 Hz, 1 H) 7.37 - 7.52 (m, 1 H) 7.52 - 7.65 (m, 1 H) 7.65
7.84 (m, 1 H) 8.06 (d, J = 6.63 Hz, 1 H) 9.13 - 9.39 (m, 1 H) 11.08 (s, 1 H).
Example 7 (2R)-4-{5-Fluoro-2-oxo-4-r4-(2,2,2-trifluoroethoxv)Dhenvr|pvridin-1 (2H)-vll-N-hvdroxv-2methvl-2“(methylsulfonvl)butanamide
NHOH
Step A) (2R)-4-f5-Fluoro-2-oxo-4-f4-(2,2,2-trifluoroethoxv)phenvllpyridin-1(2H)-vl}2-meÎhvl-2-(methylsulfonvl)-N-(tetrahvdro-2H-pyran-2-vloxy)butanamide
The title compound (860 mg, 78.6%) was obtained as a solid from [4-(2,2,2trifluoroethoxy)phenyl]boronic acid (554 mg, 2.52 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)yl}-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 565 (M+1).
Step B) (2R)-445-FÎuoro-2-oxo-4-[4-(2.2.2-trifluoroethoxv)phenvl]pvridin-1(2H)-vl)N-hvdroxv-2-meÎhyl-2-(methvlsulfonvl)butanamide
The title compound (310 mg, 42.3%) was obtained as a solid from (2R)-4-(5-fluoro-2oxo-4-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (860 mg, 1.52 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-tetrazol-2yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamideI Example 1, Step C. MS (LCMS) m/z 419 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (s, 3 H) 2.06 - 2.22 (m, 1 H) 2.37 - 2.45 (m, 1 H) 3.08 (s, 3 H) 3.74 (td, J = 11.76, 4.98 Hz, 1 H) 3.93 - 4.10 (m, 1 H) 4.81 (q, J = 8.98 Hz, 2 H) 6.49 (d, J = 7.61 Hz, 1 H) 7.16 (d, J = 8.98 Hz, 2 H) 7.49 - 7.62 (m, 2 H) 7.98 (d, J = 6.63 Hz, 1 H) 9.21 (br. s., 1 H) 11.07 (s,
Example 8 (2RÎ-4-f4-(3.4-Dihydro-2H-chromen-6-yl)-5-Îluoro-2-oxopyridin-1 (2H)-vl1-N-hvdroxv-2methyl-2-(methvlsulfonvl)butanamide
NHOH
Step A) (2R)-4-r4-(3.4-Dihvdro-2H-chromen-6-yl)-5-fluoro-2-oxoDvridin-1 (2H)-yl1-2methvl-2-(methylsulfonvl)-N-(tetrahydro-2H-Dvran-2-yloxv)butanamide
The title compound (500 mg, 82.3%) was obtained as a solid from 3,4-dihydro-2Hchromen-6-ylboronic acid (228 mg, 1.28 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridÎn-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 523 (M+1).
Step B) (2R)-444-(3,4-Dihvdro-2H-chromen-6-yl)-5-fluoro-2-oxopyridin-1(2H)-yllN-hvdroxy-2-methyl-2-(methvlsulfonvl)butanamide
The title compound (240 mg, 57.1%) was obtained as a solid from (2R)-4-(4-(3,4dihydro-2H-chromen-6-yl)-5-fluoro-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (500 mg, 0.957 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-tetrazol-2yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(meÎhylsulfonyl)butanamide, Example 1, Step C. MS (LCMS) m/z 439 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.52 (s, 3 H) 1.83-1.97 (m, 2 H) 2.12 (ddd, J = 13.03, 11.27, 5.17 Hz, 1 H) 2.34-2.44 (m, 1 H) 2.75 (t, J = 6.34 Hz, 2 H) 3.07 (s, 3 H) 3.71 (td, 7= 11.76, 5.17 Hz, 1 H) 3.92-4.07 (m, 1 H) 4.08 - 4.20 (m, 2 H) 6.42 (d, J = 7.61 Hz, 1 H) 6.79 (d, J = 8.39 Hz, 1 H) 7.20 - 7.32 (m, 2 H) 7.94 (d, J = 6.83 Hz, 1 H) 9.20 (br. s., 1 H) 11.07 (s, 1 H).
Example 9 (2R)-4-{5-Fluoro-4-f4-(methvlthio)phenyl1-2-oxoDvridin-1 (2Η)-νΙΑΝ-Ι^Γθχν-2-ΓΤΐθΐΐΊνΙ-2(methylsulfonvDbutanamide
ΝΗΟΗ
Step A) Ethyl (2R)-4-(5-fluoro-4-[4-(methylthio)ohenyl1-2~oxoovridin-1 (2Η)-νΙΕ2methyl-2-(methvlsulfonvl)butanoate
1,4-Dioxane (10 ml) and 3 M aq K3PO4 (1.12 mL, 3.3 mmol) was added to a flask containing [4-(methyîthio)phenyl]boronic acid (0.283 g, 1.68 mmol), Pd(dppf)Cl2 (82 mg, 0.112 mmol) and ethyl (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2(methylsulfonyl)butanoate, T2, (500 mg, 1.12 mmol) that was previously flushed with nitrogen. The mixture was heated to 60 °C and stirred at this température for 1 h. The reaction mixture was diluted with EtOAc and washed with water. The organics were dried (MgSO4), filtered, and concentrated. The crude product was purified via flash chromatography on a 40 g silica column and an eluent of EtOAc in n-heptane (0-100%) to afford the title compound as a gum (492 mg, 99%). MS (LCMS) m/z 442.1 (M+1). 1H NMR (400 MHz, CHLOROFORM-7) δ ppm 1.17 -1.27 (m, 3 H) 1.74 (s, 3 H) 2.38 - 2.61 (m, 5 H) 3.09 (s, 3 H) 3.88 - 4.02 (m, 1 H) 4.17 - 4.32 (m, 3 H) 6.57 (d, 7=7.61 Hz, 1 H) 7.21 - 7.34 (m, 3 H) 7.37 - 7.48 (m, 2 H).
Step B) /2Η)-445-ΡΙυθΓθ-444-(πΊθίΐΊνΙϋΊΐο)ρΙ'ΐθπνΙΐ-2-οχορνπΡίη-1(2Η)-νΙΕ2-ΓηθίΐΊνΙ2-(methvlsulfonvl)butanoic acid
Lithium hydroxide monohydrate (165 mg, 6.68 mmol) was added to a solution of ethyl (2R)-4-{5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoate (0.492 g, 1.12mmol) in THF:water (1:1,14 mL) and the réaction was allowed to stir at rt for 18 h. The reaction mixture was acidified using 4 M aq HCl to afford a precipitate. The solid was collected via filtration and dried under vacuum to afford the title compound as a solid (339 mg, 73%). MS (LCMS) m/z 414.1 (M+1). 1H NMR (400 MHz, DMSO-de)Cô ppm 1.54 (s, 3 H) 2.17 (ddd, 7=13.42, 10.00, 5.07 Hz, 1 H) 2.41 - 2.45 (m, 1 H) 2.49 (s, 3 H), 3.14 (s, 3 H) 3.78 - 4.15 (m, 2 H) 6.46 (d, 7=7.81 Hz, 1 H) 7.28 - 7.39 (m, 2 H) 7.43 - 7.55 (m, 2 H) 8.01 (d, 7=6.83 Hz, 1 H).
Step C) (2RÎ-4-f5-Fluoro-4-[4-(meÎhylthio)phenvn-2-oxopyridin-1(2H)-vl}-2-methyl2-(methvlsulfonvl)-N-(tetrahydro-2H-pvran-2-vloxy)butanamide
/V,A/-Diisopropylethylamine (450 uL, 2.45 mmol), 0-(tetrahydro-2H-pyran-2yl)hydroxylamine (192 mg, 1.64 mmol) and HATU (447 mg, 1.23 mmol) were added to a solution of (2R)-4-{5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoic acid (339 mg, 0.82 mmol) in DMF (10 mL). The reaction was allowed to stir at rt for 18 h. The reaction mixture was diluted with EtOAc and washed with brine. The organics were dried (MgSO^, filtered and concentrated. The crude residue was purified via flash chromatography using a 40 g silica column and an eluent of EtOAc in n-heptane (0-100%) to afford the title compound (420 mg, 100%). MS (LCMS) m/z 511.4 (M-1).
Step D) (2R)-445-Fluoro-4-ί4-(meΐhvlthio)DhenyΠ-2-oxoDvridiπ-1(2H)-vll·Nhvdroxv-2-methyl-2-(methylsulfonvl)butanamide
Aqueous HCl (4 M, 3 mL) was added to a solution of 2R)-4-(5-fluoro-4-[4(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide (437 mg, 0.852 mmol) in THF (10 mL) and the reaction was allowed to stir at rt for 3 h. The reaction mixture was concentrated and then azeotroped with EtOAc and n-heptane several times to give the title compound as an off-white solid (233 mg, 64%). MS (LCMS) m/z 429.1 (M+1). 1H NMR (400 MHz, METHANOL-cQ δ ppm 1.69 (s, 3 H) 2.37 (ddd, J=13.51, 10.59, 5.17 Hz, 1 H) 2.51 (s, 3 H) 2.57 - 2.74 (m, 1 H) 2.82 (s, 3 H) 3.09 (s, 3 H) 3.97 (ddd, J=13.12, 10.59, 5.56 Hz, 1 H) 4.27 (ddd, J=13.03, 10.49, 5.17 Hz, 1 H) 6.68 (d, J=7.22 Hz, 1 H) 7.25 - 7.40 (m, 2 H) 7.47 - 7.59 (m, 2 H) 7.90 (d, J=6.05 Hz, 1 H).
Example 10 (2R)-4-[4-(4-EthoxyDhenvl)-5-fluoro-2-oxoDvridin-1(2H)-vl1-N-hydroxy-2-methvl-2(methvlsulfonyl)butanamide
Step A) Ethvl (2R)-4-(4-(4-ethoxvphenvl)-5-fluoro-2-oxopyridin-1 (2H)-yll-2-methvl2-(methylsulfonyl)butanoate
The title compound (320 mg, 64%) was obtained as a gum from (4ethoxyphenyl)boronic acid (280 mg, 1.68 mmol) using a procedure analogous to that
described for ethyl (2R)-4-{5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-2meÎhyl-2-(methylsulfonyl)butanoate, Example 9, Step A. MS (LCMS) m/z 440.3 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.22 (t, J=7.12 Hz, 3 H) 1.40 (t, J=7.02 Hz, 3 H) 1.73 (s, 3 H) 2.36 - 2.61 (m, 2 H) 3.09 (s, 3 H) 3.85 - 3.98 (m, 1 H) 4.07 (dd, J=14.93, 7.12 Hz, 2 H) 4.25 (m, 3 H) 6.51 - 6.58 (m, 1 H) 6.93 (d, J=8.98 Hz, 3 H) 7.22 -
7.31 (m, 1 H) 7.44 (d, J=7.02 Hz, 1 H).
Step B) (2R)-4-r4-(4-EthoxvDhenvl)-5-fluoro-2-oxopvridin-1(2H)-vl1-2-methvl-2(methvlsulfonvl)butanoic acid
Lithium hydroxide (108 mg, 4.37 mmol) was added to a solution of ethyl (2R)-4-[4-(4ethoxyphenyl)-5-fluoro-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanoate (320 mg, 0.728 mmol) in tetrahydrofuran:water (1:1, 20 mL) and the reaction was allowed to stir at rt until complété. The reaction mixture was acidified with 4 M aq HCl and extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated to afford the title compound as a solid (220 mg, 73%). MS (LCMS) m/z 412.2 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.26-1.40 (m, 3 H) 1.54 (s, 3 H) 2.07 - 2.26 (m, 1 H) 2.43 (d, J=6.24 Hz, 1 H) 3.14 (s, 3 H) 3.83 - 4.15 (m, 4 H) 6.42 (d, J=7.81 Hz, 1 H) 6.93 - 7.07 (m, 2 H) 7.50 (dd, J=8.68, 1.85 Hz, 2 H) 7.97 (d, J=6.83 Hz, 1 H).
Step C) (2R)-4-r4-(4-Ethoxyphenyl)-5-fluoro-2-oxoDyridin-1 (2H)-vl1-2-meÎhvl-2(methvlsulfonvl)-N-(tetrahydro-2H-pyran-2-vloxv)butanamide
The title compound (273 mg, 100%) was obtained from (2R)-4-[4-(4-ethoxyphenyl)-5fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanoic acid (220 mg, 0.535 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-4-[4(methylthio)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide, Example 9, Step C. MS (LCMS) m/z 509.4 (M+1).
Step D) (2R)-4-f4-(4-Ethoxvphenyl)-5-fluoro-2-oxopvridin-1(2H)-vll-N-hvdroxv-2methyl-2-(methylsulfonyl)butanamide
The title compound (205 mg, 83%) was obtained as a solid from (2R)-4-[4-(4ethoxyphenyl)-5-fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide (297 mg, 0.582 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-y IJ-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 9, Step D. MS (LCMS) m/z
427.2 (M+1). 1H NMR (400 MHz, METHANOL-cf4) δ ppm 1.40 (t, J=6.93 Hz, 3 H) 1.69 (s, 3 H) 2.28 - 2.42 (m, 1 H) 2.54 - 2.69 (m, 1 H) 3.09 (s, 3 H) 3.86 - 3.99 (m, 1 H) 4.09 (q, J=7.02 Hz, 2 H) 4.18 - 4.32 (m, 1 H) 6.60 (d, J=7.42 Hz, 1 H) 7.01 (d, J=8.96 Hz, 2
H) 7.54 (dd, J=8.78, 1.56 Hz, 2 H) 7.82 (d, J=6.24 Hz, 1 H).
Example 11 (2R)-4-[5-Fluoro-2-oxo-4-(4-propvlphenyl)pyridin-1 (2Η)-νΠ-Ν4ινάΓθχν-2-ιτΐ6ΐΐΊνΙ-2(methylsulfonvl)butanamide
Step A) (2R)-4-r5-Fluoro-2-oxo-4-(4-propylphenvl)pvridin-1(2H)-vll-2-methyl-2(methylsulfonvl)-N-(tetrahvdro-2H-ovran-2-vloxy)butanamide
The title compound (75.5 mg, 21%) was obtained as a solid from (2R)-4-(5-fluoro-4iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (360 mg, 0.697 mmol) and (4-propylphenyl)boronic acid (171 mg, 1.04 mmol) using a procedure analogous to that described for ethyl (2R)-4-{5fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoate, Example 9, Step A. MS (LCMS) m/z 507.4(M-1),
Step B) (2R)-4-[5-Fluoro-2-oxo-4-(4-propvlphenyl)pyridin-'l(2H)-vll-N-hydroxy-2methyl-2-(methvlsulfonyl)butanamide
The title compound (58 mg, 94%) was obtained as a solid from (2R)-4-[5-fluoro-2-oxo-4(4-propylphenyl)pyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide (75 mg, 0.15 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1(2H)-yl}-N-hydroxy-2-methyl2-(methylsulfonyl)butanamide, Example 9, Step D. MS (LCMS) m/z 425.2 (M+1). 1H NMR (400 MHz, METHANOL-af4) δ ppm 0.89 - 1.00 (m, 3 H) 1.57 - 1.76 (m, 5 H) 2.29 2.45 (m, 1 H) 2.55 - 2.69 (m, 3 H) 3.09 (s, 3 H) 3.86 - 4.04 (m, 1 H) 4.17 - 4.34 (m, 1 H)
6.63 (d, J=7.02 Hz, 1 H) 7.31 (d, J=8.00 Hz, 2 H) 7.44 - 7.55 (m, 2 H) 7.85 (d, J=5.85 Hz, 1 H).
K/
Example 12 (2R)-4-{5-Fluoro-2-oxo-4-[4-(pentafluoro-6À-sulfanyl)phenvllpyridin-1 (2H)-yn-N-hvdroxy2-methyl-2-(methvlsulfonvl)butanamide
NHOH
Step A) (2R)-4-(5-Fluoro-2-oxo-4-i4-(penÎafluoro-6X-sulfanvl)Dhenvllpvridin-1(2H)vl]-2-meÎhvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2yloxy)butanamide
1,4-Dioxane was added to 1 -bromo-4-(pentafluoro-6X-sulfanyl)benzene (500 mg, 1.77 mmol), 4,4,4,)4',5,5,5’,5’-octamethyl-2,2l-bi-1,3l2-dioxaborolane (628 mg, 2.47 mmol), potassium acetate (347 mg, 3.53 mmol) and Pd(dppf)CI2 (130 mg, 0.177 mmol). The mixture was heated to 80 °C and stirred at this température for 3 h. (2R)-4-(5-fluoro-4iodo^-oxopyridin-lfëHJ-yO-Z-methyl^-imethylsulfonyO-N-itetrahydro-^H-pyran^yloxy)butanamide, T3, (456 mg, 0.883 mmol) and aq Na2CC>3 (2.0 N, 1.77 mL, 3.53 mmol) were added and the reaction was stirred at 80 °C ovemight. The mixture was diluted with EtOAc and washed with brine. The organics were dried (MgSO4), filtered, and concentrated. The crude residue was purified via flash chromatography using a 40 g silica column and an eluent of EtOAc in n-heptane (0-100%) to afford the title compound (205 mg, 39.2%). MS(LCMS) m/z 591.4 (M-1).
Step B) (2R)-4-Î5-Fluoro-2-oxo-4-r4-(pentafluoro-6Â-sulfanvl)phenvllpyridin-1(2H)yl}-N-hvdroxv-2-methvl-2-(methvlsulfonvl)butanamide
Aqueous HCl (1.0 M) was added to a solution of (2R)-4-{5-fluoro-2-oxo-4-[4(pentafluoro-6X-sulfanyl)phenyl]pyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (81 mg, 0.14 mmol) and the réaction was stirred at rt ovemight. The réaction was concentrated in vacuo to afford the title compound as a solid (70 mg, 100%). MS(LCMS) m/z 509.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1,58 (s, 3 H) 2.06 - 2.26 (m, 1 H) 3.11 (s, 3 H) 3.70 - 3.89 (m, 1 H) 3.97 - 4.14 (m, 1 H) 6.64 (d, J=7.41 Hz, 1 H) 7.81 (d, 2 H) 8.04 (d, J=8.78 Hz, 2 H) 8.11 (d, J=6.44 Hz, 1 H).
Example 13 (2R)-445-Fluoro-4-(3-methvlphenvl)-2-oxopyridin-1 (2H)-vH-N-hydroxv-2-methvl-2(methylsulfonyl)butanamide
NHOH
Step A) (2R)-4-[5-Fluoro-4-(3-methvlphenvl)-2-oxopyridin-1(2H)-yl1-2-methyl-2(methylsulfonvl)-N-(tetrahvdro-2H-pyran-2-vloxy)butanamide
The title compound (510 mg, 55%) was obtained as a gum from (3methylphenyl)boronic acid (384 mg, 2.82 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-tetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 479.4 (M-1 ).
Step B) (2R)-4-[5-Fluoro-4-(3-methvlphenvD-2-oxoDvridin-1 (2l~0-vH-N-hvdroxv-2methvl-2-(methylsulfonyl)butanamide
The title compound (255 mg, 61%) was obtained as a solid from (2R)-4-[5-fluoro-4-(3methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (510 mg, 1.06 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin-1 (2H)-yl}-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 9, Step D. MS (LCMS) m/z 397.1 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.70 (s, 3 H) 2.28 - 2.44 (m, 4 H) 2.62 (dd, J=10.44, 5.37 Hz, 1 H) 3.09 (s, 3 H) 3.96 (ddd, J=12.98, 10.63, 5.46 Hz, 1 H) 4.19 - 4.35 (m, 1 H) 6.64 (d, J=7.22 Hz, 1 H) 7.27 - 7.45 (m, 4 H) 7.88 (d, J=5.85 Hz, 1 H).
Example 14 (2R)-4-r5-Fluoro-4-(4-fluoro-3-methvlDhenyl)-2-oxopvridin-1(2HÎ-vll-N-hvdroxv-2-methvl2-(methvlsulfonvl)butanamide
ΝΗΟΗ
Step A) /'2R)-4-r5-Fluoro-4-(4-fluoro-3-methylphenyl)-2-oxopvridin-1(2H)-vl1-2methvl^-imethvIsulfonvD-N-ftetrahvdro^H-Dvran^-vloxylbutanamide
The title compound (360 mg, 38%) was obtained as a gum from (4-fluoro-3methylphenyl)boronic acid (434 mg, 2.82 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-Îetrazol-2-yl)phenyl]pyridin-1 (2H)-yl}~2methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 1, Step B. MS (LCMS) m/z 497.0 (M-1).
Step B) (2R)-4-F5-Fluoro-4-(4-fluoro-3-methy|phenvl)-2-oxopyridin-1 (2H)-yl|-Nhydroxv-2-methyl-2-(methvlsulfonvl)butanamide
The title compound (271 mg, 91%) was obtained as a white solid from (2R)-4-(5-fluoro-
4-(4-fluoro-3-methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (360 mg, 0.722 mmol) using a procedure analogous to that described for (2R)-4~(5-fluoro-4-[4-(methylthio)phenyl]-2-oxopyridin1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 9, Step D. MS (LCMS) m/z 415.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (s, 3 H) 2.13 (ddd, J=13.12, 11.17, 4.98 Hz, 1 H) 2.26 (s, 3 H) 2.40-2.45 (m, 1 H) 3.08 (s, 3 H) 3.75 (td, J=11.85, 5.17 Hz, 1 H) 4.02 (td, J=11.85, 4.98 Hz, 1 H) 6.49 (d, J=7.61 Hz, 1 H) 7.20 7.28 (m, 1 H) 7.38 - 7.45 (m, 1 H) 7.50 (d, J=7.41 Hz, 1 H) 8.01 (d, J=6.63 Hz, 1 H).
Example 15
5-Fluoro-1-r(3R)-3-(hydroxvamino)-3-(methylsulfonvl)butyn-4-f4-(oxetan-3vloxv)phenvnpvridin-2(1 H)-one
Step A) 3-(4-Bromophenoxy)oxetane
4-Bromophenol (2.5g, 14.5 mmol) and K2CO3 (5.45g, 39.4 mmol) were added to a solution ot oxetan-3-yl 4-methylbenzenesulfonate (3.00g, 13.1 mmol) in DMF (10 mL) in a sealed tube. The reaction was heated to 100 °C and stirred at this température for 24 h. The reaction was diluted with EtOAc and washed with water. The organic layer was dried (MgSO4), filtered and concentrated to afford the title compound. MS (GCMS) m/z 228. This material was used in subséquent steps without further purification.
Step B) 4l4,5.5-TetrameÎhvl-2-r4-(oxetan-3-vloxv)Dhenyl]-1,3.2-dioxaborolane The title compound (3.11 g, 86%) was obtained from 3-(4-bromophenoxy)oxetane (3.00 g, 13.1 mmol) using a procedure analogous to that described for 2-[4-(4,4,5,5tetramethyM ,3,2-dioxaborolan-2-yl)phenyl]-2H-tetrazole, Example 1, Step A. MS (GCMS) m/z 276. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.31 (s, 12 H) 4.70 4.79 (m, 2 H) 4.91 - 5.00 (m, 2 H) 5.18 - 5.27 (m, 1 H) 6.67 (d, J=8.78 Hz, 2 H) 7.73 (d, J=8.78 Hz, 2 H).
Step C) 5-Fluoro-1-i(3R)-3-(methylsulfonvl)-3-[(tetrahydro-2H-Dyran-2vloxy)amÎno1butyl)-444-(oxetan-3-vloxv)DhenvllDyridin-2(1H)-one
1,4-Dioxane (20 mL) and water (5 mL) were added to a flask containing (2R)-4-(5fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, T3 (287 mg, 0.56 mmol), 4,4,5,5-tetramethyl-2-[4-(oxetan-3yloxy)phenyl]-1,3,2-dioxaborolane (301 mg, 1.09 mmol), Pd(PPh3)4 (65 mg, 0.06 mmol), and potassium carbonate (230 mg, 1.67 mmol), which was previously flushed with N2.
The mixture was heated to 80 °C and stirred ai that température overnight. The reaction was concentrated and purified via flash chromatography using two 12 g silica gel columns. The first column was eluted with methanol in dichloromethane (0-20%). The second column was eluted with EtOAc in n-heptane (0-100%) followed by methanol in dichloromethane (0-20%) to afford the title compound as a solid (164 mg, 54%). MS (LCMS) m/z 537.4 (M-1).
Step D) 5-Fluoro-1-r(3R)-3-(hydroxvamino)-3-(methvlsulfonyl)butyll-4-[4-(oxetan-3vloxy)phenyl]pyridin-2(1 H)-one
Trifluoroacetic acid (1 mL) was added to a solution of 5-fluoro-1-{(3R)-3(methylsulfonyl)-3-[(tetrahydro-2H-pyran-2-yloxy)amino]butyl}-4-[4-(oxetan-3yioxy)phenyl]pyridin-2(1 H)-one (164 mg, 0.304 mmol) in DCM (10 mL). The reaction was allowed to stir at rt overnight and then concentrated under vacuum. The residue was re-dissolved in dichloromethane and n-heptane and concentrated again to afford the title compound as a solid. (113 mg, 82%). MS (LCMS) m/z 455.1 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.69 (s, 3 H) 2.35 (ddd, /=13.66, 10.63, 5.17 Hz, 1 H) 2.53 - 2.67 (m, 1 H) 3.09 (s, 3 H) 3.91 (ddd, /=12.98, 10.63, 5.27 Hz, 1 H) 4.16 4.30 (m, 1 H) 4.69 (dd, /=7.51, 4.78 Hz, 2 H) 5.02 (t, /=6.73 Hz, 2 H) 5.33 (t, /=5.46 Hz, 1 H) 6.58 (d, /=7.42 Hz, 1 H) 6.85 - 6.91 (m, 2 H) 7.55 (dd, /=8.68, 1.85 Hz, 2 H) 7.80 (d, /=6.24 Hz, 1 H).
Example 16 (2R)-4-r4-(4-Chloro-2-fluorophenvl)-5-fluoro-2-oxopvridin-1i2H)-vn-N-hydroxv-2-methvl·
2-(methylsulfonvl)butanamide
ΝΗΟΗ
Step A) (2R)-4-r4-(4-Chloro-2-fluoroDhenvl)-5-fluoro-2-oxoDvridin-1(2H)-vll-2methvl-2-(methylsulfonyl)butanoic acid
To a 3 L flask with mechanical stirring was added ethyl (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate, T2 (100 g, 225 mmol), (4chloro-2-fluorophenyl)boronic acid (25.5 g, 146 mmol) and Pd(dppf)2CI2 (4.93 g, 6.74 mmol). The flask was purged with N2, then degassed 2-methyltetrahydrofuran (1 L) and 3 M aq K3PO4 (225 mL, 674 mmol) were added. The reaction mixture was heated to 75 °C and stirred at this température for 30 min. Additional (4-chloro-2fluorophenyl)boronic acid (25.5 g, 146 mmol) was added and the reaction was allowed to heat for 1.5 h. The mixture was allowed to cool to rt and the aqueous layer was separated. The organic layer was passed through a celite pad and placed back in the reaction vessel. Lithium hydroxide (28 g, 667 mmol) in water (700 mL) was added and the mixture was heated to 50 °C and stirred at this température for 1 h. The mixture was allowed to cool and the aqueous layer separated. Celite was added to the aqueous layer and the mixture was filtered through a plug of celite. The filtrate was placed in a flask with overhead stirrer and carefully acidified with 4 M aq HCl and heated to 50 °C with stirring until a precipitate formed. The solid was collected via filtration and dried under vacuum to afford the title compound as a tan solid (68.7 g, 74%). MS (LCMS) m/z
420.6 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (s, 3 H) 2.18 (ddd, J=13.17,
10.24, 5.07 Hz, 1 H) 2.41 - 2.45 (m, 1 H) 3.10 - 3.19 (s, 3 H) 3.87 - 4.08 (m, 2 H) 6.47 (d, J=7.02 Hz, 1 H) 7.42 (dd, J=8.39, 1.95 Hz, 1 H) 7.48 - 7.56 (m, 1 H) 7.60 (dd,
J=9.95, 1.95 Hz, 1 H) 8.06 (d, J=6.05 Hz, 1 H).
Step B) (2R)-4-[4-(4-Chloro-2-fluorophenvlÎ-5-fluoro-2-oxopyridin-1(2H)-vn-2methyl-2-(methvlsulfonvl)-N-(Îetrahvdro-2H-pyran-2-vloxv)butanamide N-Methylmorpholine (54 mL, 491 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (43.1 g, 245 mmol) were added to a solution of (2R)-4-[4-(4-chloro-2-fluorophenyl)-5fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanoic acid (68.7 g, 164 mmol) in 2-methyltetrahydrofuran (1 L) and the réaction was stirred at rt for 2 h. O(Tetrahydro-2H-pyran-2-yl)hydroxylamine (28.8 g, 245 mmol) was added and the reaction was allowed to stir at rt for 1 h. The mixture was filtered and the filtrate was concentrated. The crude residue was purified via column chromatography using silica gel and eluting with 40% EtOAc in n-heptane (4L) and EtOAc (6L). The desired fractions were combined and concentrated to afford the title compound as a white gummy solid. (74.82g, 88%). MS (LCMS) m/z 517.9 (M-1).
Step C) (2R)-4-[4-(4-Chloro-2-fluorophenvl)-5-fluoro-2-oxopyridin-1(2H)-vl1-Nhydroxy-2-methvl-2-(methvlsulfonyl)butanamide
Water (312 mL) and 1 N aq HCl (23.9 mL, 23.9 mmol) were added to a solution of (2R)4-[4-(4-chloro-2-fluorophenyl)-5-fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (74.7 g, 144.1 mmol) in éthanol (126 mL). The reaction was heated to 70 °C and stirred at this température overnight. The reaction was allowed to cool and the solid was collected via filtration and washed with water until the filtrate had a pH of ~5. The solid was dried under vacuum to afford the title compound as a white solid (46.48 g, 74%). MS (LCMS) m/z 435.6 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.56 (s, 3 H) 2.09 - 2.21 (m, 1 H) 2.44 (d, J=5.27 Hz, 1 H) 3.10 (s, 3 H) 3.77 (td, J=11.90, 5.07 Hz, 1 H) 4.04 (td, J=11.95, 4.98 Hz, 1 H) 6.51 (d, J=7.02 Hz, 1 H) 7.44 (dd, J=8.29, 2.05 Hz, 1 H) 7.50 - 7.56 (m, 1 H) 7.62 (dd, J=9.95, 1.95 Hz, 1 H) 8.04 (d, J=5.85 Hz, 1 H) 9.22 (s, 1 H) 11.05 (s, 1 H).
Example 17 (2RÎ-4-r5-fluoro-4-(2-fluoro-3-methoxyphenvl)-2-oxoDvridin-1(2H)-vl1-N-hydroxy-2· methvl-2-(methvlsulfonyl)butanamide
Step A) (2R)-4-r5-Fluoro-4-(2-fluoro-3-meÎhoxvphenvl)-2-oxopvridin-1(2H)-vl1-2methyl-2-(methvlsulfonvl)butanoic acid ,r-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex (5.90 g, 7.22 mmol) was added to a mixture of ethyl (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate, T2 (29.63 g, 66.55 mmol), (2-fluoro-3-methoxyphenyl)boronic acid (18.50 g, 108.9 mmol) and potassium phosphate tribasic (54.5 g, 205 mmol) in 2-methyltetrahydrofuran (450 mL) and deionized water (225 mL). The mixture was heated to 60 °C and stirred at this température overnight. The reaction was allowed to cool to rt. The aqueous layer was separated from the organics and the organics were washed with water (200 mL) and brine (200 mL), dried (MgSO4), and filtered. Darco® G-60 -100 mesh, powder was added to the filtrate and was stirred for 1 h. Solids were removed via filtration over celite and the filtered pad was washed with EtOAc (-300 mL). The combined filtrâtes were concentrated to afford a red oil (30.62 g). The oil was dissolved in 2methyltetrahydrofuran (450 mL) and deionized water (225 mL). Potassium hydroxide (26.1 g, 465 mmol) was added to the mixture and the reaction was heated to 50 °C and stirred at this température overnight. The reaction was allowed to cool to rt. The aqueous layer was separated and washed with diethyl ether (2x200 mL). The aqueous layer was slowly acidified while stirring using concentrated HCl to a pH of 1 and the suspension was stirred for 1 h. The suspension was filtered and the solids were washed with water (3x100 mL) and hexanes (3x300 mL). The solids were dried in vacuo to afford the title compound as a tan solid (26.49 g, 94.54%). MS (LCMS) m/z 416.0 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 1.57 (s, 3 H) 2.14-2.28 (m, 0 H) 2.42 - 2.54 (m, 1 H) 3.18 (s, 3 H) 3.88 (s, 3 H) 3.90 - 4.09 (m, 2 H) 6.44 (d, J=7.03 Hz, 1 H) 6.92 - 7.04 (m, 1 H) 7.20 - 7.36 (m, 2 H) 8.06 (d, J=5.95 Hz, 1 H) 13.90 (br. s., 1 H).
Step B) (2R)-4-r5-Fluoro-4-(2-fluoro-3-methoxvphenvl)-2-oxopyridin-1(2H)-vl1-2methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pyran-2-vloxv)butanamide /V-Methylmorpholine (11 mL, 96.2 mmol) was added to a solution of CDMT (13.5 g, 116 mmol) and (2R)-4-[5-fluoro-4-(2-fluoro-3-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2xZ methyl-2-(methylsulfonyl)butanoic acid (26.49 g, 63.77 mmol) in 2methyltetrahydrofuran (640 mL) and the reaction was stirred for 2 h. THPhydroxylamine (13.5 g, 116 mmol) was added to the reaction and the reaction was stirred overnight at rt. The reaction was quenched with saturated aqueous sodium bicarbonate (500 mL). The organic layer was separated and washed with water (300 mL) and brine (300 mL), then dried (MgSO4), and filtered. Darco G-60,-100 mesh, powder was added to the filtrate and the suspension was stirred for 1 h. The charcoal was removed via filtration through a celite pad and the filter pad was washed with EtOAc (1 L). The filtrate was concentrated to afford the title compound as a yellowishwhite solid (30.49, 92.93%). MS (LCMS) m/z 513.9 (M-1).
Step C) (2R)-4-r5-Fluoro-4-f2-fluoro-3-methoxvphenvl)-2-oxopyridin-1(2H)-yl]-Nhydroxv-2-methvl-2-(methylsuÎfonyl)butanamide
Pyridinium p-toluenesulfonate (190 mg, 0.76 mmol) was added to a solution of (2R)-4[5-fluoro-4-(2-fluoro-3-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (777 mg, 1.51 mmol) in éthanol (15 mL). The reaction was heated to 50 °C and stirred at this température overnight. Additional pyridinium p-toluenesulfonate (118 mg, 0.47 mmol) was added to the solution and the reaction was heated at 60 °C for 3 h. The reaction was allowed to cool to rt and the precipitate was collected via filtration. The solid was washed with éthanol (15 mL) and hexanes (15 mL) and dried in vacuo to afford the title compound as a white solid (413 mg, 63.5%). MS (LCMS) m/z 431.0 (M+1). 1H NMR (400 MHz, DMSO-tfe) δ ppm 1.57 (s, 1 H) 2.08 - 2.25 (m, 0 H) 2.41 - 2.56 (m, 1 H) 3.02 - 3.19 (m, 3 H) 3.71 - 3.85 (m, 1 H) 3.88 (s, 3 H) 3.98 - 4.13 (m, 1 H) 6.47 (d, 4=7.02 Hz, 1 H) 6.93 7.08 (m, 1 H) 7.19 - 7.36 (m, 2 H) 8.04 (d, 4=5.66 Hz, 1 H) 9.24 (d, 4=1.56 Hz, 1 H) 11.07 (d, J=1.56 Hz, 1 H).
Example 18 (2R)-4-Γ5-Fluoro-444-Γ(trans-4-hvdroxvcvclohexvl)methoxylphenvll·2-oxopyridin-1(2H)vl1-N-hvdroxv-2-methvl-2-(methvlsulfonyl)butanamide
o o
Step A) Ethyl 4-(tetrahvdro-2H-pvran-2-vloxv)cvclohexanecarboxvlate Pyridinium-4-toluenesulfonate (2.57 g, 10.2 mmol) was added to a solution of ethyl 4hydroxycyclohexanecarboxylate (8.8 g, 51.10 mmol) and 3,4-dihydro-2H-pyran (8.60 g, 102 mmol) in DCM (200 mL) and the reaction was stirred at rt for 16 h. The réaction was quenched with saturated aq NaHCC>3. The layers were separated and the organic layer was washed with water. The organic layer was dried (Na2SO4), filtered, and concentrated. Purification via flash chromatography on a 200 g siiica column using an eluent of EtOAc in hexanes (5-10%) afforded the title compound as a clear oil (11.1 g, 85%).
Step B) fcls-4-(Tetrahydro-2H-pvran-2-vloxv)cyclohexvl1methanol and i+Z-Mtrans4- (tetrahvd ro-2H-pyran-2-vloxv) cyclohexvll methano I
Sodium borohydride (3.69 g, 97.5 mmol) was added to a solution of ethyl 4-(tetrahydro2H-pyran-2-yloxy)cyclohexanecarboxylate (2.50 g, 9.75 mmol) in éthanol (100 mL) at 0 °C. The reaction was allowed to warm to rt as the ice bath expired. After 2 days the reaction was cooled to 0 °C and quenched by the addition of 1 N aq HCl until the effervescence ceased, pH 5-6. The reaction was concentrated and the resulting residue was partitioned between EtOAc and water. The layers were separated, and the aqueous layer was extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered, and concentrated. Purification on a siiica gel 100g column and an eluent of EtOAc in hexanes (10-40%) afforded the two sets of enantiomers as clear oils.
Î+/-)-rcis-4-(tetrahydro-2H-pvran-2-vloxv)cyclohexyrimethanol (387 mg, 18%).
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.30 -1.65 (m, 12 H) 1.64 -1.76 (m, 1 H) 1.76 -1.94 (m, 3 H) 3.33 - 3.64 (m, 3 H) 3.80 - 4.01 (m, 2 H) 4.59 - 4.75 (m, 1 H).
(+/-Î-ftrans-4-(teÎrahvdro-2H-pvran-2-vloxv)cvclohexyl1methanol (824, 39.4%) ’HNMR (400 MHz, CHLOROFORM-d) δ ppm 0.86-1.11 (m, 2 H) 1.16 -1.31 (m, 1 H)
1.31 -1.64 (m, 7 H) 1.64-1.77 (m, 1 H) 1.78-1.93 (m, 3 H) 1.99-2.14 (m, 2 H) 3.353.67 (m, 4 H) 3.80 - 4.04 (m, 1 H) 4.63 - 4.79 (m, 1 H).
Step C) 2-[(trans-4-fr4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2vl)phenoxylmeÎhvl}cyclohexvl)oxv1tetrahvdro-2H-ovran
Diisopropyl azodicarboxylate (2.1 mL, 10.5 mmol) was added to a solution of [trans-4(tetrahydro-2H-pyran-2-yloxy)cyclohexyl]methanol (2.05 g, 9.57 mmol), 4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (2.3 g, 10.7 mmol), triphenylphosphine (2.76 g, 10.5 mmol), and triethylamine (1.5 mL,10.5 mmol) in THF (150 mL) at 0 °C. The reaction was allowed to warm to rt and stirred overnight. Water (200 mL) was added and the reaction was extracted with EtOAc (600 mL). The organics were washed with 1 M aq NaOH (4x100 mL), brine, then dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue was purified via flash chromatography using an eluent of 20% EtOAc in hexanes to afford the title compound as a white solid (1.9 g, 48%). MS (APCI) m/z 417.3 (M+1).
Step D) Ethyl (2RÎ-4-r5-fluoro-2-oxo-4-(4-4[trans-4-(tetrahydro-2H-oyran-2yloxylcvclohexvllmethoxvlDhenvnDyridin-lfëHI-vIl^-methyl^(methylsulfonyl)butanoate
Pd(dppf)CI2 (350 mg, 0.431 mmol) was added to a solution of ethyl (2R)-4-(5-fluoro-4iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (1.6 g, 3.6 mmol), 2[(trans-4-{[4-(4,4,5I5-tetramethyl·1,3,2-dioxaborolan-2yl)phenoxy]methyl}cyclohexyl)oxy]tetrahydro-2H-pyran (1.9 g, 4.49 mmol), and potassium phosphate tribasic (2.9 g, 10.8 mmol) in 2-methyl tetrahydrofuran/water (5:1, 240 mL). The reaction mixture was heated to 80 °C and stirred at this température for 16 h. The reaction was allowed to cool to rt, and water (50 mL) was added. The mixture was extracted with EtOAc (3x150 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated under reduced pressure to afford the title compound as a light tan solid (1.4 g, 64%). MS (LCMS) m/z 608.2 (M+1 ).
Step E) (2R)-4-[5-Fluoro-2-oxo-4-(4-fftrans-4-itetrahvdro-2H-pyran-2νΙοχν)ονοΙοίΊθχνΙ1ΐ'ηθίΐΊθχν]-ρΐΊ6ηνΙ)ρνπΡίη-1(2Η)-νΠ-2-ππ6ΐΙ,ΊνΙ-2(methylsulfonyl)butanoic acid
Aqueous lithium hydroxide (2.0 M, 5.8 mL, 2.3 mmol) was added to a solution of ethyl (2R)-4-[5-fluoro-2-oxo-4-(4-([trans-4-(tetrahydro-2H-pyran-2-yloxy)cyclohexyl]methoxy}phenyl)pyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanoate (1.4 g, 2.3 mmol) in éthanol (40 mL). The reaction was heated to 50 °C for 3 h. The reaction was allowed to cool to ambient température and then acidified to a pH of ~3 with 1.0 N aq. HCl. The mixture was extracted with EtOAc (3x150 mL). The combined organic phases were kZ dried (Na2SO4), filtered, and concentrated under reduced pressure to afford the title compound as a white solid (1.28 g, 98%). MS (LCMS) m/z 580.3 (M+1).
Step F) (2R)-4-f5-Fluoro-2-oxo-4-(4-(rtrans-4-(tetrahvdro-2H-Dyran-2vloxv)cvclohexvrimethoxv)~Dhenvl)Dvridin-1 (2H)-vll-2-methvl-2(methvlsulfonvl)-N-(tetrahydro-2H-Dvran-2-vloxv)butanamide N-Methyl morpholine (340 uL, 3.09 mmol) was added to a suspension of (2R)-4-[5fluoro-2-oxo-4-(4-{[trans-4-(tetrahydro-2H-pyran-2-yloxy)cyclohexyl]methoxy}phenyl)pyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanoic acid (1.28 g, 2.21 mmol), 2-chloro-4,6-dimethoxy-1,3,5-triazine (510 mg, 2.87 mmol) in 2-methyltetrahydrofuran (30 mL) and the réaction was stirred for 1 h at rt. O-(Tetrahydro-2H-pyran-2yl)hydroxylamine (61 mg, 0.52 mmol) was added, and the reaction was stirred overnight at rt. Water (50 mL) was added, and the mixture was extracted with EtOAc (3x150 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude material was purified via flash chromatography using an eluent of EtOAc in n-heptane (75-100%) to afford the title compound as a light brown residue (700 mg, 46%). MS (LCMS) m/z 677.4 (M+1).
Step G) (2R)-4-i5-fluoro-4-f4-[(trans-4-hvdroxvcvclohexvl)methoxv]Dhenyl}-2oxoDvridin-1(2H)-vll-N-hvdroxy-2-methvl-2-(methylsulfonvl)butanamide Hydrochloric acid (4.0 M in 1,4-dioxane, 1.7 mL, 6.63 mmol) was added to a solution of (2R)-4-[5-fluoro-2-oxo-4-(4-([trans-4-(tetrahydro-2H-pyran-2yloxy)cyclohexyl]methoxy}phenyl)-pyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (450 mg, 0.66 mmol) in 1,4dioxane:DCM:water (2:2:1,5 mL) at room température. After 1 h, the reaction was concentrated under reduced pressure. The crude residue was triturated in éthanol (10 mL) overnight. The solid was collected via filtration, washed with éthanol (5 mL), and dried under reduced pressure to afford the title compound as a white solid (110 mg, 33%). MS (LCMS) m/z 511.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 0.97-1.19 (m, 4 H) 1.54 (s, 3 H) 1.58 - 1.72 (m, 1 H) 1.72 - 1.89 (m, 4 H) 2.04 - 2.23 (m, 1 H) 2.41 (m, 1 H) 3.08 (s, 3 H) 3.18 - 3.40 (m, 1 H) 3.65 - 3.84 (m, 3 H) 4.01 (td, /=11.61,4.88 Hz, 1 H) 4.49 (br. s„ 1 H) 6.45 (d, /=7.81 Hz, 1 H) 6.94 - 7.06 (m, 2 H) 7.36 - 7.54 (m, 2 H) 7.96 (d,/=6.83 Hz, 1 H) 9.21 (s, 1 H) 11.07 (s, 1 H) 11.12 (s, 1 H).
y
Example 19 (2R)-4-r5-Fluoro-4-(3-fluoro-4-methoxvphenvh-2-oxoovridin-1(2H)-yl1-N-hvdroxv-2methyl-2-(methvlsulfonyl)butanamide
Step A) (2R)-4-r5-Fluoro-4-(3-fluoro-4-methoxvphenvl)-2-oxopyridin-1(2H)-vll-2methyl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pyran-2-yloxv)butanamide
Pd Encat™ (580 mg, 0.17 mmol) was added to a mixture of potassium carbonate (723 mg, 5.2 mmol), (3-fluoro-4-methoxyphenyl)boronic acid (318 mg, 2.1 mmol), and (2R)-4(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, T3, (900 mg, 1.7 mmol) in 1,4-dioxane:water (5:1,24 mL). The reaction was heated to 80 °C and allowed to stir at this température ovemight. The reaction was filtered through a pad of celite, which was washed with methanol (250 mL). The filtrate was concentrated under reduced pressure, and the resulting crude material was purified via flash chromatography using an eluent of EtOAc in heptanes (20-100%), then 10% methanol in EtOAc to provide the title compound as a light tan residue (800 mg, 99%). MS (LCMS) m/z 495.1 (M-1).
Step B) (2R)-4-f5-Fluoro-4-(3-fluoro-4-methoxvphenvl)-2-oxoovridin-1 (2H)-vl1-Nhydroxy-2-methvl-2-(methvlsulfonvl)butanamide
The title compound (400 mg, 58%) was obtained as a solid from (2R)-4-[5-fluoro-4-(3fluoro-4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (800 mg, 1.65 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-{4-[(trans-4hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 413.1 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.54 (s, 3 H) 2.06 - 2.18 (m, 1 H) 2.38 - 2.47 (m, 1 H) 3.08 (s, 3 H) 3.74 (td, 7=12.00, 4.88 Hz, 1 H) 3.87 (s, 3 H) 4.02 (td, 7=11.85, 4.98 Hz, 1 H) 6.52 (d, 7=7.81 Hz, 1 H) 7.21 - 7.31 (m, 1 H) 7.34 - 7.51 (m, 2 H) 7.99 (d, 7=6.83 Hz, 1 H) 9.20(8,1 H) 11.06 (br. s, 1 H).
kZ (2R)-4-r5-Fluoro-2-oxo-4-(4-pvrimidin-2-vlohenyl)pvridin-1(2H)-vl1-N-hvdroxy-2-methvl54
Example 20
2-(methvlsulfonvl)butanamide
MeO2St
Step A) 2-r4-(4.4.5.5-Tetramethvl-1,3,2-dioxaborolan-2-vl)phenvllpyrimidine
A degassed solution of 2-bromopyrimidine (1.5 g, 9.4 mmol), 2,2'-(1,4phenylene)bis(4,4l5l5-tetramethyl-1,3,2-dioxaborolane) (5.1 g, 16.0 mmol), 1.0 M aq K3PO4 (28.3 mL, 28.3 mmol), and Pd(PPh3)4 (330 mg, 0.31 mmol) in DMF (140 mL) was heated to 80 °C and stirred at this température for 16 h. Water (100 mL) was added to the reaction mixture and was extracted with EtOAc (3x200 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude material was purified via flash chromatography using an eluent of 17% EtOAc in π-heptane to afford the title compound as a white solid (0.7 g, 28%). MS (LCMS) m/z 283.1 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36 (s, 12 H) 7.19 (t, 7=4.68 Hz, 1 H) 7.93 (d, 7=8.00 Hz, 2 H) 8.43 (d, 7=7.81 Hz, 2 H) 8.81 (d, 7=4.68 Hz, 2 H).
Step B) Ethyl (2R)-4-(5-Fluoro-2-oxo-4-(4-pyrimidin-2-vlphenvl)pvridin-1 (2H)-yl]-2methyl-2-(methylsulfonvl)butanoate
The title compound (278 mg, 87%) was obtained as a light tan solid from 2-(4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine (270 mg, 0.94 mmol) and ethyl (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoatel T2, (300 mg, 0.67 mmol) using a procedure analogous to that described for the préparation of ethyl (2R)-4-[5-fluoro-2-oxo-4-(4-([trans-4-(tetrahydro-2H-pyran-2yloxy)cyclohexyl]methoxy}phenyl)pyridin-1(2H)-yl]-2-methyl-2(methylsulfonyl)butanoate, Example 18, Step D. MS (LCMS) m/z 474.2 (M+1).
Step C) (2R)-4-(5-Fluoro-2-oxo-4-(4-pvrimidin-2-vlphenvl)pvridin-1(2H)-vl]-2methyl-2-(methylsulfonvl)butanoic acid
The title compound (250 mg, 98%) was obtained as a light brown gum from ethyl (2R)4-[5-fluoro-2-oxo-4-(4-pyrimidin-2-ylphenyl)pyridin-1(2H)-yl]-2-methyl-2(methylsulfonyl)butanoate (270 mg, 0.57 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-2-oxo-4-(4-{[trans-4-(tetrahydro-2Hpyran-2-yloxy)cyclohexyl]methoxy}-phenyl)pyridin-1(2H)-yl]-2-methyl-2(methylsulfonyl)butanoic acid, Example 18, Step E. MS (LCMS) m/z 446.1 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.73 (s, 3 H) 2.39 - 2.51 (m, 1 H) 2.62 - 2.75 (m, 1 H) 3.17 (s, 3 H) 4.20 - 4.46 (m, 2 H) 6.86 (d, J=7.02 Hz, 1 H) 7.65 (t, J=5.07 Hz, 1 H) 7.83 (d, J=7.02 Hz, 2 H) 8.09 (d, J=5.85 Hz, 1 H) 8.53 (d, J=8.39 Hz, 2 H) 9.06 (d, J=4.88 Hz, 2 H).
Step D) (2R)-4-r5-Fluoro-2-oxo-4-(4-Dyrimidin-2-vlDhenyl)Dvridin-1(2H)-yri-2methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pyran-2-vloxv)butanamide The title compound (290 mg, 94%) was obtained as a light brown gum from (2R)-4-[5fluoro-2-oxo-4-(4-pyrimidin-2-ylphenyl)pyridin-1(2H)-yl]-2-methyl-2(methylsulfonyl)butanoic acid (250 mg, 0.56 mmol) and O-(tetrahydro-2H-pyran-2yl)hydroxylamine (87 mg, 0.74 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-2-oxo-4-(4-{[trans-4-(tetrahydro-2H-pyran-2yloxy)cyclohexyl]methoxy}-phenyl)pyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 18, Step F. MS (LCMS) m/z 543.0 (M+1).
Step E) (2R)-4-[5-Fluoro-2-oxo-4-(4-pyrimidin-2-vlphenvl)pvridin-1 (2H)-vl]-Nhydroxv-2-methyl-2-(methylsulfonvl)butanamide
The title compound (80 mg, 30%) was obtained as a tan solid from (2R)-4-[5-fluoro-2oxo-4-(4-pyrimidin-2-ylphenyl)pyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (312 mg, 0.57 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4-[(trans-4hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 461.1 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.70 (s, 3 H) 2.31 - 2.45 (m, 1 H) 2.56 - 2.71 (m, 1 H) 3.10 (s, 3 H) 3.87 - 4.01 (m, 1 H) 4.19 - 4.33 (m, 1 H) 6.70 (d, J=7.42 Hz, 1 H)
7.38 (t, J=4.88 Hz, 1 H) 7.73 (dd, J=8.59, 1.76 Hz, 2 H) 7.87 (d, J=6.05 Hz, 1 H) 8.53 (d, J=8.59 Hz, 2 H) 8.87 (d, J=4.88 Hz, 2 H).
A
Example 21 (2R)-4-f5-Fluoro-4-r4-(5-methoxvpyrimidin-2-yl)phenvll-2-oxopvridin-1 (2Η)-νΙ}-Νhvd roxy-2-methyl-2- (meth visu Ifonvl) butanam id e
Step A) 5-Methoxy-2-r4-(4,4.5.5-tetramethvl-1.3.2-dîoxaborolan-2yl)phenvllpyrimidine
The title compound (700 mg, 17%) was obtained as a white solid from 2-chloro-5methoxypyrimidine (1.85 g, 12.8 mmol) and 2,2-(1,4-phenylene)bis(4,4,5,5-tetramethyl-
1,3,2-dioxaborolane) (6.9 g, 21.0 mmol) using a procedure analogous to that described for the préparation of 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]pyrimidine, Example 20, Step A. MS (LCMS) m/z 313.1 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.33 (s, 12 H) 3.93 (s, 3 H) 7.83 - 7.90 (m, 2 H) 8.28 8.34 (m, 2 H) 8.45 (s, 2 H).
Step B) (2R)-4-f5-Fluoro-4-[4-(5-methoxypvrimidin-2-vl)phenvl]-2-oxopvridin1 (2H)-vl)-2-methvl-2-(methvlsulfonyl)-N-(tetrahydro-2H-pyran-2vloxy)butanamide
The title compound (900 mg, 95%) was obtained as a tan solid from 5-methoxy-2-[4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine (719 mg, 2.3 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yi)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide, T3, (850 mg, 1.65 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxyjbutanamide, Example 19 Step A. MS (LCMS) m/z 573.2 (M+1).
Step C) (2R)-445-Fluoro-4-r4-(5-methoxvpvrimidin-2Vl)phenyll-2-oxoovridin1(2H)-vll-N-hvdroxy-2-methvl-2-(methylsulfonyl)butanamide
The title compound (50 mg, 6%) was obtained as a light brown solid from (2R)-4-{5fluoro-4-[4-(5-methoxypyrimidin-2-yl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2xZ (methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (900 mg, 1.57 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-{4[(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2-(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 491.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.53 (s, 3 H) 2.08 - 2.19 (m, 1 H) 2.39 2.48 (m, 1 H) 3.07 (s, 3 H) 3.69 - 3.78 (m, 1 H) 3.92 (s, 3 H) 3.96 - 4.08 (m, 1 H) 6.56 (d, J=7.71 Hz, 1 H) 7.67 (m, J=8.70, 2.00 Hz, 2 H) 8.01 (d, J=6.54 Hz, 1 H) 8.34 - 8.38 (m, 2 H) 8.64 (s, 2 H) 9.19 (br. d, J=1.80 Hz, 1 H) 11.04 (br. d, J=1.90 Hz, 1 H).
Example 22 (2R)-4-i5-Fluoro-4-r4-(4-methoxv-2H-1,2.3-triazol-2-vl)phenvH-2-oxopvridin-1 (2H)-vl)-Nh vd roxy-2-methvl-2- (methvlsu Ifonvl) butanam ide
Step A) 2-(4-Bromophenvl)-4-methoxv-2H-1.2.3-triazole
Césium carbonate (4.5 g, 13.7 mmol) was added to a solution of 2-(4-bromophenyl)-2H-
1,2,3-triazol-4-ol (1.1 g, 4.6 mmol) and methyl iodide (0.36 mL, 5.7 mmol) in THF (50 mL). The reaction was heated to 60 °C and stirred at this température for 16 h. Water (20 mL) was added to the reaction, and the resulting mixture was extracted with EtOAc (2x150 mL). The combined organic phases were dried over potassium carbonate, filtered, and concentrated under reduced pressure to afford the title compound as a tan solid (1.1 g, 95%). 1H NMR (400 MHz, METHANOL-O4) δ ppm 3.98 (s, 3 H) 7.39 (s, 1 H) 7.55 - 7.62 (m, 2 H) 7.79 - 7.86 (m, 2 H).
Step B) 4-Methoxv-2-r4-(4.4.5,5-tetramethyl-1.3.2-dioxaborolan-2-vl)phenvll-2H-
1,2,3-triazole
Pd(dppf)Cl2 (0.71 g, 0.87 mmol) was added to a mixture of 2-(4-bromophenyl)-4methoxy-2H-1,2,3-triazole (1.1 g, 2.6 mmol), 4,4,4',4',5,5,5’,5'-octamethyl-2,2,-bi-1,3,2dioxaborolane (1.3 g, 5.2 mmol), potassium acetate (1.3 g, 13.0 mmol), in 2-methyl tetrahydrofuramwater (5:1, 60 mL). The reaction was heated to 80 °C and stirred at this température for 16 h. The reaction was allowed to cool to rt, and water (50 mL) was
V added. The reaction was filtered through celite, which was washed with EtOAc (150 mL). The filtrate was concentrated under reduced pressure, and the resulting crude material was purified by flash chromatography using an eluent of EtOAc in n-heptane (10-60%) to afford the title compound as a light tan solid (1.2 g, 92%). MS (LCMS) m/z 302.3 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.33 (s, 12 H) 4.01 (s, 3 H) 7.40 (s, 1 H) 7.78 - 7.84 (m, 2 H) 7.88 - 7.95 (m, 2 H).
Step C) (2R)-4-{5-Fluoro-4-r4-(4-methoxv-2H-1.2,3-triazol-2-yl)Dhenvl1-2oxopvridin-1(2H)-vll·2-methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvraπ2-yloxy)butanamide
The title compound (1.15 mg, 88%) was obtained as tan solid from 4-methoxy-2-[4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3-triazole (0.98 g, 1.4 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (1.2 g, 2.3 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19 Step A. MS (LCMS) m/z 562.0 (M+1).
Step D) (2R)-4-f5-Fluoro-4-f4-(4-methoxv-2H-1,2t3-Îriazol-2-vl)Dhenvn-2oxoDvridin-1(2H)-yl}-N-hvdroxv-2-methvl-2-(methylsulfonyl)butanamide
The title compound (700 mg, 70%) was obtained as a light tan solid from (2R)-4-(5fluoro-4-[4-(4-methoxy-2H-1,2,3-triazol-2-yl)phenyl]-2-oxopyridin“1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (1.15 g, 2.04 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-{4[(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2methyl-2-(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 480.2 (M+1). Ή NMR (400 MHz, DMSO-cf6) δ ppm 1.53 (s, 3 H) 2.07 - 2.18 (m, 1 H) 2.39 2.48 (m, 1 H) 3.06 (s, 3 H) 3.69 - 3.77 (m, 1 H) 3.95 (s, 3 H) 3.97 - 4.08 (m, 1 H) 6.54 (d, J=7.62 Hz, 1 H) 7.65 - 7.73 (m, 2 H) 7.75 (s, 1 H) 7.90 - 7.98 (m, 2 H) 8.03 (d, J=6.64 Hz, 1 H) 11.06 (br. s., 1 H).
Example 23 (2R)-4-(5-Fluoro-4-[4-(4-methvl-2H-1,2.3-triazol-2-vl)Dhenvl1-2-oxQDvridin-1 (2H)-vl}-Nhydroxv-2-methvl-2-(methvlsulfonvl)butanamide
Step A) 4-Methyl-2-(4-(4.4,5,5-tetramethyl-1,3.2-dioxaborolan-2-vl)phenvl)-2H-
1,2,3-triazole
Pd(dppf)CI2 ( 592 mg, 0.718 mmol) was added to a solution of potassium acetate (705 mg, 7.18 mmol), 2-(4-bromophenyl)-4-methyl-2H-1,2,3-triazole (600 mg, 2.52 mmol), and 4,4,4',4',5,5,5',5l-octamethyl-2,2'-bi-1,3,2-dioxaborolane (729 mg, 2.87 mmol) in
1,4-dioxane (20 mL). The reaction was heated to 80 °C and stirred at this température for 16 h. The reaction was filtered through celite, and the filter pad was washed with EtOAc (150 mL). The combined filtrâtes were concentrated under reduced pressure, and the crude material was purified via flash chromatography using EtOAc in n-heptane (10-60%) to afford the title compound as a light tan solid (720 mg, 98%). MS (LCMS) m/z 286.2 (M+1). 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.32 (s, 12 H) 2.36 (s, 3 H) 7.66 (s, 1 H) 7.77 - 7.84 (m, 2 H) 7.92 - 8.00 (m, 2 H).
Step B) (2R)-4-i5-Fluoro-4-r4-(4-methvl-2H-1.2,3-triazol-2-vDnhenyil-2-oxopvridin1 (2Η)-νΙ)-2-Γη6ΐΡνΙ-2-(ΐ'η6ΐΙ~ινΐ3υΙίοηνΙ)-Ν-(ΐθΐΓ3ΐ~^Γθ-2Η-ρνΓ3η-2yloxylbutanamide
The title compound (0.99 g, 98%) was obtained as a tan gum from 4-methyl-2-(4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2H-1,2,3-triazole (0.70 g, 2.4 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (0.90 g, 2.0 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 546.5 (M+1).
Step C) (2R)-4-i5-Fluoro-4-r4-(4-methyl-2H-1,2,3-triazol-2-vl)phenvn-2-oxopyridin1 (2H)-yll·N-hvdroxv-2-meΐhyl-2-(methylsulfonvl)butanamide
The title compound (450 mg, 53%) was obtained as a tan solid from (2R)-4~(5-fluoro-4[4-(4-methyl-2H-1,2,3-triazol-2-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (0.99 g, 1.81 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-{416551 [(trans-4-hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2-(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 464.2 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.53 (s, 3 H) 2.06 - 2.20 (m, 1 H) 2.33 (br. s, 3 H) 2.38 - 2.49 (m, 1 H) 3.06 (s, 3 H) 3.68 - 3.80 (m, 1 H) 3.90 - 4.11 (m, 1 H) 6.55 (d, J=7.61 Hz, 1 H) 7.65 - 7.76 (m, 2 H) 7.90 (br. s, 1 H) 7.96 - 8.10 (m, 2 H) 11.05 (br. s., 1 H).
Example 24 (2R)-4-(5-Fluoro-2-oxo-4-quinoxalin-6-vlpvridin-1 (2H)-vl)-N-hvdroxy-2-methvl-2(methvlsulfonvl)butanamide
Step A) (2R)-4-(5-Fluoro-2-oxo-4-quinoxalin-6-vlpvridin-1 (2H)-vl)-2-methvl-2(methylsulfonyl)-N-(tetrahvdro-2H-pyran-2-vloxv)butanamide
The title compound (480 mg, 95%) was obtained as a light brown gum from 6-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline (347 mg, 1.36 mmol) and (2R)-4-(5fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, T3, (500 mg, 0.97 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19 Step A. MS (LCMS) m/z 517.1 (M+1).
Step B) (2R)-4-i5-Fluoro-2-oxo-4-quinoxalin-6-vlpyridin-1 (2H)-vl)-N-hydroxy-2methvl-2-(methylsulfonyl)butanamide
The title compound (110 mg, 28%) was obtained as a light tan solid from (2R)-4-(5fluoro-2-oxo-4-quinoxar[n-6-ylpyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (0.48 g, 0.93 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4-[(trans-4hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 433.2 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.54 (s, 3 H) 2.09 - 2.19 (m, 1 H) 2.44 - 2.52 (m, 1 H) 3.07 (s, 3 H) 3.73 - 3.84 (m, 1 H) 4.04 (m, 1 H) 6.71 (d, J=7.61 Hz, 1 H) 7.99 (dt,
A
H) 8.89 9.05 (m, 2 H) 9.20 (br. s., 1 H) 11.03 (br. s., 1 H).
Example 25 (2R)-4-Î5-Fluoro-4-(3-methoxvphenvl)-2-oxopyridin-1(2H)-yll-N-hvdroxv-2-methvl-2(methylsulfonyl)butanamide
NHOH
Step A) (2R)-4-r5-Fluoro-4-(3-methoxyphenvl)-2-oxopvridin-1 (2H)-vll-2-methvl-2(methylsulfonvl)-N-(tetrahydro-2H-pyran-2-yloxv)butanamide
The title compound (800 mg, 99%) was otained as a light tan gum from (3methoxyphenyljboronic acid (318 mg, 2.09 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (900 mg, 1.74 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 495.1 (M+1).
Step B) (2R)-445-Fluoro-4-(3-methoxvohenvl)-2-oxopvridin-1 (2H)-vl1-N-hvdroxv-2methyl-2-(methylsulfonyl)butanamide
The title compound (400 mg, 58%) was obtained as a tan solid from (2R)-4-[5-fluoro-4(3-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (0.82 g, 1.65 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fiuoro-4-{4-[(trans-4hydroxycyclohexyl)methoxy]phenyl}-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 18, Step G. MS (LCMS) m/z 413.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.52 (s, 3 H) 2.05 - 2.18 (m, 1 H) 2.36 - 2.50 (m, 1 H) 3.06 (S, 3 H) 3.66 - 3.78 (m, 4 H) 3.95 - 4.08 (m, 1 H) 6.50 (d, J=7.61 Hz, 1 H) 6.98 7.11 (m, 3 H) 7.32-7.40 (m, 1 H) 7.98 (d, J=6.54 Hz, 1 H) 9.18 (br. s., 1 H) 11.04 (s, 1 H).
Example 26 (2Η)-4-ί5-ΡΙυοΓθ-2-οχο-4-[4-(2Η-1.2,3-ΐΓί3ΖθΙ-2-νΙΪρΐΊ6ηνΙ1ρνπόίη-1(2Ηΐ-νΙ>-Ν-Κν(ΐΓθχν-2methyl-2-(methvlsulfonvl)butanamide
Step A) 2-[4-{4,4.5.5-Tetramethvl-1,3,2-dioxaborolan-2-vÎ)phenvl1-2H-1,2,3-triazole Pd(dppf)CI2 (280 mg, 0.343 mmol) was added to a mixture of 2-(4-bromophenyl)-2H-
1,2,3-triazole (255 mg, 1.14 mmol), 4,4,4,,4',5,5,5,,5'-octamethyl-2,2'-bi-1,3,2dioxaborolane (350 mg, 1.38 mmol), and potassium acetate (340 mg, 3.46 mmol) in 1,4dioxane (10 mL). The reaction was heated to 80 °C and stirred at this température ovemight. The reaction was allowed to cool to rt and was diluted with EtOAc (30 mL) and brine (30 mL). The mixture was filtered through celite, and the organic layer was separated from the filtrate. The aqueous layer was extracted with EtOAc (2x30 mL) and the organics were combined, dried (MgSO4), filtered and concentrated. The crude material was purified via flash chromatography using an Analogix SF15-12g column and an eluent of EtOAc in n-heptane (0-10%) to afford the title compound as an orange solid (240.6 mg, 78.0%). MS (LCMS) m/z 272.4 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.37 (s, 12 H) 7.83 (s, 2 H) 7.94 (d, 2 H) 8.10 (d, J=8.59 Hz, 2 H).
Step B) Ethyl (2R)-4-i5-fluoro-2-oxo-4-r4-(2H-1.2.3-triazol-2-yl)phenvllpyridin1 (2H)-vl)--2-methvl-2-(methvlsulfonvl)butanoate
Pd(dppf)CI2 (484 mg, 0.59 mmol) was added to a mixture of ethyl (2R)-4-(5-fluoro-4iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate, T2, (2.20 g, 4.94 mmol), 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3-triazole (2.01 g, 7.41 mmol), and potassium phosphate (3.95 g, 14.8 mmol) in 2methyltetrahydrofuran (200 mL) and deionized water (40 mL). The reaction was heated to 60 °C and was vigorously stirred at this température ovemight. The reaction was diluted with EtOAc (100 mL) and water (100 mL) and was filtered through a celite pad (~1 inch). The filter pad was washed with EtOAc (100 mL) and the filtrâtes were combined. The aqueous layer was separated and was extracted with EtOAc (2x100
K.Z mL). The combined organics were washed with brine (100 mL), dried (MgSO4), filtered and concentrated. The crude material was purified via flash chromatography using a Varian SF25-40g column and an eluent of EtOAc in hexanes (30-100%) to afford the title compound as a yellow solid (1.54 g, 67.4%). MS (LCMS) m/z 463.0 (M+1). 1H NMR (400 MHz, DMSO-76) δ ppm 1.23 (t, 3 H) 1.62 (s, 3 H) 2.18 - 2.32 (m, 1 H) 2.52 2.66 (m, 1 H) 3.16 (s, 3 H) 3.92 - 4.07 (m, 2 H) 4.08 - 4.24 (m, 2 H) 6.59 (d, 7=7.81 Hz, 1 H) 7.72 - 7.84 (m, 2 H) 8.10 (d, 7=6.63 Hz, 1 H) 8.12 - 8.17 (m, 2 H) 8.18 (s, 2 H).
Step C) (2R)-4~f5-Fluoro-2-oxo-4-r4-(2H-1.2.3-triazol-2-vDDhenvllDvridin-1(2H)-vll· 2-methvl-2-(methvlsulfonvl)butanoic acid
Potassium hydroxide (1.30 g, 23.2 mmol) was added to a solution of ethyl (2R)-4-{5fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoate (1.54 g, 3.33 mmol) in 2-methyltetrahydrofuran:water (2::1 42.5 mL) and the solution was stirred at rt overnight. Methanol (5 mL) was added and the reaction was heated to 60 °C. The reaction mixture was stirred at this température for 2 h. The reaction was concentrated and triturated in 3 M aq HCl. The solid was collected via filtration and washed with water (20 mL) and hexanes (20 mL). The solid was dried under vacuum to afford the title compound as a white solid (1.39 g, 96.1%). MS (LCMS) m/z 435.0 (M+1). 1H NMR (400 MHz, DMSO-76) δ ppm 1.58 (s, 3 H) 2.13 2.30 (m, 0 H) 2.41 - 2.61 (m, 1 H) 3.17 (s, 3 H) 3.89-4.13 (m, 2 H) 6.59 (d, J=7.81 Hz, 1 H) 6.56 - 6.63 (m, 1 H) 7.79 (dd, 7=8.78, 1.76 Hz, 3 H) 8.09 (d, 7=6.83 Hz, 1 H) 8.12 8.17 (m, 2 H) 8.19 (s, 2 H).
Step D) (2R)-4-i5-Fluoro-2-oxo-4-r4-(2H-1.2.3-triazoi-2-yl)DhenvriDvridin-1(2H)-yl}2-methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2-vloxv)butanamide W-Methylmorpholine (540 pL, 4.9 mmol) was added to a solution of CDMT (750 mg, 4.27 mmol) and (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanoic acid (1.39 g, 3.20 mmol) in 2methyltetrahydrofuran (30 mL) and the reaction was stirred for 1 h at rt. 0-(Tetrahydro2H-pyran-2-yl)hydroxylamine (670 mg, 5.72 mmol) was added to the reaction and the reaction was stirred overnight at rt. The reaction was quenched with saturated aq NaHCO3 (100 mL) and the aqueous layer was extracted with EtOAc (3x100 mL). The combined organics were washed with brine (100 mL), dried (MgSO4), filtered and concentrated. The crude product was purified via flash chromatography using a Varian
SF25-40g column and eîuent of EtOAc in hexanes (30-100%) to afford the title compound as a white solid (1.53 g, 89.6%). MS (LCMS) m/z 532.2(M-1).
Step E) (2R)-4-ï5-Fluoro-2“OXO-4-r4-(2H-1,2,3-triazol-2-yl)DhenynDVridin-1 (2H)-vll· N-hydroxy-2-methvl-2-(methvlsulfonvl)butanamide
Pyridinium p-toluenesulfonate (360 mg, 0.50 mmol) was added to a solution of (2R)-4{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (1.53 g, 2.87 mmol) in éthanol (60 mL). The solution was heated to 70 °C and was stirred at this température for 3 h. The reaction was allowed to cool and was stirred at rt for three days. The solid was collected via filtration, washed with éthanol (20 mL) and hexanes (20 mL). The solid was dried under vacuum to afford the title compound as a white solid (1.05 g, 81.5%). MS (LCMS) m/z 450.0 (M+1), 1H NMR (400 MHz, DMSO-de) δ ppm 1.58 (s, 3 H) 2.08 - 2.27 (m, 0 H) 2.38 - 2.59 (m, 1 H) 3.12 (s, 3 H) 3.72 - 3.90 (m, 1 H) 4.00 - 4.17 (m, 1 H) 6.62 (d, J=7.61 Hz, 1 H) 7.70 - 7.88 (m, 2 H) 8.08 (d, J=6.63 Hz, 1 H) 8.12 8.18 (m, 2 H) 8.19 (s, 2 H) 9.25 (d, J=1.95 Hz, 1 H) 11.09 (d, J=1.76 Hz, 1 H).
Example 27 (2R)-4-r5-FluorQ-4-(2-Îluoro-4-methoxvDhenvl)-2-oxoDvridin-1(2H)-yll-N-hydroxv-2methvl-2-(meÎhvlsulfonvl)butanamide
Step A) (2R)-4-[5-Fluoro-4-i2-fluoro-4-methoxvDhenvl)-2-oxoDyridin-1(2H)-vl1-2methvl-2-(methylsulfonyl)-N-(tetrahvdro-2H-Dvran-2-yloxv)butanamide
The title compound (1.5 g, 94%) was obtained from (2-fluoro-4-methoxyphenyl)boronic acid (737 mg, 4.34 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (1.6 g, 3.1 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4(3-fluoro-4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 513.3 (M+1).
Step B) (2R)-4-[5-Fluoro-4-(2-fluoro-4-methoxvDhenvl)-2-oxoDvridin-1 (2H)-vll-Nhydroxy-2-methyl-2-(methvlsulfonvÎ)butanamide
A solution of HCl (4 M in 1,4-dioxane, 4.4 mL, 17.5 mmol) was added to a solution of (2R)-4-[5-fluoro-4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (1.5 g, 2.9 mmol) in 1,4dioxane (20 mL), DCM (20 mL), and water (5 mL) and the reaction was stirred for 20 min at rt. The réaction was concentrated under reduced pressure, isopropyl alcohol (10 mL) was added to the residue and the mixture was concentrated. Isopropyl alcohol (30 mL) was added to the residue and the solution was stirred overnight at rt to afford a precipitate. The precipitate was collected via filtration, washed with isopropyl alcohol, and dried under vacuum to afford the title compound as a light brown solid (725 mg, 58%) MS (LCMS) m/z 431.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.57 (s, 3 H) 2.07 - 2.25 (m, 1 H) 2.42 - 2.48 (m, 1 H) 3.11 (s, 3 H) 3.71 - 3.81 (m, 1 H) 3.83 (s, 3 H) 4.00 - 4.11 (m, 1 H) 6.44 (d, J=7.02 Hz, 1 H) 6.92 (dd, J=8.59, 2.54 Hz, 1 H) 7.00 (dd, J=12.39, 2.44 Hz, 1 H) 7.42 (t, J=8.49 Hz, 1 H) 8.03 (d, J=5.85 Hz, 1 H) 9.25 (br. s., 1 H) 11.10 (s, 1 H).
Example 28 (2R)-4-[5-Fluoro-4-(4-methoxyphenyn-2-oxopyridin-1 (2H)-yl1-N-hydroxy-2-methyl-2(methylsulfonvl)butanamide
Step A) (2R)-4-r5-Fluoro-4-(4-methoxvDhenvlÎ-2-oxoDvridin-1(2H)-vÎl-2-methvl-2(methvlsulfonvn-N-(tetrahvdro-2H-Dvran-2-vloxvlbutanamide
The title compound (1.90 g, 98.8%) was obtained as a yellow solid from (4methoxyphenyl)boronic acid (902 mg, 5.94 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxyjbutanamide, T3, (2.0 g, 3.87 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 495.4 (M-1).
Step B) (2R)-445-Fluoro-4-f4-methoxvDhenvlÎ-2-oxopvridin-1(2HÎ-vl1-N-hydroxv-266 methyl-2-(methylsulfonvl)butanamide
The title compound (651 mg, 41.3%) was obtained as a white solid from (2R)-4-[5fluoro-4-(4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (1.90 g, 3.83 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-Îluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide Example 26, Step E. MS (LCMS) m/z 413.0 (M+1). 1H NMR (400 MHz, DMSO-t/6) δ ppm 1.57 (s, 3 H) 2.08 - 2.23 (m, 1 H) 2.41 - 2.48 (m, 1 H) 3.11 (s, 3 H) 3.72 - 3.80 (m, 1 H) 3.81 (s, 3 H) 3.97 - 4.13 (m, 1 H) 6.49 (d, J=7.81 Hz, 1 H) 6.95 - 7.15 (m, 2 H) 7.46 - 7.67 (m, 2 H) 7.99 (d, J=6.63 Hz, 1 H) 9.24 (s, 1 H) 11.11 (s, 1 H).
Example 29 (2R)-4-F5-Fluoro-4-(4-methvlphenyl)-2-oxopyridin-1(2H)-vl1-N-hydroxv-2-methvl-2(methylsulfonyl)butanamide
MeOjS^.
Step A) Ethyl (2R)-4-r5-fluoro-4-(4-methvlphenvlÎ-2-oxopyridin-1(2H)-yl1-2-methvl2-(methvlsulfonyl)butanoate
The title compound (484 mg) was obtained as a brown gum from (4methylphenyl)boronic acid (229 mg, 1.68 mmol) and ethyl (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate ,T2, (500 mg, 1.12 mmol) using a procedure analogous to that described for the préparation of ethyl (2R)-4-{5fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}-2-methyl-2(methylsulfonyl)butanoate, Example 27, Step B. MS (LCMS) m/z 410.1 (M+1).
Step B) (2R)-4-r5-Fluoro-4-(4-methvlphenyl)-2-oxopvridin-1(2H)-vl1-2-methvl-2(methylsulfonyl)butanoic acid
The title compound (294 mg, 65.2%) was obtained as a white solid from ethyl (2R)-4-[5-fluoro-4-(4-methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2(methylsulfonyl)butanoate (484 mg, 1.18 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2yl)phenyljpyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)butanoic acid, Example 26, Step
C. MS (LCMS) m/z 382.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.57 (s, 3 H)
2.14 - 2.25 (m, 0 H) 2.36 (s, 3 H) 2.43 - 2.54 (m, 1 H) 3.17 (s, 3 H) 3.89 - 4.07 (m, 2 H)
6.46 (d, 4=7.81 Hz, 1 H) 7.31 (d, 4=8.00 Hz, 2 H) 7.42 - 7.52 (m, 2 H) 8.03 (d, 4=6.83
Hz, 1 H).
Step C) (2R)-4-i5-Fluoro-4-(4-methvÎphenvl)-2-oxopyridin-1(2H)-vn-2-meÎhyl-2(methvlsulÎonvl)-N-(tetrahvdro-2H-pyran-2-yloxv)butanamide
The title compound (331 mg, 89.3%) was obtained as a white solid from (2R)-4-[5fluoro-4-(4-methylphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanoic acid (294 mg, 0.77 mmol) using a procedure analogous to that described for the préparation of 2R)-4~[5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl)~ 2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 26, Step D. MS (LCMS) m/z 479.3 (M-1).
Step D) (2R)-445-Fluoro-4-(4-methvlphenvl)-2-oxopvridin-1i2H)-yl1-N-hvdroxv-2methyl^-fmethylsulfonvDbutanamide
The title compound (96 mg, 34%) was obtained as a white solid from (2R)-4-[5-fluoro-4(4-methylphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (331 mg, 0.69 mmol) using a procedure analogous to that described for the préparation of 2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2yl)phenyl]pyridin-1(2H)-yl}-2-methyl-2-(meÎhylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 397.0 (M+1). 1H NMR (400 MHz, DMSO-46) δ ppm 1.58 (s, 3 H) 2.10 2.25 (m, 1 H) 2.37 (s, 3 H) 2.42 - 2.49 (m, 1 H) 3.12 (s, 3 H) 3.71 - 3.84 (m, 1 H) 4.00 4.12 (m, 1 H) 6.51 (d, 4=7.81 Hz, 1 H) 7.32 (d, 4=7.81 Hz, 2 H) 7.48 (dd, 4=8.20, 1.76 Hz, 2 H) 8.02 (d, 4=6.83 Hz, 1 H) 9.24 (d, 4=1.76 Hz, 1 H) 11.11 (d, 4=1.95 Hz, 1 H).
Example 30 (2R)-4-ί5-Fluoro-2-oxo-4-[4-ίtrifluoromethoxv)pheπvl1pvridin-1(2H)-vll·-N-hvdroxv-2methvl-2-(methvlsulfonvl)butanamide
NHOH x/
Step A) (2R)-4~i5-Fluoro-2-oxo-4-r4-(trifluoromeÎhoxv)ohenyllpyridin-1 (2Η)-νΙΤ2methvl-2-(methylsulfonvl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide
The title comppund (69.7 mg, 49.1%) was obtained as a yellow-white solid from [4(trifluoromethoxy)phenyl]boronic acid (82.3 mg, 0.47 mmol) and (2R)-4-(5-fluoro-4-iodo2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (133 mg, 0.26 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 20, Step A. MS (LCMS) m/z 551.1 (M-1).
Step B) (2R)-4-(5-Fluoro-2-oxo-4-[4-(trifluoromethoxv1iphenvllPvridin-1 (2Η)-νΙΤ·Νhvdroxv-2-methvl-2-(methylsulfonvl)butanamide
The title compound (12.2 mg, 20.9%) was obtained as a white solid from (2R)-4-{5fluoro-2-oxO“4-[4-(trifluoromethoxy)phenyl]pyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)N-(tetrahydro-2H-pyran-2-yloxy)butanamide (68.9 mg, 0.13 mmol) using a procedure analogous to that described for the préparation of (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 467.0(M+1). 1H NMR (400 MHz, DMSO-cf6) δ ppm 1.57 (s, 3 H) 2.07 - 2.25 (m, 0 H) 2.39 - 2.55 (m, 1 H) 3.11 (s, 3 H) 3.72 - 3.86 (m, 1 H) 3.97 - 4.13 (m, 1 H) 6.58 (d, 1 H) 7.50 (d, J=8.00 Hz, 2 H) 7.65 - 7.77 (m, 2 H) 8.06 (d, J=6.44 Hz, 1 H) 9.23 (d, J=1.17 Hz, 1 H) 11.08 (s, 1 H).
Example 31 (2R)-4-[5-Fluoro-4-(4-fluoroDhenvl)-2-oxopyridin-1(2H)-vll-N-hydroxv-2-methyl-2(methvlsulfonvl)butanamide
NHOH
Step A) (2R)-4-f5-Fluoro-4-(4-fluorophenvl)-2-oxoovridin-1(2H)-vÎl-2-methvl-2(methvlsulfonvl)-N-(tetrahydro-2H-pvran-2-vloxv)butanamide
The title compound (67 mg, 54%) was obtained as a white solid from (4fluorophenyl)boronic acid (66.2 mg, 0.47 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-
yloxy)butanamide, T3, (133 mg, 0.26 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxyjbutanamide, Example 19, Step A. MS (LCMS) m/z 483.1 (M-1).
Step B) (2R)-4-r5-Fluoro-4-(4-fluoroDhenyl)-2-oxoDyridin-1 (2H)-vll-N-hvdroxy-2methvl-2-(methvlsulfonvl)butanamide
The title compound (7.9 mg, 14%) was obtained as a white solid from (2R)-4-[5-fluoro-4(4-fluorophenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (67 mg, 0.14 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 401.0 (M+1). 1H NMR (400 MHz, DMSO-de) ô ppm 1.58 (s, 3 H) 2.10 - 2.24 (m, 1 H) 2.42 - 2.50 (m, 1 H) 3.12 (s, 3 H) 3.71 - 3.88 (m, 1 H) 3.99 - 4.14 (m, 1 H) 6.55 (d, J=7.61 Hz, 1 H) 7.25 - 7.45 (m, 2 H) 7.58 - 7.72 (m, 2 H) 8.05 (d, J=6.83 Hz, 1 H) 9.24 (s, 1 H) 11.10 (s, 1 H).
Example 32 (2R)-4-ί5-Fluoro-4-F4-ί6-methoxvpvridin-3-vlΐphenyll·2-oxopvridin-1(2H)-vll·N-hvdroxv2-methvl-2-(methylsulfonyl)butanamide
Step A) 2-Methoxv-5-f4-(4.4.5,5-tetramethvl-1,3l2-dioxaborolan-2vDphenyllpyridine
The title compound (1.40 g) was obtained as a white solid from 5-(4-bromophenyl)-2methoxypyridine (1.0 g, 3.8 mmol) using a procedure analogous to that described for the préparation of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3triazole, Example 26, Step A. MS (LCMS) m/z 312.1 (M+1).
Step B) (2R)-4-i5-Fluoro-4-[4-(6-methoxypyridin-3-vl)phenvÎl-2-oxopyridin-1(2H1νΙ>-2-ωθΐήνΙ-2-^θΐΚνΐ3υΙίοηνύ-Ν-(ΐθΐΓ3ήνάΐΌ-2Η-ρνΓ3η-2vloxy)butanamide
The title compound (273 mg, 61.4%) was obtained as a yellow solid from 2-methoxy-5[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyridine (362 mg, 1.16 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide, T3, (400 mg, 0.78 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 574.0 (M+1).
Step C) (2R)-445-Fluoro-4-[4-(6-methoxvpyridin-3-yl)phenvn-2-oxoovridin-1(2H)yl}-N-hvdroxy-2-methyl-2-(methvlsulfonvl)butanamide
The title compound (156 mg, 67%) was obtained as a white solid from (2R)-4-{5-fiuoro4-[4-(6-methoxypyridin-3-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2-(methylsulfonyl)N-(tetrahydro-2H-pyran-2-yloxy)butanamide (273 mg, 0.48 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 490.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.58 (s, 3 H) 2.09 - 2.27 (m, 0 H) 2.43 - 2.57 (m, 1 H) 3.12 (s, 3 H) 3.73 - 3.86 (m, 1 H) 3.91 (s, 3 H) 4.00-4.14 (m, 1 H) 6.59 (d, J=7.61 Hz, 1 H) 6.94 (d, J=8.59 Hz, 1 H) 7.60 - 7.73 (m, 2 H) 7.75 - 7.86 (m, 2 H) 7.98 - 8.19 (m, 2 H) 8.57 (d, J=2.54 Hz, 1 H) 9.25 (br. S., 1 H) 11.10 (s, 1 H).
Example 33 (2Ην4-ί4-Γ4-(ΡΐΑυοΓθΠΊθΐΙιοχν)ρΐΊθηνΠ-5-ίΙυοΓθ-2-οχορνΓ'^ΐη-1(2Η)-νΙ>-Ν-ΐΊνόΓθχν-2methvl^-fmethvIsulfonvDbutanamide
NHOH
Step A) | (2R)-4-i4-[4-(Difluoromethoxv)phenvll-5-fluoro-2-oxopvridin-1 (2H)-vl}-2- methyl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2-vloxv)butanamide |
x/
The title compound (69.7 mg, 49.1%) was obtained as a yellow solid from 2-[4(difluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (82.3 mg, 0.47 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (133 mg, 0.26 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 531.2 (M-1).
Step B) (2R)-4-f4-r4-(Difluoromethoxy)phenvl1-5-fluoro-2-oxoovridin-1(2H)-yl}-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide
The title compound (9.0 mg, 18%) was obtained as a white solid from (2R)-4-{4-[4(difluoromethoxy)phenyl]-5-fluoro-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (58.0 mg, 0.11 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-2-oxo-4-[4-(2H-1,2,3trrazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 449.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.58 (s, 3 H) 2.09 - 2.26 (m, 1 H) 2.40 - 2.48 (m, 1 H) 3.12 (s, 3 H) 3.71 - 3.86 (m, 1 H) 3.98-4.14 (m, 1 H) 6.55 (d, 1 H) 7.13-7.57 (m, 3 H) 7.61 -7.80 (m, 2 H) 8.05 (d, J=6.63 Hz, 1 H) 9.24 (d, 7=1.76 Hz, 1 H) 11.10 (d, 7=1.56 Hz, 1 H).
Example 34 (2R)-4-Î5-Fluoro-4-(4-methoxv-3-methvlphenvl)-2-oxopvridin-1(2H)-vll-N-hvdrexy-2methvl-2-(methylsulfonyl)butanamide
NHOH
Step A) (2RÏ-445-Fluoro-4-(4-methoxv-3-methvlphenvl)-2-oxopyridin-1(2H)-vl1-2methvl-2-(methylsulfonvl)-N-(tetrahydro-2H-pvran-2-vloxv)butanamide
The title compound (332.1 mg, 65.2%) was obtained as a yellow solid from (4-methoxy3-methylphenyl)boronic acid (280 mg, 1.69 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (500 mg, 0.97 mmol) using a procedure analogous to that v/ described for the préparation of (2R)-4-[5-fiuoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxyjbutanamide, Example 19, Step A, MS (LCMS) m/z 511.0 (M+1).
Step B) (2R)-4-r5-Fluoro-4-(4-methoxy-3-methylDhenyn-2-oxoDvridin-1(2H)-vl]-Nhvdroxv-2-methvl-2-(methvlsulfonvl)butanamide
The title compound (46 mg, 17%) was obtained as a white solid from (2R)-4-[5-fluoro-4(4-methoxy-3-methylphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (322 mg, 0.63 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 427.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.57 (s, 3 H) 2.08 - 2.25 (m, 4 H) 2.38 - 2.49 (m, 1 H) 3.11 (s, 3 H) 3.70 - 3.81 (m, 1 H) 3.84 (s, 3 H) 3.97 - 4.11 (m, 1 H) 6.48 (d, 1 H) 7.05 (d, J=8.39 Hz, 1 H) 7.28 - 7.50 (m, 2 H) 7.98 (d, J=6.63 Hz, 1 H) 9.24 (br. S., 1 H) 11.11 (s, 1 H).
Examole 35 (2R)-4-(4-Γ4-(difluoromethoxy)-3-fluoroDhenvll-5-fluoro-2-oxoDyridin-1(2H)-yll·Nhydroxv-2-methyl-2-(methylsulfonvnbutanamide
Step A) (2R)-4-(4-r4-(DifluoromethoxyÎ-3-fluoroDhenvl1-5-fluoro-2-oxoDvridin1 (2H)-vn-2-methvl-2-(methylsulfonyl)-N-(tetrahvdro-2H-Dvran-2vloxvlbutanamide
The title compound (227 mg, 42.6%) was obtained as a yellow-white solid from 2-[4(difluoromethoxy)-3-fluorophenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (630 mg, 2.19 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (500 mg, 0.97 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 549.3 (M-1).
Step B) (2R)-4-{4-r4-(Difluoromethoxy)-3-fluoroDhenyn-5-fluoro-2-oxopvridin1 (2H)-vlÎ-N-hydroxy-2-methvl-2-(rneÎhylsulfonvl)butanamide
The title compound (92 mg, 62%) was obtained as a white solid from (2R)-4-{4-[4(difluoromethoxy)-3-fluorophenyl]-5-fluoro-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (227 mg, 0.41 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5“fluoro-2oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 467.0 (M+1). 1H NMR (400 MHz, DMSO-cf6) δ ppm 1.57 (s, 3 H) 2.08 - 2.22 (m, 1 H) 2.40 - 2.48 (m, 1 H) 3.11 (s, 3 H) 3.70 - 3.86 (m, 1 H) 3.97 - 4.14 (m, 1 H) 6.61 (d, 1 H) 7.09 - 7.38 (m, 1 H) 7.42 - 7.57 (m, 2 H) 7.69 (d, /=11.12 Hz, 1 H) 8.07 (d, /=6.63 Hz, 1 H) 9.24 (br. S., 1 H) 11.08 (s, 1 H).
Example 36 (2R)-4-Î5-Fluoro-4-r3-fluoro-4-(2H-1.2.3-triazol-2-yl)DhenyH-2-oxopvridin-1 (2H)-vll-N hvdroxv-2-methyl-2-(methylsulfonvl)butanamide
MeO2S.
Step A) (1 E,2E)-Ethanedial bis[(4-bromo-2-fluorophenvl)hvdrazonel (4-Bromo-3-fluorophenyl)hydrazine-hydrochloride (5.0 g, 24.3 mmol) was added to a mixture of EtOAc (60 mL) and 3 N aq NaOH (60 mL) and the mixture was stirred until ail solids went into solution. The organic layer was separated and the aqueous layer was extracted with EtOAc (2x60 mL). The combined organics were washed with brine (60 mL), dried (MgSO4), filtered and concentrated to afford an orange solid (3.27 g, 15.9 mmol). The solid was suspended in toluene (25 mL). Oxalaldéhyde (40% aq solution, 912 uL, 7.92 mmol) was added dropwise to the solution and the reaction was stirred overnight at rt. The precipitate was collected via filtration and washed with toluene (25 mL) and hexanes (50 mL). The solid was dried under vacuum to afford the title compound as a yellow solid (2.61 g, 78.1%). MS (LCMS) m/z 431.1 (M-1).
Step B)
2-(4-Bromo-2-fluorophenvl)-2H-1,2.3-triazole
Copper (II) trifluoromethanesulfonate (218 mg, 0.60 mmol) was added to a slurry of (1 E,2E)-ethanedial bis[(4-bromo-2-fluorophenyl)hydrazone] (2.61 g, 6.04 mmol) in toluene (25 mL). The reaction was heated to reflux and stirred at this température overnight. The réaction was allowed to cool and was filtered through celite, and the filter pad was washed with EtOAc (100 mL). The combined filtrâtes were washed with 1 N aq HCl (3x100 mL), water (100 mL), and brine (100 mL) and then dried (MgSO4), filtered and concentrated. The crude product was purified via flash chromatography using a Varian SF25-40g column and an eluent of EtOAc in hexanes (0-50%) to afford the title compound as a yellow solid (1.08 g, 73.9%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.44 (ddd, 1 H) 7.47-7.54 (m, 1 H) 7.76 (t, 1 H) 7.90 (s, 2 H).
Step C) 2-(2-Fluoro-4-(4,4.5.5-tetramethvl-1.3.2-dioxaborolan-2-vl)Dhenvl1-2H-
1,2,3-triazole
The title compound (1.54 g) was obtained as a yellow solid from 2-(4-bromo-2fluorophenyl)-2H-1,2,3-triazole (1.08 g, 4.82 mmol) using a procedure analogous to that described for the préparation of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]-2H-1,2,3-triazole, Example 26, Step A. MS (LCMS) m/z 290.1 (M+1).
Step D) fëRM-ÎS-Fluoro^-fS-fluoro^-tëH-I^.S-triazol^-yDDhenvIl^-oxoDyridin1 (2H)-vlL2-methvl-2-(methvlsulÎonvl)-N-(tetrahvdro-2H-Dvran-2vloxv)butanamide
The title compound (275 mg, 51.5%) was obtained as a yellow solid from 2-[2-fluoro-4(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3-triazole (420 mg, 1.45 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (500 mg, 0.97 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 550.3 (M-1 ).
Step E) (2R)-4-Î5-Fluoro-4-(3-fluoro-4-(2H-1,2,3-triazol-2-yl)Dhenyn-2-oxoDvridin1 (2H)-yn-N-hvdroxy-2-methyl-2-(methylsulfonvl)butanamide
The title compound (133 mg, 57%) was obtained as a white solid from (2R)-4-(5-fluoro4-[3-fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl]-2-oxopyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-y1oxy)butanamide (275 mg, 0.50 mmol)
V through a procedure analogous to that described for the préparation of (2R)-4-(5-fluoro2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyndin-1 (2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z468.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.58 (s, 3 H) 2.10-2.25 (m, 0 H) 2.43-2.56 (m, 1 H) 3.12 (s, 3 H) 3.74-3.89 (m, 1 H) 4.00-4.15 (m, 1 H) 6.70 (d, J=7.61 Hz, 1 H) 7.60 - 7.66 (m, 1 H) 7.75 - 7.86 (m, 1 H) 8.00 (t, J=8.20 Hz, 1 H) 8.10 (d, J=6.63 Hz, 1 H) 8.23 (s, 2 H) 9.24 (br. S., 1 H) 11.08 (s, 1 H).
Examole 37 (2R)-4-f5-Fluoro-4-r3-methvl-4-(2H-1.2,3-triazol-2-vl)phenvll-2-oxopyridin-1 (2H)-yl}-N hvdroxv-2-meÎhyl-2-(methvlsulfonvl)butanamide
Step A) (1 E,2E)-Ethanedial bisK4-bromo-2-meÎhvlphenyl)hydrazone1
The title compound (1.45 g, 87.9%) was obtained as a yellow solid from (4-bromo-2methylphenyl)hydrazine-hydrochloride (2.00 g, 8.42 mmol) and oxalaldéhyde (40% aq solution, 450 uL, 3.9 mmol) through a procedure analogous to that described for the préparation of (1 E,2E)-ethanedial bis[(4-bromo-2-fluorophenyl)hydrazone], Example 36, Step A. MS (LCMS) m/z 425.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 2.20 (s, 6 H) 7.09 - 7.33 (m, 6 H) 7.95 (s, 2 H) 9.73 (s, 2 H).
Step B) 2-(4-Bromo-2-methvlohenvl)-2H-1.2.3-triazole
The title compound (608 g, 59.0%) was obtained as a yellow solid from (1 E,2E)ethanedial bis[(4-bromo-2-methylphenyl)hydrazone (1.45 g, 3.42 mmol) through a procedure analogous to that described for the préparation of 2-(4-bromo-2fluorophenyl)-2H-1,2,3-triazole, Example 36, Step B. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.38 (s, 3 H) 7.44 - 7.48 (m, 2 H) 7.50 - 7.53 (m, 1 H) 7.85 (s, 2 H).
Step C) 2-f2-Methyl-4-(4,4,5,5-tetramethvl-1.3,2-dioxaborolan-2-vl)phenvl1-2H-
1,2,3-triazole
The title compound (688 mg, 82.3%) was obtained as an orange solid from 2-(4-bromo2-methylphenyl)-2H-1,2,3-triazole (698 mg, 2.93 mmol) through a procedure analogous to that described for the préparation of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]-2H-1,2,3-triazole, Example 26, Step A. 1H NMR (400 MHz, CHLOROFORMtf) δ ppm 1.36 - 1.41 (m, 12 H) 2.42 (s, 3 H) 7.61 (d, J=8.00 Hz, 1 H) 7.76 (d, J=7.81 Hz, 1 H) 7.80 (S, 1 H) 7.85 (s, 2 H).
Step D) (2R)-4-Î5-Fluoro-4-[3-methvl-4-(2H-1,2,3-triazol-2-yl)phenvH-2-oxopvridin1(2H)-yl>-2-methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2yloxv)butanamide
The title compound (630 mg, 71.5%) was obtained as a yellow solid from 2-[2-methyl-4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-1,2,3-triazole (688 mg, 2.41 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, T3, (830 mg, 1.61 mmol) through a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3fluoro-4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 546.2(M-1).
Step E) (2R)-4-i5-Fluoro-4-Î3-methyl-4-(2H-1.2.3-triazol-2-vl)ohenvl1-2-oxopyridin1 (2Η)-νΙ>-Ν-Ι^Γθχν-2-Γη6ίήνΙ-2-(|·ϊΐ6ίΐΊνΐ3υΙΐοηνΙ^υΐ3η3ηΤ^θ
The title compound (253 mg, 47.5%) was obtained as a white solid from (2R)-4-{5fluoro-4-[3-methyl-4-(2H-1,2,3-triazol·2-yl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (630 mg, 1.15 mmol) through a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 464.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.58 (s, 3 H) 2.11 - 2.26 (m, 1 H) 2.39 (s, 3 H) 3.11 (s, 3 H) 3.74 - 3.87 (m, 1 H) 3.99 - 4.16 (m, 1 H) 6.64 (d, J=7.61 Hz, 1 H) 7.60 (d, J=8.00 Hz, 1 H) 7.63 - 7.77 (m, 2 H) 8.08 (d, J=6.63 Hz, 1 H) 8.16 (s, 2 H) 9.24 (br. s., 1 H) 11.09 (s, 1 H).
Example 38 (2R)-4-(3,5-Difluoro-2-oxo-4-phenvlpvridin-1 (2H)-yl)-N-hydroxy-2-methyl-2(methvlsulfonvl)butanamide
J
Step A) 3,5-Difluoro-4-iodopyridin-2(1H)-one
2,3I5-Trifluoro-4-iodopyridine (6.03 g, 23.3 mmol) was suspended in 6 M aq HCl (250 mL). The mixture was heated to reflux and was stirred at this température overnight. The reaction was concentrated to dryness to afford the title compound as an orange solid (4.14 g, 69.2%). MS (LCMS) m/z 257.9 (M+1).
Step B) Ethyl (2R)-4-(3,5-difluoro-4-iodo-2-oxopvridin-1 (2H)-vl)-2-methvl-2(methvlsulfonyl)butanoate
Césium carbonate (1.90 g, 5.84 mmol) was added to a solution of the 3,5-difluoro-4iodopyridin-2(1 H)-one (1.0 g, 3.9 mmol) and ethyl (2R)-4-bromo-2-methyl-2(methylsulfonyl)butanoate, T1, (1.45 g, 5.06 mmol) in tetrahydrofuran:t-butanol (1:1,50 mL). The resulting suspension was heated to reflux and was stirred at this température for 72 h. The reaction was filtered through celite, and the filter pad was washed with EtOAc (3x50 mL). The combined filtrâtes were concentrated and the crude product was purified via flash chromatography on an Analogix SF15-24g column using an eluent of EtOAc in hexanes (0-50%) to afford the title compound as a yellow solid (575.6 mg, 32%). MS (LCMS) m/z 463.9(M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.23 (s, 3 H) 1.58 (s, 3 H) 2.20 (dt, 7=13.90, 7.00 Hz, 1 H) 2.52 - 2.62 (m, 1 H) 3.14 (s, 3 H) 4.00 (t, 7=7.61 Hz, 2 H) 4.05 - 4.22 (m, 2 H) 7.94 (dd, 7=4.20, 2.05 Hz, 1 H).
Step C) Ethyl (2R)-4-(3,5-difluoro-2-oxo-4-phenylpyridin-1(2H)-vl)-2-methvl-2(methylsulfonvl)butanoate
The title compound (110 mg, 63%) was obtained as a white solid from phenylboronic acid (98.8 mg, 0.81 mmol) and ethyl (2R)-4-(3,5-difluoro-4-iodo-2-oxopyridin-1 (2H)-yl)2-methyl-2-(methylsulfonyl)butanoate (250 mg, 0.54 mmol) using a procedure analogous to that described for the préparation of ethyl (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-
1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)butanoate, Example 26, Step B. MS (LCMS) m/z 414.0 (M+1). 1H NMR (400 MHz, CHLOROFORM-7) δ ppm 1.33 - 1.46 (m, 3 H) 1.78 (s, 3 H) 2.44 - 2.65 (m, 2 H) 3.14 (s, 3 H) 3.98 - 4.16 (m, 1 H) 4.25 - 4.43 (m, 3 H) 7.23 (dd, J=5.07, 2.15 Hz, 1 H) 7.40 7.61 (m, 5 H).
Step D) (2R)-4-(3,5-Difluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-methyl-2(methvlsulfonyl)butanoic acid
The title compound (91 mg, 79.2%) was obtained as a white solid from ethyl (2R)-4(3,5-difluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-methyl-2-(methylsuifonyl)butanoate (110 mg, 0.27 mmol) using a procedure analogous to that described for the préparation of (2R)-4~(5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoic acid, Example 26, Step C. MS (LCMS) m/z 386.0 (M+1).
Step E) (2R)-4-(3,5-Difluoro-2-oxo-4-phenylovridin-1(2H)-vl)-2-methyl-2(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2-yloxv)butanamide
The title compound (75.9 mg, 66%) was obtained as an off-white solid from (2R)-4-(3,5difluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (91 mg, 0.36 mmol) using a procedure analogous to that described for the préparation of 2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 26, Step D. MS (LCMS) m/z 483.2 (M+1).
Step F) (2R)-4-(3,5-Difluoro-2-oxo-4-phenylpyridin-1 (2HÎ-yl)-N~hvdroxv-2-meÎhvl2-(methyisulfonv1)butanamide
The title compound (13.9 mg, 22%) was obtained as a white solid from (2R)-4-(3,5difluoro-2-oxo-4-phenylpyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide (75 mg, 0.16 mmol) using a procedure analogous tothat described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide Example 26, Step E. MS (LCMS) m/z 401.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.59 (s, 3 H) 2.11-2.22 (m, 1 H) 2.52-2.62 (m, 1 H) 3.10 (s, 3 H) 3.79-3.99 (m, 1 H) 4.03 -4.20 (m, 1 H) 7.40 - 7.64 (m, 5 H) 7.98 (dd, J=5.85, 1.95 Hz, 1 H) 9.24 (br. S., 1 H) 11.01 (s, 1 H).
Example 39 (2R)-4-(5-Fluoro-3-methoxv-2-oxo-4-phenvlpyridin-1 (2H)-vl)-N-hvdroxv-2-methvl-2(methylsulfonyl)butanamide x/
ΝΗΟΗ
Step A) (2R)-4-(5-Fluoro-3-methoxv-2-oxo-4-DhenylDvridin-1 (2H)-vl)-2-methvl-2(methylsulfonyl)butanoic acid
Potassium hydroxîde (100 mg, 1.78 mmol) was added to a solution of ethyl (2R)-4-(3,5difluoro-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate (77 mg, 0.19 mmol) in tetrahydrofuran:methanol:water (2:2:1 10 mL). The solution was heated to 50 °C and stirred at this température for 4 h. The reaction was concentrated and the residue was dissolved in 1 N aq NaOH (50 mL). The aqueous layer was washed with EtOAc (3x50 mL) and acidified to a pH of 3 using concentrated HCl. The solid was collected via filtration and was washed with water (30 mL) and hexanes (30 mL) to afford the title compound as a white solid (70 mg, 95%). MS (LCMS) m/z 398.0(M+1). 1H NMR (400 MHz, METHANOL-^) δ ppm 1.69 -1.79 (m, 3 H) 2.30 - 2.46 (m, 1 H) 2.55 - 2.72 (m, 1 H) 3.18 (s, 3 H) 3.66 (s, 3 H) 4.08 - 4.22 (m, 1 H) 4.23 - 4.38 (m, 1 H)
7.39 - 7.51 (m, 5 H) 7.60 (d, 1 H).
Step B) (2R)-4-(5-Fluoro-3-methoxv-2-oxo-4-DhenylDvridin-1 (2H)-vl)-2-methvl-2(methvlsulfonvl)-N-(tetrahvdro-2H-Dvran-2-yloxv)butanamide
The title compound (52 mg, 83%) was obtained as an off-white solid from (2R)-4-(5fluoro-3-methoxy-2-oxo-4-phenylpyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid (50 mg, 0.13 mmol) using a procedure analogous to that described for the préparation of 2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2t3-triazol-2-yl)phenyl]pyridin-1 (2H)-y)}2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 26, Step D. MS (LCMS) m/z 497.0 (M+1).
Step C) (2R)-4-(5-Fluoro-3-methoxv-2-oxo-4-DhenvlDvridin-1(2H)-vl)-N-hydroxy-2methyl-2-(methvlsulfonyl)butanamide
The title compound (20.2 mg, 48%) was obtained as an off-white solid from (2R)-4-(5fluoro-3-methoxy-2-oxo-4-phenylpyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (75 mg, 0.16 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,
Example 26, Step E. MS (LCMS) m/z 413.0 (M+1). 1H NMR (400 MHz, METHANOLd4) δ ppm 1.72 (s, 3 H) 2.30 - 2.50 (m, 1 H) 2.55 - 2.78 (m, 1 H) 3.10 (s, 3 H) 3.68 (s, 3
H) 3.95 - 4.06 (m, 1 H) 4.21 - 4.37 (m, 1 H) 7.37 - 7.55 (m, 5 H) 7.61 (d, 1 H).
Example 40 (2R)-4-(5-Fluoro-3-hvdroxv-2-oxo-4-phenvlpyridin-1(2H)-vl)-N-hvdroxv-2-meÎhvl-2(methylsulfonvl)butanamide
NHOH
Step A) (2R)-4-(5-Fluoro-3-hvdroxv-2-oxo-4-phenvlpyridin-1 (2H)-vl)-N-hvdroxy-2methvl-2-(methylsulfonvl)butanamide
Boron tribromide (760 pL, 0.76 mmol, 1.0 M in dichloromethane) was added to a solution of (2R)-4-(5-fluoro-3-methoxy-2-oxo-4-phenylpyridin-1 (2H)-yl)-N-hydroxy-2methyl-2-(methylsulfonyl)butanamide (156 mg, 0.378 mmol) in DCM (16.0 mL) at 0 °C. The reaction was allowed to warm to rt and stirred overnight. The reaction mixture was concentrated to afford a brown solid. The crude product was purified via prepratory HPLC to afford the title compound as a yellow solid (25.4 mg, 16.9%). MS (LCMS) m/z 399.0 (M+1). 1H NMR (400 MHz, DMSO-cfe) δ ppm 1.59 (s, 3 H) 2.11 - 2.25 (m, 1 H) 3.07 (s, 1 H) 3.13 (s, 2 H) 3.70 - 3.88 (m, 1 H) 4.02 - 4.26 (m, 1 H) 7.11 (d, J=7.81 Hz, 1 H) 7.37 - 7.65 (m, 5 H).
Example 41 (2R)-4-f5-Fiuoro-4-(4-isoxazol-3-ylphenvl)-2-oxopvridin-1(2H)-vn-N-hydroxy-2-methvl-2(methylsulfonvl)butanamide
NHOH
Step A) 3-(4-(4,4,5,5-Tetramethvl-1,3,2-dioxaborolan-2-yl)phenvl)isoxazole
The title compound (730 mg, 67.0%) was obtained as a white solid from 3-(4bromophenyl)isoxazole (900 mg, 4.02 mmol) using a procedure analogous to that described for the préparation of 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]-2H-1,2,3-triazole, Example 26, Step A. MS (APCI) m/z 272.1 (M+1). 1H
NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36-1.41 (m, 12 H) 2.42 (s, 3 H) 7.61 (d, J=8.00 Hz, 1 H) 7.76 (d, J=7.81 Hz, 1 H) 7.80 (s, 1 H) 7.85 (s, 2 H). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.35 (s, 12 H) 6.66 - 6.70 (m, 1 H) 7.83 (s, 2 H) 7.88 (s, 2 H) 8.42-8.48 (m, 1 H).
Step B) (2R)-4-f5-Fluoro-4-(4-isoxazol-3-ylphenvl)-2-oxODvridin-1(2HÎ-vll-2-methvl2-(methvlsulfonvl)-N-(tetrahvdro-2H-Dvran-2-vloxy)butanamide
The title compound (655 mg, 63.4%) was obtained as a colorless oil from 3-(4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoxazole (525 mg, 1.94 mmol) and (2R)-4(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H15 pyran-2-yloxy)butanamide, T3, (1.00 g, 1.94 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (APCI) m/z 532.3 (M-1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.53 -1.97 (m, 9 H) 2.31 - 2.47 (m, 1 H) 2.47 - 2.60 (m,
1 H) 3.19 (d, J=2.54 Hz, 3 H) 3.53 - 3.74 (m, 1 H) 4.00 (br. s., 1 H) 4.12 (s, 1 H) 4.27 -
4.40 (m, 1 H) 5.15 (d, J=14.24 Hz, 1 H) 6.63 - 6.75 (m, 2 H) 7.42 (d, J=5.46 Hz, 1 H) 7.62 (d, J=8.00 Hz, 2 H) 7.92 (d, J=8.59 Hz, 2 H) 8.49 (d, J=1.56 Hz, 1 H) 11.85 (d, J=17.76Hz, 1 H).
Step C) (2Rl-4-r5-Fluoro-4-(4-isoxazol-3-vlDhenvl)-2-oxoDvridin-1(2H)-yll-Nhvdroxy-2-methyl-2-(methvlsulfonvl)butanamide
A solution of 1.0 M aq HCl (15 mL) was added slowly to a solution of (2R)-4-[5-fluoro-4(4-isoxazol-3-ylphenyl)-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro2H-pyran-2-yloxy)butanamide (655 mg, 1.23 mmol) in 1,4-dioxane (30 mL) at rt. The reaction was allowed to stir at rt overnight. The reaction was concentrated to a crude material. Water (30 mL) was added to the crude material and the mixture was boiled for 5 minutes. The mixture was allowed to cool to rt and the solid that formed was collected via filtration and dried under high vacuum to afford the title compound as a light yellow solid (314 mg, 56.9%). MS (APCI) m/z 450.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 3 H) 2.10 - 2.21 (m, 1 H) 2.42 - 2.49 (m, 1 H) 3.09 (s, 3 H) 3.66 - 3.85 (m,
H) 3.96 - 4.09 (m, 1 H) 6.59 (d, J=7.61 Hz, 1 H) 7.21 (d, J=1.56 Hz, 1 H) 7.71 (dd,
J=8.39, 1.76 Hz, 2 H) 8.00 (d, J=8.39 Hz, 2 H) 8.04 (d, J=6.44 Hz, 1 H) 9.03 (d, J=1.56
Hz, 1 H) 9.16 - 9.28 (m, 1 H) 11.06 (s, 1 H).
Example 42 (2R)-445-Fluoro-4-r4-(1.3-oxazol-2-yl)Dhenvl1-2-oxoDvridin-1(2H)-vl}-N-hydroxv-2methvl-2-(methylsulfonvl)butanamide
NHOH
Step A) 2-(4-(4,4,5,5-Tetramethvl-1.3,2-dioxaborolan-2-yl)Dhenvl1-1.3-oxazole
The title compound (240 mg, 34.3%) was obtained as a white solid from 2-(4iodophenyl)-1,3-oxazole (700 mg, 2.58 mmol) using a procedure analogous to that described for the préparation of 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]-2H-1,2,3-triazole, Example 26, Step A. MS (APCI) m/z 272.2 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.35 (s, 12 H) 7.23 - 7.24 (m, 1 H) 7.69 7.73 (m, 1 H) 7.86 - 7.91 (m, 2 H) 7.98 - 8.05 (m, 2 H).
Step B) (2R)-445- Fluoro-4-(4-( 1, 3-oxazol-2-vl)Dhenvl1-2-oxopvridin-1 (2Η)-νΙΤ·2methyl-2-(methylsulfonvl)-N-(tetrahvdro-2H-pvran-2-yloxy)butanamide The title compound (145 mg, 30.7%) was obtained as a colorless oil from 2-(4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazole (240 mg, 0.89 mmol) and (2R)4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, T3, (435 mg, 0.84 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (APCI) m/z 532.5 (M-1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.52- 1.98 (m, 9 H) 2.35 - 2.47 (m, 1 H) 2.48 - 2.60 (m, 1 H) 3.20 (d, J=2.93 Hz, 3 H) 3.56 - 3.71 (m, 1 H) 3.96 - 4.07 (m, 1 H) 4.12 - 4.22 (m, 1 H) 4.32 - 4.46 (m, 1 H) 5.12 - 5.23 (m, 1 H) 6.69 - 6.75 (m, 1 H) 7.27 (s, 1 H) 7.37 - 7.45 (m, 1 H) 7.63 (dd, J=8.39, 1.56 Hz, 2 H) 7.75 (s, 1 H) 8.14 (d, J=8.39 Hz, 2 H) 11.79 11.95 (m, 1 H).
Step C) (2R)-4-45-Fluoro-4-[4-(1 .a-oxazolAvIlDhenyll-AoxoDvridin-l (2Η)-νΙΪ-Νhvdroxv-2-methyl-2-(methylsulfonvl)butanamide
The title compound (31 mg, 25%) was obtained as a solid from (2R)-4-{5-fluoro-4-[4(1,3-oxazol-2-yl)phenyl]-2-oxopyridin-1(2H)-yl}-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (145 mg, 0.27 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4-isoxazol-3ylphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 41, Step C. MS (APCI) m/z 450.2 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 3 H) 2.11 - 2.23 (m, 1 H) 2.39 - 2.47 (m, 1 H) 3.09 (s, 3 H) 3.61 - 3.84 (m, 1 H) 3.91 - 4.12 (m, 1 H) 6.58 (d, J=7.61 Hz, 1 H) 7.41 (s, 1 H) 7.72 (d, J=7.02 Hz, 2 H) 7.91 -8.12 (m, 3 H) 8.25 (s, 1 H) 9.12-9.29 (m, 1 H) 10.87 -11.17 (m, 1 H).
Example 43 (2R)-4-[5-Fluoro-4-(4-Îrideuteromethvlphenvh-2-oxopyridin-1(2H)-vll-N-hydroxv-2methvl-2-(methylsulfonvl)butanamide
Step A) (2R)-4-r5-Fluoro-4-(4-trideuteromethylphenvl)-2-oxopvridin-1(2H)-vl1-2meÎhvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pvran-2-yloxy)butanamide
The title compound (216 mg, 76.9%) was obtained as a light orange oil from (4trideuteromethylphenyl)boronic acid (85 mg, 0.61 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide,T3, (300 mg, 0.58 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (APCI) m/z 482.4 (M-1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.50 - 1.97 (m, 9 H) 2.32 - 2.44 (m, 1 H) 2.44 - 2.59 (m, 1 H) 3.17 (d, J=2.34 Hz, 3 H) 3.53 - 3.69 (m, 1 H) 4.00 (br. s., 1 H) 4.10 - 4.20 (m, 1 H)
4.31 (br. s., 1 H) 5.14 (d, J=14.44 Hz, 1 H) 6.65 (dd, J=7.22, 1.56 Hz, 1 H) 7.21 -7.28 (m, 2 H) 7.36 (d, J=5.27 Hz, 1 H) 7.38 - 7.44 (m, 2 H) 11.89 -12.06 (m, 1 H).
Step B) (2R)-4-[5-Fluoro-4-(4-trideuteromethvlDhenvn-2-oxoDvridin-1 (2H)-vl1-Nhydroxv-2-methvl-2-(methvlsulfonyl)butanamide
The title compound (62 mg, 35%) was obtained as a solid from (2R)-4-[5-fluoro-4-(4trideuteromethylphenyl)-2-oxopyridin-1(2H)-yl]-2-meÎhyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (145 mg, 0.27 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4-isoxazol-3ylphenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 41, Step C. MS (APCI) m/z 400.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (s, 3 H) 2.14 (br. s., 1 H) 2.47 (br. s., 1 H) 3.08 (s, 3 H) 3.75 (br. s., 1 H) 4.02 (br. s., 1 H) 6.47 (d, J=7.61 Hz, 1 H) 7.28 (d, J=8.00 Hz, 2 H) 7.44 (d, J=7.02 Hz, 2 H) 7.98 (d, J=6.63 Hz, 1 H) 9.21 (s, 1 H) 11.07 (s, 1 H).
Example 44 (2R)-4-[5-Fluoro-4-(4-trideuteromethoxvDhenvl)-2-oxopyridin-1 (2H)-vll-N-hydroxv-2methyl-2-(methvlsulfonyl)butanamide
Step A) (2R)-4-f5-Fluoro-4-(4-trideuteromethoxyphenvn-2-oxopyridin-1(2H)-yl1-2methyl-2-(methylsulfonvn-N-ftetrahvdro-2H-pyran-2-vloxv)butanamide
The title compound (216 mg, 76.9%) was obtained as a colorless oil from (4trideuteromethoxyphenyl)boronic acid (120 mg, 0.78 mmol) and (2R)-4-(5-fluoro-4-iodo2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (400 mg, 0.78 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. (122 mg, 31.5%). MS (APCI) m/z 498.3 (M-1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 -1.98 (m, 9 H) 2.38 (dd, J=7.12, 3.80 Hz, 1 H) 2.44 - 2.61 (m, 1 H) 3.18 (d, J=2.54 Hz, 3 H) 3.65 (d, J=11.51 Hz, 1 H) 3.89-4.04 (m, 1 H) 4.11 -4.22 (m, 1 H) 4.24-4.38 (m, 1 H) 5.15 (d, J=14.63 Hz, 1 H)
6.64 (dd, J=7.41, 1.37 Hz, 1 H) 6.96 (d, J=8.78 Hz, 2 H) 7.35 (d, J=5.66 Hz, 1 H) 7.43 7.51 (m, 2 H) 12.02 (d, J=15.02 Hz, 1 H).
\Z
Step B) (2R)-4-i5-fluoro-4-(4-trideuteromethoxvohenvl)-2-oxopvridin-1 (2H)-vll-Nhvdroxv-2-methyl-2-(methvlsulfonvl)biJtariamide
The title compound (55 mg, 55%) was obtained as a solid from (2R)-4-[5-fluoro-4-(4trideuteromethoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methy1sulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (120 mg, 0.24 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4-isoxazol-3ylphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamidef Example 41, Step C. MS (APCl) m/z 416.1 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.54 (s, 3 H) 2.14 (br. s., 1 H) 2.47 (br. s., 1 H) 3.08 (s, 3 H) 3.74 (br. s„ 1 H) 4.02 (br. s., 1 H) 6.46 (d, 4=7.81 Hz, 1 H) 7.02 (d, 4=8.39 Hz, 2 H) 7.51 (d, 4=7.41 Hz, 2 H) 7.96 (d, 4=6.63 Hz, 1 H) 9.20 (s, 1 H) 11.07 (s, 1 H).
Example 45 (2R)-4-f4-(4-Pentadeuteroethoxyphenvl)-5-fluoro-2-oxopyridin-1(2H)-yl1-N-hydroxy-2methvl-2-(methvlsulfonyl)butanamide
NHOH
Step A) (2R)-4-f4-i4-Pentadeuteroethoxvohenyl)-5-fluoro-2-oxopyridin-1(2H)-vll-2methvl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-pyran-2-yloxv)butanamide
The title compound (184 mg 46.0%) was obtained as a colorless oil from (4pentadeuteroethoxyphenyl)boronic acid (132 mg, 0.78 mmol) and (2R)-4-(5-fluoro-4iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (400 mg, 0.78 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (APCl) m/z 514.4 (M-1). 1H NMR (400 MHz, CHLOROFORM-4) δ ppm 1.53 - 1.97 (m, 9 H) 2.39 (dt, 4=7.27, 3.68 Hz, 1 H) 2.45 - 2.60 (m, 1 H) 3.19 (d, 4=2.73 Hz, 3 H) 3.65 (d, 4=11.51 Hz, 1 H) 3.90 - 4.04 (m, 1 H) 4.16 (dd, 4=11.22, 2.44 Hz, 1 H) 4.24-4.38 (m, 1 H) 5.16 (d, 4=14.83 Hz, 1 H) 6.64 (dd, 4=7,42, 1.17 Hz, 1 H) 6.95 (d, 4=8.59 Hz, 2 H) 7.34 (d, 4=5.66 Hz, 1 H) 7.40 - 7.52 (m, 2 H) 12.03 (br. s., 1 H).
Step B) (2R)-4-i4-i'4-Pentadeuteroethoxvphenvl)-5-fluoro-2-oxoDvridin-1 (2H)-vll-Nhydroxv-2-methvl-2-(methvlsulfonyl)butanamide
The title compound (152 mg, 98.7%) was obtained as an off-white solid from (2R)-4-[4(4-pentadeuteroethoxyphenyl)-5’fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran’2-yloxy)butanamide (120 mg, 0.24 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(4isoxazol-3“ylphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 41, Step C. MS (APCI) m/z 432.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.54 (s, 3 H) 1.89 - 2.22 (m, 1 H) 2.32 - 2.47 (m, 1 H) 2.92 - 3.15 (m, 3 H) 3.57 - 3.80 (m, 1 H) 4.01 (br. s., 1 H) 6.45 (d, J=7.81 Hz, 1 H) 7.01 (d, J=8.78 Hz, 2 H) 7.50 (d, J=7.22 Hz, 2 H) 7.96 (d, J=6.83 Hz, 1 H) 9.21 (br. s., 1 H) 11.08 (s, 1 H).
Example 46 (2R)-4-i4-[4-(Cyclopropvloxy)phenvll-5-fluoro-2-oxopyridin-1 (2H)-vl}-N-hvdroxy-2methyl-2-(methvlsulfonvl)butanamide
NHOH
Step A) 2-r4-(Cyclopropyloxy)phenyll-4,4.5.5-tetramethvl-1,3.2-dioxaborolane
Pd(dppf)CI2 (770 mg, 0.94 mmol) was added to a degassed suspension of 1-bromo-4(cyclopropyloxy)benzene (2.0 g, 9.39 mmol), potassium acetate (2.76 g, 28.12 mmol), and 4,4l4,,4'l5l5,5',5'-octamethyl-2,2,-bi-1,3)2-dioxaborolane (2.62 g, 10.32 mmol) in anhydrous DMSO (20 mL). The réaction was heated to 80 °C and stirred at this température for 5 h. The réaction was allowed to cool to rt and diluted with water and diethyl ether. The organic phase was separated and the aqueous phase was extracted with diethyl ether. The organics were combined, dried (MgSO4), filtered, and concentrated in vacuo. Hexanes were added to the residue and the resulting yellow solution was decanted from the brown residue. The yellow solution was concentrated, and the residue was purified via column chromatography using an eluent of 2% ethyl
acetate in hexanes to afford title compound as a colorless oil (878 mg, 36%). MS (LCMS) m/z 261.2 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.74 - 0.83 (m, 4 H) 1.34 (s, 12 H) 3.73 - 3.82 (m, 1 H) 7.05 (d, 2 H) 7.75 (d, 2 H).
Step B) (2R)-4i4-r4-(Cvclopropvloxy)phenvl1-5-fluoro-2-oxopyridin-1 (2H)-vl>-2methvl-2-(methvlsulfonyD-N-ftetrahvdro-2H-Dvran-2-vloxv)butanamide The title compound (560 mg 55.3%) was obtained as a colorless oil from 2-[4(cyclopropyloxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (554 mg, 2.13 mmol) and (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide,T3, (1.0 g, 1.94 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2Hpyran-2-yloxy)butanamide, Example 19, Step A. MS (APCI) m/z 521.4 (M-1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.57 - 0.82 (m, 4 H) 1.42 -1.91 (m, 9 H) 2.27 -
2.41 (m, 1 H) 2.41 - 2.58 (m, 1 H) 3.13 (s, 4 H) 3.45 - 3.64 (m, 1 H) 3.72 (dd, J=5.46, 2.93 Hz, 1 H) 3.80-3.98 (m, 1 H) 4.12 (d, J=10.93 Hz, 1 H) 4.17 - 4.31 (m, 1 H) 5.11 (d, J=13.85 Hz, 1 H) 6.59 (d, J=7.41 Hz, 1 H) 6.97 - 7.13 (m, 2 H) 7.36 (d, J=5.46 Hz, 1 H) 7.43 (d, J=8.59 Hz, 2 H) 11.82 -12.08 (m, 1 H).
Step B) (R)-4-(4-(4-Cvclopropoxvphenyl)-5-fluoro-2-oxopyridin-1(2H)-vn-Nhvdroxy-2-methyl-2-(methylsulfonvl)butanamide
The title compound (280 mg, 59.6%) was obtained as an off-white solid from (2R)-4-(4(4-cyclopropoxyphenyl)-5-fluoro-2-oxopyridin-1 (2H)-yl)-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (560 mg, 1.07 mmol) using a procedure analogous to that described for the préparation of (R)-4-(5-fluoro-4-(4-(isoxazol-3yl)phenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, Example 41, Step C. MS (APCI) m/z 439.0 (M+1). 1H NMR (400 MHz, DMSO-d6) r“ ppm 0.55 - 0.69 (m, 2 H) 0.74 - 0.85 (m, 2 H) 1.54 (s, 3 H) 2.03 - 2.26 (m, 1 H) 2.33 -
2.46 (m, 1 H) 3.08 (s, 3 H) 3.64 - 3.80 (m, 1 H) 3.88 (dt, J=6.05, 3.02 Hz, 1 H) 3.94 4.10 (m, 1 H) 6.46 (d, J=7.81 Hz, 1 H) 7.02 - 7.23 (m, 2 H) 7.52 (dd, J=8.78, 1.95 Hz, 2 H) 7.97 (d, J=6.63 Hz, 1 H) 9.21 (s, 1 H) 11.08 (s, 1 H).
Example 47 (2R)-444-(2,2-Difluoro-1.3-benzodioxol-5-yl)-5-fluoro-2-oxopyridin-1 (2H)-vn-N-hvdroxv2-methyl2-(methylsulfonvl)butanamide
ΝΗΟΗ
Step A) (2R)-4-[4-(2.2-Difluoro-1.3-benzodioxol-5-vl)-5-fluoro-2-oxopyridin-1 (2H)vn-2-meÎhyl-2-(meÎhylsulfonvn-N-(tetrahvdro-2H-pyran-2vloxv)butanamide
The title compound (560 mg 55.3%) was obtained as a colorless oil from (2,2-difluoro-
1.3- benzodioxol-5-yl)boronic acid (129 mg, 0.639 mmol) and (2R)-4-(5-fluoro-4-iodo-2oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, T3, (300 g, 0.581 mmol) using a procedure analogous to that described for the préparation of (2R)-4-[5-fluoro-4-(3-fluoro-4-methoxyphenyl)-2oxopyridin-1(2H)-yl]-2~methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2yloxy)butanamide, Example 19, Step A. MS (LCMS) m/z 545.3 (M-1).
Step B) (2Η)-4-Γ4-(2,2-ΡίίΙυθΓθ-1,3·^6ηζοάιοχοΙ-5-νΙ)-54ΙυοΓθ-2-οχορνπάΐη-1(2Η)vl1-N-hvdroxy-2-methvl-2-(methvlsulfonvl)butanamide
Aqueous HCl (1.42 mL, 1.42 mmol) was added to a solution of (2R)-4-[4-(2,2-Difluoro-
1.3- benzodioxol-5-yl)-5-fluoro-2-oxopyridin-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (259 mg, 0.474 mmol) in éthanol (5 mL) and water (2 mL) and the reaction was stirred overnight at rt. The solid was collected via filtration, washed with water (5x3 mL) and dried under reduced pressure to afford the title compound (143 mg, 65.3%). 1H NMR (400 MHz, DMSO-de) d ppm 1.58 (s, 3 H) 2.07 - 2.24 (m, 1 H) 2.36 - 2.49 (m, 1 H) 3.11 (s, 3 H) 3.68 - 3.86 (m, 1 H) 3.98 - 4.13 (m, 1 H) 6.58 (d, /=7.61 Hz, 1 H) 7.36 - 7.49 (m, 1 H) 7.55 (d, /=8.39 Hz, 1 H) 7.68 (s, 1 H) 8.06 (d, /=6.63 Hz, 1 H) 9.24 (br. s., 1 H) 11.08 (s, 1 H).
Example 48 (2R)-4-r5-Fluoro-2-oxo-4-(phenvlethvnvl)pyridin-1(2H)-vll-N-hvdroxy-2-methvl-2(methylsulfonvl)butanamide
Step A) Ethyl (2RM-f5-fluoro-2-oxo-4-(Dhenvlethvnvl)Dyridin-1 (2H)-yl]-2-methyl-2(methylsulfonvl)butanoate
A solution of ethyl (2R)-4-(5-fluoro-4-iodo-2-oxopyridin-1 (2H)-yl)-2-methyl-2(methylsulfonyl)butanoate (500 mg, 1.12 mmol) and diisopropylethylamine (6.0 mL, 30 mmol) in tetrahydrofuran (15 mL) was degassed with nitrogen. Pd(PPh3)4 (65.4 mg, 0.056) and copper iodide (21.8 mg, 0.112 mmol) were added to the solution, followed by phenylacetylene (150 uL, 1.4 mmol). The reaction was allowed to stir until complété via TLC. The reaction was diluted with EtOAc (100 mL) and washed with saturated aq NH4CI (100 mL) and brine (100 mL), dried (MgSO4), filtered, and concentrated. The crude residue was purified via flash chromatography using a Varian SF15-24g column and an eluent of EtOAc in hexanes (30-80%) to afford the title compound as a yellow solid (389 mg, 82.6 %). MS (LCMS) m/z 420.0 (M+1). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.35 (t, 3 H) 1.75 (s, 3 H) 2.42 - 2.61 (m, 2 H) 3.11 (s, 3 H) 3.91 - 4.00 (m, 1 H) 4.19 - 4.27 (m, 1 H) 4.30 (q, J=7.02 Hz, 2 H) 6.72 (d, J=6.63 Hz, 1 H) 7.27 (t, J=2.34 Hz, 2 H) 7.35 - 7.44 (m, 2 H) 7.55 - 7.60 (m, 2 H).
Step B) (2R)-445-Fluoro-2-oxo-4-(DhenylethynyODvridin-1(2H)-vll-2-methyl-2(methylsulfonvllbutanoic acid
The title compound (195.1 mg, 72.1%) was obtained as a white solid from ethyl (2R)-4[5-fluoro-2-oxo-4-(phenylethynyl)pyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)butanoate (290 mg, 0.52 mmol) using a procedure analogous to that described for the préparation of ethyl (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-ΐΠ3ΖθΙ-2-γl)phenyl]pyridin-1 (2H)-yl}-2methyl-2-(methylsulfonyl)butanoate, Example 26, Step C. MS (LCMS) m/z 392.0 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (s, 3 H) 2.10 - 2.24 (m, 0 H) 2.40 - 2.56 (m, 1 H) 3.16 (s, 3 H) 3.87 - 4.06 (m, 2 H) 6.65 (d, J=6.83 Hz, 1 H) 7.43 - 7.55 (m, 3 H) 7.57 -
7.65 (m, 2 H) 8.07 (d, J=5.46 Hz, 1 H).
Step C) (2R)-4-[5-Fluoro-2-oxo-4-(Dhenylethvnvl)Dvridin-1 (2H)-yl1-2-methyl-2(methylsulfonyl)-N-(tetrahydro-2H-Dvran-2-vloxv)butanamide
The title compound (232 mg, 95.0%) was obtained as a white solid from (2R)-4-[5fluoro-2-oxo-4-(phenylethynyl)89yridine-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)butanoic acid (195.1 mg, 0.50 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yI}2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide Example 26,
Step D.
Step D) (2R)-4-r5-Fluoro-2-oxo-4-(phenvlethvnyl)90vridine-1 (2H)-vl1-N-hvdroxv-2methvl-2-(methylsulfonvl)butanamide
The title compound (124.4 mg, 64.7%) was obtained as a white solid from (2R)-4-[5fluoro-2-oxo-4-(phenylethynyl)90yridine-1 (2H)-yl]-2-methyl-2-(methylsulfonyl)-N(tetrahydro-2H-pyran-2-yloxy)butanamide (232 mg, 0.47 mmol) using a procedure analogous to that described for the préparation of (2R)-4-{5-Fluoro-2-oxo-4-[4-(2H-
1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 407.0 (M+1). 1H NMR (400 MHz, DMSO-de) δ ppm 1.56 (s, 3 H) 2.04 - 2.21 (m, 1 H) 2.37 - 2.49 (m, 1 H) 3.10 (s, 3 H) 3.69-3.85 (m, 1 H) 3.92-4.12 (m, 1 H) 6.69 (d, 1 H) 7.39-7.57 (m, 3 H) 7.57 - 7.68 (m, 2 H) 8.05 (d, 7=5.46 Hz, 1 H) 9.22 (s, 1 H) 11.04 (s, 1 H).
Example 49 (2R)-4-(5-Fluoro-2-oxo-4-r3-(1.3-thiazol-2-vloxv)phenvllpvridin-1 (2Η)-νΙ)-Ν->~^Γθχν-2methyl-2-(methvlsulfonyl)butanamide
NHOH
Step A) 2-(3-lodophenoxv)-1,3-thiazole
Césium carbonate (4.52 g, 13.87 mmol) was added to 2-bromo-1,3-thiazole (1.90 g, 11.6 mmol) and 3-iodophenol (2.54 g, 11.5 mmol) in anhydrous DM F (30 mL). The reaction was heated to 135 °C and stirred at this température overnight. The reaction was allowed to cool, then was poured into water (100 mL), and extracted with EtOAc (3x100 mL). The combined organics were washed with brine (100 mL), dried (MgSO4), filtered, and concentrated. The crude product was purified via flash chromatography using a Varian SF15-24g column and an eluent of EtOAc in hexanes (0-10%) to afford the title compound as a yellow oil (2.52 g, 71.8%). MS (LCMS) m/z 304.1 (M+1).
Step B) 243-(4,4,5.5-Tetramethvl-1.3.2-dioxaborolan-2-yl)Dhenoxvl-1,3-thiazole
The title compound (1.33 g) was prepared as a crude brown solid from 2-(3iodophenoxy)-1,3-thiazole (500 mg, 1.65 mmol) using a procedure analogous to that described for 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-tetrazole, Example 1, Step A. MS (LCMS) m/z 304.0 (M+1).
Step C) Ethyl (2R)-445-fluoro-2-oxo-4-r341.3-thiazol-2-yloxv)phenvllpyridin-1 (2H)vl}-2-methvl-2-(methvlsulfonyl)butanoate
The title compound (534 mg) was prepared as a crude brown oil from 2-(3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]-1,3-thiazole (1.33 g, 4.39 mmol) and T2 (400 mg, 0.90 mmol) using a procedure analogous to that described for ethyl (2R)-4-(5f I uo ro -2-ΟΧΟ-4- (44(t ran s -4- (tetrahyd ro-2 H -py ran-2yloxy)cyclohexyl]methoxy}phenyl)pyridin-1 (2H)-yl]-2-methyl-2(methylsulfonyl)butanoate, Example 18, Step D. MS (LCMS) m/z 495.2 (M+1).
Step D) (2Ρ)-445-ΡΙυοΓθ-2-οχο-443-(1,3-ΐΐΊΪ3ΖθΙ-2-νΙοχν)ρΐΊθηνΙ1ρνπάΐη-1(2Η)-νΙ}-2methvl-2-(methvlsulfonvl)butanoic acid
The title compound (144 mg, 28.4%) was prepared as an off-white solid from ethyl (2R)4-{54luoro-2-oxo-4-[3-(1,3-thiazol-2-yloxy)phenyl]pyridin-1(2H)-yl}-2-methyl-2(methylsulfonyl)butanoate (538 mg, 1.09 mmol) using a procedure analogous tothat described for (2R)-4~(5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-y I}2-methyl-2-(methylsulfonyl)butanoic acid, Example 26, Step C. MS (LCMS) m/z 467.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.57 (s, 3 H) 2.12 - 2.27 (m, 1 H) 3.17 (s, 3 H) 3.85 - 4.11 (m, 2 H) 6.55 (d, J=7.61 Hz, 1 H) 7.24 - 7.35 (m, 2 H) 7.44 - 7.66 (m, 4 H) 8.07 (d, J=6.44 Hz, 1 H).
Step E) (2R)-445-Fluoro-2-oxo-4-r3-(1,3-thiazol-2-vloxv)DhenvllPvridin-1(2H)-yl}-2methyl-2-(methvlsulfonvl)-N-(tetrahvdro-2H-Dvran-2-yloxy)butanamide
The title compound (115 mg, 65.8%) was prepared as an off-white solid from (2R)-4-{5fluoro-2-oxo-4-[3-(1,3-thiazol-2-yloxy)phenyl]pyridin-1 (2H)-yl}-2-methyl-2(methylsulfonyl)butanoic acid (144 mg, 0.31 mmol) using a procedure analogous to that described for (2R)-4-{5-fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1 (2H)-yl}2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide, Example 26, Step D. MS (LCMS) m/z 566.2 (M-1).
n/
Step F) f2R)-4-i5-fluoro-2-oxo-4-Î3-(1.3-thiazol-2-vloxv)phenvnpvridin-1 (2Ηΐ-νΙΕΝhvdroxy-2-meÎhvl-2-(methylsulfonvl)butanamide
The title compound (66.8 mg, 68.4%) was prepared as a white solid from (2R)-4-{5fluoro-2-oxo-4-[3-(1,3-thiazol-2-yloxy) phenyl] pyridin-1 (2H)-yl}-2-m ethyl-2(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide (115 mg, 0.20 mmol) using a procedure analogous to that described for (2R)-4-(5-fluoro-2-oxo-4-[4-(2H-1,2,3triazol-2-yl)phenyl]pyridin-1(2H)-yl}-N-hydroxy-2-methyl-2-(meÎhylsulfonyl)butanamide, Example 26, Step E. MS (LCMS) m/z 482.2 (M+1). 1H NMR (400 MHz, DMSO-tfe) δ ppm 1.57 (s, 3 H) 2.09 - 2.23 (m, 1 H) 3.11 (s, 3 H) 3.70 - 3.87 (m, 1 H) 3.97 - 4.14 (m, 1 H) 6.58 (d, 7=7.61 Hz, 1 H) 7.25 - 7.35 (m, 2 H) 7.45 - 7.67 (m, 4 H) 8.06 (d, 7=6.44 Hz, 1 H) 9.23 (s, 1 H) 11.08 (s, 1 H).
BIOLOGICAL EXAMPLES
In order to assess the compounds biological activity, selected in vitro assays were conducted on selected compounds. One of the assays measured the compounds ability to disrupt the synthesis of lipopolysaccharide, LPS, which is a component of the outer membrane of Gram-negative bacteria. Disruption of this synthesis is léthal to the bacteria. The assay determined the compound’s ability to inhibit LpxC, which is the first enzyme in the biosynthetic pathway for LPS (measured as IC50). Additionally, MICs (minimal inhibitory concentrations) were determined for several bacteria. The spécifie protocols are described below:
A) ICsn assay, LoxC enzyme from P. aeruainosa (labeled as PA LpxC enzyme ICm):
IC50 détermination in the LpxC enzyme assay was carried out in a similar manner to that described by Malikzay et al in the 2006 Poster, Screening LpxC (UDP-3-O-(R-3hydroxymyristoyl)-GlcNAc deacetylase) using BioTrove RapidFire HTS Mass Spectrometry (aNew Lead Discovery and ^Inflammation and Infectious Disease, cStructural Chemistry, Schering-Plough Research Institute, Kenilworth, NJ 07033, (BioTrove, Inc. 12 Gill St., Suite 4000, Woburn, MA 01801). Briefly, Pseudomonas aeruginosa LpxC enzyme (0.1 nM) purified from E. co/i-overexpressing bacteria was incubated at 25 °C in a final volume of 50 ul containing 0.5 uM UDP-3-O-(R-3hydroxydecanoyl)-N-acetylglucosamine, 1 mg/mL BSA, and 50 mM sodium phosphate buffer, pH 8.0 in the presence and absence of inhibitor compound. At the end of 1 hour, 5 ul of 1 N HCl was added to stop the enzyme reaction, the plates were centrifuged, and then processed with the BioTrove Rapidfire HTMS Mass Spectrometry System. A noxZ enzyme control was used in calculating the IC50 values from the percent conversion values.
B) MIC déterminations: The in vitro antibacterial activity of compounds described in the Examples was evaluated by minimum inhibitory concentration (MIC) testing according to Clinical and Laboratory Standards Institute (CLSI). See: Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Eighth Edition. CLSI document M7-A8 [ISBN 1-56238-689-1]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006; also Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplément. CLSI document M100-S20 [ISBN1-56238-716-2].CIinical and Laboratory Standards Institute.
The MIC détermination is a standard laboratory method for evaluating the antibacterial activity of a compound. The MIC represents the lowest drug concentration that inhibits visible growth of bacteria following ovemight incubation, ln order to détermine the MIC value, a range of drug concentrations (e.g. 0.06 pg/mL to 64 pg/mL) are incubated with a defined strain of bacteria. Typically, the drug concentration range is broken down into 2-fold incréments (e.g. 0.06 pg/mL , 0.12 pg/mL. 0.25 pg/mL, 0.50 pg/mL, 1.0 pg/mL, etc.) and the various drug concentrations are ail individually incubated ovemight with approximately the same number of bacteria. The MIC is then determined by visually inspecting the drug effect at each concentration, and identifying the lowest drug concentration that has inhibited bacterial growth as compared to the drug free control. Typically, bacteria continue to grow at drug concentrations lower than the MIC and don’t grow at concentrations at and above the MIC.
The MIC values described in Table 2 and 3 below were derived from assays wherein each test compound was evaluated in duplicate. ln cases where the duplicate values varied by 0 - 2-fold, the lower of the two values was reported below. Generally speaking, if the duplicate values varied by more than 2-fold, the assay was considered non-valid and was repeated until the variation between duplicate runs was £ 2-fold. ln line with the CLSI guidelines referred to above, both control organisms and reference compounds were utilized in each MIC assay to provide proper quality control. MIC values generated with these control organisms and reference compounds were required to fall within a defined range for the assay to be considered valid and be included herein. Those skilled in the art will recognize that MIC values can and do vary from
experiment to experiment. Generally speaking, it should be recognized that MIC values often vary +/- 2-fold from experiment to experiment. While a single MIC is reported for each compound and each microorganism, the reader should not conclude that each compound was only tested once. Several of the compounds were subjected to multiple tests. The data reported in Tables 2 and 3 is reflective of the compounds relative activity and different MICs may have been generated on these occasions in line with the guidelines described above.
The following bacterial strains were used in these MIC déterminations:
1) Pseudomonas aeruginosa UI-18: Wild-type, labeled as PA-7 in Tables 2 and 3;
2) Acinetobacter baumannii/haemolyticus: Multidrug-resistant clinical isolate labeled as AB-3167 in Tables 2 and 3;
3) Escherichia coli EC-1: VOGEL, mouse virulent labeled as EC-1 in Tables 2 and 3;
4) Klebsiella pneumoniae: Ciprofloxacin-resistant isolate, expresses extendedspectrum beta-lactamases (ESBL), clinical isolate, labeled as KP-3700 in Tables 2 and 3.
Table 2, below, shows the results that were obtained with the final products described in Examples 1 -47. If a particular table entry is left blank, then the data is not available at the current time.
Column 1 corresponds to the Example number, column 2 provides the IUPAC name, column 3 provides the results from the LpxC enzyme assay described above, and columns 4-7 provide the MIC data as described above.
Table 2
Example | IUPACNAME | PA:IC50 (μΜ) | AB3167 (pg/mL) | EC-1 (pg/mL) | KP3700 (M9/mL) | PA-7 (pg/mL) |
1 | (2 R) - 4 —(5-1 lu oro-2-oxo -4- [4- (2 Htetrazol-2-yl) pheny IJpyrid in -1 (2 H)yl}-N-hydroxy-2-mathyl-2(methylsu If onyl) butanam ide | 0.00149 | >64.0 | >64.0 | >64.0 | 32 |
2 | (2R)-4-[5-fluoro-4-(2-fluoro-3methylphenyl)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000595 | >64.0 | 0.25 | 1 | 0.25 |
3 | (2R)-4-[4-(4-chlorophenyl)-5-fluoro- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000325 | 64 | 0.25 | 1 | 0.25 |
4 | (2R)-4-[5-fluoro-4-(2-fluorophenyl)- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2- | 0.000717 | >64.0 | 2 | 4 | 0.5 |
methyl-2(methylsulfonyl)butanamide | ||||||
5 | (2R)-4-[4-(2,3-dihydro-1benzofuran-5-yl)-5-fluoro-2oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000822 | >64.0 | 1 | 2 | 1 |
6 | (2R)-4-[4-(3,4-difluorophenyl)-5fluoro-2-oxopyridin-1 (2H)-yl]-Nhydroxy-2- m ethyl-2(methylsu Ifonyl) butanam ide | 0.000833 | >64.0 | 1 | 2 | 0.5 |
7 | (2R)-4-{5-fluoro-2-oxo-4-[4-(2,2,2trifluoroethoxy)phenyl]pyridin-1 (2H)yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000576 | >64.0 | 0.25 | 2 | 1 |
8 | (2R)-4-[4-{3,4-dihydro-2H-chromenè-y I) -5-f luoro-2-oxopyrid in-1 (2 H) -y ΟΝ - hyd roxy-2-methy I-2(methylsulfonyl)butanamide | 0.000377 | >64.0 | 0.5 | 2 | 1 |
19 | (2R)-4-{5-f!uoro-4-[4- (methylthio)phenylJ-2-oxopyridin1 (2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.00051 | >64.0 | 0.25 | 1 | 0.5 |
10 | (2R)-4-[4-(4-ethoxyphenyl)-5-fluoro- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methvlsu Ifonyl) butanam ide | 0.000823 | >64.0 | 0.25 | 1 | 1 |
11 | (2R)-4-[5-fluoro-2-oxo-4-(4propylphenyl)pyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methvlsulfonyl)butanamide | 0.000482 | >64.0 | 0.125 | 0.5 | 0.5 |
12 | (2R) - 4-{5-f luoro-2-oxo-4- [4(pentafluoro-6Asulfanyl)phenyl]pyridin-1(2H)-yl}-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.00114 | >64.0 | 4 | 16 | 4 |
13 | (2R)-4-[5-fluoro-4-(3-methylphenyl)- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.00105 | >64.0 | 1 | 4 | 1 |
14 | (2R)-4-[5-fluoro-4-(4-fluoro-3methylphenyl)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000758 | >64.0 | 0.5 | 2 | 0.5 |
15 | (2 R) -4-{5-f luoro-4-[4-(oxetan-3yloxy)phenyl]-2-oxopyrîdin-1(2H)yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.00205 | >64.0 | 16 | 32 | 16 |
16 | (2R)-4-[4-(4-chloro-2-fluorophenyl)- 5-f Iuoro-2-oxopyrid in-1 (2H) -yl]-Nhydroxy-2-methyl-2{methylsulfonyl)butanamide | 0.000336 | >64.0 | 0.25 | 1 | 0.5 |
17 | (2R)-4-[5-fluoro-4-(2-flUoro-3methoxyphenyl)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(methylsu Ifonyl) butanam ide | 0.0005 | >64.0 | 0.5 | 1 | 1 |
18 | (2R)-4-[5-fluoro-4-{4-[(trans-4hyd roxycycl ohexy I) m ethoxy] pheny I}2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methytsulfonyl)butanamide | 0.000463 | >64.0 | 0.125 | 2 | 1 |
19 | (2R)-4-[5-fluoro-4-(3-fluoro-4- | 0.000879 | >64.0 | 2 | 4 | 1 |
methoxyphenyl)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(m ethylsu If onyl) butanam ide | ||||||
20 | (2R)-4-[5-fluoro-2-oxo-4-(4pyrimidin-2-ylphenyl)pyridin-1(2H)y I] - N-h yd roxy-2-m ethyl-2(m ethylsu Ifony I) b utan a mid e | 0.000945 | >64.0 | 0.125 | 0.5 | 1 |
21 | (2R)-4-{5-fluoro-4-[4-(5methoxypyrimidin-2-yl)phenyl]-2oxopyrid i n-1 (2H) - y)}- N - hyd roxy-2m ethyl-2(methylsulfonyl)butanamide | 0.000436 | >64.0 | 0.125 | 0.5 | 1 |
22 | (2R)-445-fluoro-4-[4-(4-methoxy2H-1,2,3-triazol-2-yl)phenyl]-2oxo py rid in-1 (2 H) -y l}-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000181 | >64.0 | £0.0600 | 0.125 | 0.5 |
23 | (2R)-445-tluoro-4-[4-(4-methyl-2H- 1,2,3-triazol-2-yl)phenyl]-2oxopyridin-1(2H)-yl}-N-hydroxy-2methyl-2- (m ethylsu Ifo nyl) butan amide | 0.000287 | >64.0 | 0.06 | 0.125 | 0.5 |
24 | (2R)-4-(5-fluoro-2-oxo-4-quinoxalin- 6-y Ipy rid i n-1 (2H) -y I) -N-hyd roxy-2methyl-2(methvlsulfonyl)butanam ide | 0.00123 | >64.0 | 4 | 8 | 4 |
25 | (2R)-4-[5-fluoro-4-(3methoxyphenyl)-2-oxopyridln-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000412 | >64.0 | 1 | 4 | 2 |
26 | (2R)-4-f5-fluoro-2-oxo-4-[4-(2H- 1,2,3-triazol-2-yl) phenyl] pyridin1 (2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl) butanam ide | 0.0000743 | >64.0 | £0.0600 | £0.0600 | 0.25 |
27 | (2R)-4-[5-fluoro-4-(2-fluoro-4methoxyphenyi)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl) butanam ide | 0.0000498 | >64.0 | 0.25 | 0.5 | 0.5 |
28 | (2R)-4-[5-fluoro-4-(4methoxyphenyl)-2-oxopyridin-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamîde | 0.000564 | >64.0 | 1 | 1 | 0.5 |
29 | (2R)-4-[5-fluoro-4-(4-methylphenyl)- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000514 | >64.0 | 0.5 | 1 | 0.5 |
30 | (2 R) -4-{5-f luo ro-2-oxo-4- [4(trifluoromethoxy)phenyl]pyridin1 (2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000106 | >64.0 | 0.25 | 2 | 0,5 |
31 | (2R)-4-[5-fluoro-4-(4-fluorophenyl)- 2-oxopyrîdin-1(2H)-yl]-N'hydroxy-2m ethyl-2(methylsulfonyl)butanamide | 0.000213 | >64.0 | 1 | 4 | 0.5 |
32 | (2R)-4-{5-fluoro-4-[4-(6methoxypyridin-3-yl)phenyl]-2oxopyridin-1(2H)-yl}-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.0004 | >64.0 | £0.0600 | 1 | 1 |
33 | (2R)-4-{4-[4- (difluoromethoxy)phenyl]-5-fluoro-2oxopy rid i n-1 (2H )-yl}-N - hyd roxy-2- | 0.0000606 | >64.0 | 0.5 | 2 | 0.5 |
methyl-2(methylsulfonyl)butanamide | ||||||
34 | (2R)-4-[5-fiuoro-4-(4-methoxy-3methylphenyl)-2-oxopyridln-1(2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000834 | >64.0 | 0.25 | 2 | 0.5 |
35 | (2R)-4-{4-[4-(difluoromethoxy)-3fluorophenyl]-5-fluoro-2-oxopyridin- 1 {2H)-yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000589 | >64.0 | 1 | 2 | 0.5 |
36 | (2R)-445-fluoro-4-[3-fluoro-4-(2H- 1,2,3-triazol-2-yl) phenyl]-2oxopyridin-1(2H)-yl}~N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000398 | >64.0 | 0.5 | 1 | 1 |
37 | (2R)-445-fiuoro-4-(3-methyl-4-(2H- 1,2,3-triazol-2-yl)phenyl]-2oxopyridin-1(2H)-yl]~N-hydroxy-2methyl-2- (m ethylsu If onyl) buta nam ide | >64.0 | 0.5 | 1 | 1 | |
38 | (2R)-4-(3,5-difluoro-2-oxo-4phenylpyrldin-1(2H)-yl)-N-hydroxy2-methyl-2(methylsulfonyl)butanamida | 0.00055 | >64.0 | 1 | 2 | 0.5 |
39 | (2R)-4-(5-fluoro-3-methoxy-2-oxo-4phenylpyridin-1(2H)-yl)-N-hydroxy2-methyl-2(methylsulfonyl)butanamide | 0.00807 | 64 | 4 | 8 | 8 |
40 | (2 R) -4- (5-fluoro-3 -h yd roxy-2-oxo-4ph e nyl pyrid in -1 (2 H) -yl)- N-hyd roxy2-methyl-2(methylsulfonyl) butanam ide | >0.100 | 64 | 16 | 32 | 16 |
41 | (2R)-4-[5-fiuoro-4-(4-isoxazol-3ylphenyl)-2-oxopyridin-1(2H)-yl]-Nh ydroxy-2-m ethyl-2(methylsu If onyl) butanam ide | 0.000237 | 16 | 0.5 | 0.25 | 0.5 |
42 | (2R)-4-(5-fluoro-4-[4-(1,3-Oxazol-2yl)phenyl]-2-oxopyridin-1(2H)-yl}-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.000328 | >64.0 | 0.25 | 0.25 | 1 |
43 | (2R)-4-[5-fluoro-4-(4-methylphenyl)- 2-oxopyridin-1(2H)-yl]-N-hydroxy-2methyl-2(methylsulfonyl)butanamide-d 3 | 0.000653 | >64.0 | 0.25 | 1 | 0.5 |
44 | (2R)-4-[5-fluoro-4-(4methoxyph eny I) -2-oxo pyrid I n-1 (2 H) yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide-d 3 | 0.000664 | >64.0 | 0.25 | 1 | 0.25 |
45 | (2R)-4-[4-(4-ethoxyphenyl)-5-fluoro- 2-oxopyrid in -1 (2H)-y I] - N -hyd roxy-2methyl-2(methylsulfonyl)butanamide-d 5 | 0.000547 | >64.0 | 0.125 | 0.5 | 0.5 |
46 | (2R)-4-{4-[4- (cyclopropyloxy)phenyl]-5-fluoro-2oxo py rid in-1 (2 H) -y l}-N-hydroxy-2methyl-2(methylsulfonyl)butanamide | 0.000229 | >64.0 | 0.125 | 0.5 | 0.5 |
47 | (2R)-4-[4-(2,2-difluoro-1,3benzodioxol-5-yl)-5-fluoro-2oxo pyrid in-1 (2 H) -y I]- N-hyd roxy-2methyl-2(methylsulfonyl)butanamide | >64.0 | 0.25 | 1 | 0.5 |
48 | (2R)-4-[5-Îluoro-2OXO-4- (phenylethynyl)pyridîn-l (2H)-yl]-Nhydroxy-2-methyl-2(mathylsulfonyl)butanamide | 0.000555 | >64.0 | 0.06 | 0.25 | 0.5 |
49 | (2R)-4-(5-Fluoro-2-oxo-4-[3-(1,3thiazol-2-yloxy)phenyl]pyridin-1(2H)yl}-N-hydroxy-2-methyl-2(methylsulfonyl)butanamlde | 0.000758 | >64 | 0.25 | 1 | 2 |
Examples 50 to 125
The compounds named below can be made following the general procedures outlined in Examples 1-49 above. Products are typically derived from a Suzuki-Miyaura cross coupling, as described above utilizing the appropriate starting materials, with optional deprotection of a terminal hydroxamic acid protecting group. Methods used to describe the synthesis of the precursors or coupling partners such as boronic acids or esters are known to those skilled in the art.
In Table 3 below, column 1 corresponds to the Example number, column 2 provides the IUPAC name, columns 3-6 provide in vitro biological data generated in the same manner as in Table 2, columns 7 and 8 provide the rétention times and mass spectra generated via LCMS, using the method described below. Ail data is not currently available for ail compounds, as indicated by a blank cell in Table 3.
The LCMS rétention times reported in column 7 were generated in the following manner:
Gradient:
0.05% TFA 95:5 to 5:95 Water:ACN
Flow rate: 1.3 mL/min
Column dimensions: Acquity UPLC BEH C18 1.7 pm 2.1x30 mm.
Runtime: 1.1 minutes
Table 3
Example Number | IUPACNAME | PA;IC50 (μΜ) | AB3167 (MS/mL) | EC-1 (pg/mL) | PA:UC12120 (pg/mL) | Rétention Time | Mass |
50 | 4-[5-fluoro-2-oxo-4-(3-oxo-2,3dihydro-1 H-isoindol-5-yl)pyridin1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0682 | >64.0 | >64.0 | >64.0 | 0.42 | 438.1 |
51 | 4-[5-f!uoro-4-(1H-indazol-6-yl)- 2-oxopyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0039 | >64.0 | >64.0 | >64.0 | 0.49 | 423.1 |
52 | 2-fluoro-4-{5-fluoro-1 -[4(hydroxyamino)-3-methyl-3(methylsulfonyl)-4-oxobutyl]-2oxo-1,2-dihydropyridin-4-yl}-N- | 0.0022 | >64.0 | 64 | 32 | 0.45 | 458.1 |
methylbenzamide | |||||||
53 | 4-[5-ftuora-4-(4-hydraxyphenyl)- 2-oxopyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0042 | >64.0 | >64.0 | 64 | 0.46 | 399 |
54 | 4-(4-(2,5-dimethoxyphenyl)-5f luoro-2-oxo pyri d in-1 (2 H) -y I] - Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | >0.100 | >64.0 | >64.0 | >64.0 | 0.58 | 443.1 |
55 | 4-(5,5'-difluoro-2'-oxo-3,4‘bipyridin-1'(2'H)-yl)-N-hydroxy2-methyl-2- (methylsu Ifonyl) butanam ide | 0.0668 | >64.0 | >64.0 | 64 | ||
56 | 4-[4-(3-chloro-5-fluorophenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhydroxy-2-methyl-2- (methylsu Ifonyl) butanamide | 0.0020 | >64.0 | 8 | 2 | ||
57 | 4-[5-fluoro-4-(2-methyl-3-oxo- 2,3-dihydro-1H-isoindol-5-yi)-2oxopyrîdin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0210 | >64.0 | >64.0 | >64.0 | 0.46 | 452.1 I |
58 | 4-[4-(4-cyano-3-fluorophenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhydroxy-2-methyl-2- (m ethylsu If ony I) butan am ide | 0.0026 | >64.0 | 32 | 8 | ||
59 | 4-[5-fluoro-4-{4- methoxyphenyl)-2-oxopyridin- 1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl) butanam ide | 0.0010 | >64.0 | 1 | 1 | ||
60 | 4-(4-(4-(1 -cyano-1methylethyl)phenyl]-5-fluoro-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsu Ifonyl) butanam ide | 0.0039 | >64.0 | 32 | 4 | 0.61 | 450.1 |
61 | 4-[4-(3-acetamidophenyl)-5fluoro-2-oxopyridin-1(2H)-yi]-Nhydroxy-2-methyl-2(methylsulfonyl) butanam ide | >0.100 | >64.0 | >64.0 | >64.0 | 0.47 | 440.1 |
62 | 4-(4-(3,5-difluoro-4- methoxyphenyl)-5-fluoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methy!-2- (methylsulfonyl) butanamide | 0.0020 | >64.0 | 4 | 2 | 0.62 | 449 |
62 | 4-[4-(3,5-difIuorophenyl)-5fluoro-2-oxopyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl) butanamide | 0.0031 | >64.0 | 8 | 1 | 0.61 | 419 |
64 | 4-[5-fluoro-4-(2-methyl-1 -oxo- 2,3-dihydro-1H-isoindol-5-yl)-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsu Ifonyl) butanam ide | 0.0072 | >64.0 | >64.0 | 64 | 0.44 | 452.1 |
65 | 4-(5,-fluoro-2'-oxo-3,4'-bipyridin- 1 ‘(2'H)-yl)-N-hydroxy-2-methyl· 2-(methylsulfonyl)butanamide | 0.0823 | >64.0 | >64.0 | 32 | 0.31 | 384.1 |
66 | 4-[4-(4-chloro-2-fluorophenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl) butanamide | 0.0008 | 64 | 0.5 | 0.5 | ||
67 | 4-[5-fluoro-4-(4-fluoro-3- m ethoxyp henyl) -2-oxopyridin - | 0.0045 | 64 | 16 | 4 | 0.59 | 431 |
100
1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | |||||||
68 | 4~{5-f luoro-1 -(4-(hydroxyamino)- 3-methyl-3-(methylsulfonyl)-4oxobutyl]-2-oxo-1,2dihydropyridin-4-yl}-N,Ndimethylbenzamide | 0.0343 | >64.0 | >64.0 | >64.0 | 0.46 | 454.1 |
69 | 4- (5 '-f lu oro-2-m eth oxy-2 ’-oxo3,4’-bipyridin-1’(2'H)-yl)-Nhydroxy-2-m eth y I-2(methylsulfonyl)butanamîde | 0.0166 | >64.0 | 64 | 8 | ||
70 | -He-cyano-S'-fluoro^'-oxo-SA'bipyridin-1'(2’H)-yl)-N-hydroxy2-methyl-2(methylsulfonyl)butanamide | 0.0333 | >64.0 | >64.0 | 64 | 0.47 | 409 |
71 | 4-[5-fluoro-4-(3-methyl-3Himidazo[4,5-b]pyridin-6-yl)-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | >0.100 | >64.0 | >64.0 | >64.0 | 0.37 | 438.1 |
72 | 4-(5-fluoro-4-furo[3,2-b]pyridin- 6-yl-2-oxopyridln-1 (2H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamlde | 0.0348 | >64.0 | 64 | 32 | 0.44 | 424 |
73 | 4-(3',5-difluoro-2-oxo-4,4'bipyridin-1(2H)-yl)-N-hydroxy-2methyl-2- (methylsulfonyl)butanamide | 0.0083 | >64.0 | >64.0 | 8 | 0.43 | 402 |
74 | 4-[4-(4-cyano-3methoxyphenyl)-5-fluoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0059 | >64.0 | 64 | 16 | ||
75 | 4-(5'-fluoro-5,6-dimethoxy-2'oxo-3,4l-bipyridin-1,(2'H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0454 | >64.0 | >64.0 | >64.0 | 0.51 | 444.1 |
76 | 4-[4-(4-ethoxyphenyl)-5-fluoro- 2-oxopyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methvlsulfonyl)butanamide | 0.0011 | >64.0 | 0.25 | 0.5 | 0.63 | 427.1 |
77 | 4-{4-[4-(2-cyanoethyl)phenyl]-5fluoro-2-oxopyridin-1(2H)-yl}-Nhydroxy-2-methyl-2- (methylsu Ifonyl) butanam ide | 0.0026 | >64.0 | 32 | 4 | 0.54 | 436.1 |
78 | 4-(5-fluoro-2-oxo-4phenylpyridin-1 (2H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0028 | >64.0 | 4 | 1 | 0.57 | 383.1 |
79 | 4- [4-{4- [(dimethylamino)methyl]phenyl}- 5- fluoro-2-oxopyridin-1(2H)-yl]N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0359 | >64.0 | >64.0 | 16 | 0.37 | 440.1 |
80 | 4- (5’-f I uoro-6- hydroxy-2'-oxo3,4,-bipyridin-1’(2'H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | >0.100 | >64.0 | >64.0 | >64.0 | 0.35 | 400 |
81 | 4-[4-(4-acetamidophenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhydroxy-2-methyl-2(methylsu Ifonyl) butanamide | 0.0243 | >64.0 | 64 | 32 | 0.45 | 440.1 i |
χΖ
101
82 | 4-[4-(3-cyanophenyl)-5-ftuoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0130 | >64.0 | 64 | 8 | ||
83 | 4-(5,5'-difluoro-6-methyl-2'-oxo- 3,4'-bipyridin-1 '(2‘H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0275 | >64.0 | >64.0 | 32 | 0.49 | 416.1 |
84 | 4-{5-fluoro-1 -[4-(hydroxyamino)- 3-methyl-3-(methylsulfonyl)-4oxobutyl]-2-oxo-1,2dihydropyridin-4-yl}-Nmethylbenzamide | 0.0145 | >64.0 | >64.0 | >64.0 | 0.43 | 440.1 |
85 | 4-[5'-fluoro-6-(hydroxymethyl)- 2'-oxo-3,4,-bipyridin-1,(2'H)-yl]N-hydroxy-2-methyl-2(methylsulfonyl) butanamide | >0.100 | >64.0 | >64.0 | >64.0 | 0.32 | 414.1 |
86 | 4-[5-fluoro-4-(4-fluorophenyl)-2- oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- ( methylsulfonyl) butanamide | 0.0017 | >64.0 | 4 | 1 | ||
87 | 4-(5-fluoro-2-oxo-4-quinolin-3ylpyridin-1 (2H)-yl)-N-hydroxy-2methyl-2- (methylsulfonyl) butanamide | 0.0061 | >64.0 | 16 | 8 | 0.46 | 434.1 |
88 | 4-{5-fluoro-4-[4-(1- methoxyethyl)pheny1]-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsu Ifonyl) butanamide | 0.0076 | >64.0 | 16 | 4 | 0.59 | 441.1 |
89 | 4-(5'-fluoro-6-methoxy-2'-oxo- 3,4'-bipyridin-1 '(2'H)-yl)-Nhydroxy-2-methyl-2(m ethylsu Ifonyl) butanam ide | 0.0031 | >64.0 | 8 | 2 | ||
90 | 4-(5-chIoro-5'-fluoro-2'-oxo-2,4'bipyridin-T(2'H)-yl)-N-hydroxy2-methyl-2- (m ethylsu Ifonyl) butanam id e | 0.0125 | >64.0 | 64 | 16 | ||
91 | 4-{4-[4-(cyanomethyl)phenyl]-5fluoro-2-oxopyridin-1 (2H)-yl}-Nhydroxy-2-methyl-2(methylsulfonyl) butanamide | 0.0023 | >64.0 | 16 | 4 | 0.52 | 422.1 |
92 | 4-(2’-ethoxy'5-f luo γο-2-οχο-4 ,4'bipyridin-1(2H)-yl)-N-hydroxy-2methyl-2- (m ethylsu lfonyl)butanam ide | 0.0057 | >64.0 | 8 | 8 | 0.54 | 428.1 |
93 | 4-[5-fluoro-4-[3- (m ethoxymethy I) ph e ny I] -2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0142 | >64.0 | 32 | 8 | ||
94 | 4-[4-(2-cyanophenyl)-5-fluoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0323 | 32 | 8 | 32 | 0.52 | 408 |
95 | 4- [4-(4-ethoxy-3-fluorophenyl)> 5- fluoro-2-oxopyridin-1(2H)-yl]N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0012 | 64 | 1 | 2 | 0.63 | 445.1 |
96 | 4-[5-fluoro-4-(2-methylquinolin- 7-yl)-2-oxopyridin-1 (2H)-yi]-Nhydroxy-2-methyl-2- | 0.0108 | >64.0 | 16 | 32 | 0.39 | 448.1 |
102
(methylsulfonyl)butanamide | |||||||
97 | 4-[4-(2,4-drfluorophenyl)-5- f lu oro-2-oxopyrid In-1 (2 H) -y I] - Nhydroxy-2-methyl-2(methylsulfonyl) butanam ide | 0.0012 | >64.0 | 4 | 1 | 0.59 | 419 |
98 | 4-[4-(3,4-dimethoxyphenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0285 | >64.0 | 64 | 32 | 0.53 | 443.1 |
99 | 4-(6-ethoxy-5'-fluoro-2'-oxo- 3,4'-bipyridin-T(2'H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl) butanam ide | 0.0025 | >64.0 | 2 | 2 | ||
100 | 4-[5-f!uoro-4-(3methoxyphenyl)-2-oxopyridln1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0025 | >64.0 | 4 | 2 | 0.58 | 413.1 |
101 | 4-(4-(4-cyan O-2methoxyphenyl)-5-fluoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0052 | >64.0 | 64 | 8 | 0.55 | 438.1 |
102 | 4- [4-(4-ch!oro-3-cyanophenyl)- 5- fluoro-2-oxopyrîdin-1 (2H)-ylJN-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0021 | >64.0 | 4 | 4 | 0.6 | 442 |
103 | 4-[5-fluoro-4-(2-fluorophenyl)-2- oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0014 | >64.0 | 4 | 0.5 | 0.57 | 401.1 |
104 | 4-(5'-fluoro-2-isopropoxy-2'-oxo- 3,4'-bipyridin-1f(2'H)-yl)-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | >0.100 | 32 | 8 | 32 | ||
105 | 4-{5-fluoro-4-[4-fluoro-3- (hyd roxymethyl) ph eny l]-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsulfonyl)butanam ide | >64.0 | >64.0 | >64.0 | 0.49 | 431.1 | |
106 | 4-[5-fluoro-2-oxo-4-(2-pyrrolidin- 1 -yl pyrim id i n-5-yl) pyrid in-1 (2H)yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0568 | >64.0 | 32 | 64 | 0.5 | 454.1 |
107 | 4-[4-(4-chlorophenyl)-5-fluoro-2- oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0010 | >64.0 | 1 | 0.25 | 0.64 | 417 |
108 | 4-[5-fluoro-2-oxo-4-(1 -oxo-2,3dihydro-1H-isoindol-5-yl)pyridin1 (2H)-yl]-N-hydroxy-2-methyl-2(m ethylsulfonyl) butan amide | 0.0072 | >64.0 | >64.0 | >64.0 | 0.4 | 438.1 |
109 | 4-[4-(4-chloro-3hydroxyphenyl)-5-fluoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl) butanam ide | 0.0073 | >64.0 | 32 | 32 | 0.56 | 433 |
110 | 4-{5-fluoro-4-[2- (methoxymethyl)phenyl]-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | >0.100 | >64.0 | >64.0 | >64.0 | 0.56 | 427.1 |
111 | 4-[5-fluoro-4-(2-fluoro-3- | 0,0030 | >64.0 | 4 | 4 | 0.61 | 445.1 |
103
methoxy-5-methylphenyl)-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | |||||||
112 | 4-[4-(3-ethoxyphenyl)-5-fluoro- 2-oxo pyrid in-1 (2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0031 | >64.0 | 2 | 4 | ||
113 | 4-[5'-fluoro-2'-oxo-6(trifluoromethyO-SZ-bipyridin1 '(2'H)-yl]-N-hydroxy-2-methyl2-(methylsulfonyl)butanamide | 0.0296 | >64.0 | >64.0 | 32 | 0.58 | 452 |
114 | 4- [4-(4-cyano-3-methylphenyl)- 5- fluoro-2-oxopyridin-1 (2H)-y!JN-hydroxy-2-methyl-2- (m ethylsu Ifonyl) butanam id e | 0.0013 | >64.0 | 4 | 2 | 0.57 | 422.1 |
115 | 4- {4-[2- (dimethylamino)pyrimidin-5-yl]- 5- fluoro-2-oxopyridin-1(2H)-yl}- N-hydroxy-2-methyl-2(methylsu Ifonyl) butanamide | 0.0741 | >64.0 | 32 | 32 | 0.48 | 428.1 I |
116 | 4-[5-f luo ro-4-(3-f I uoroph e nyl) -2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2(methylsulfonyl)butanamide | 0.0010 | >64.0 | 4 | 1 | 0.58 | 401.1 |
117 | 4-(4-(2,3-difluorophenyl)-5fluoro-2-oxopyridin-1(2H)-yl]-Nhyd roxy-2-m ethyl-2(methylsulfonyl) butanamide | 0.0008 | >64.0 | 2 | 0.5 | 0.59 | 419.1 |
118 | 4-[5-fluoro-4-(2-fluoro-3methoxyphenyl)-2-oxopyridin1 (2H)-yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide | 0.0007 | >64.0 | 1 | 1 | 0.57 | 431.1 |
119 | 4-(4-(3-cyano-5methoxyphenyl)-5-ftuoro-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2(methylsulfonyl)butanamide | 0.0508 | >64.0 | >64.0 | 64 | 0.57 | 438.1 |
120 | 4- (4-(2,3-dihydro-1 -benzofuran- 5- yl)-5-fluoro-2-oxopyridin- 1 (2H)-yl]-N-hydroxy-2-methyl-2(m ethylsu Ifonyl) butanamide | 0.0009 | >64.0 | 2 | 1 | 0.57 | 425.1 |
121 | 4-[5-fluoro-2-oxo-4-(1 H-pyrazol- 3-yl)pyridin-1 (2H)-yl]-Nhydroxy-2-methyl-2(methylsulfonyl)butanamide | >64.0 | >64.0 | >64.0 | |||
122 | 4-{5-fluoro-4-(2-fluoro-3- (h y d roxym ethyl) ph e nyl]-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0024 | 0.46 | 431.1 | |||
123 | 4~{4-[3-(2-amino-2oxoethyl)phenyl]-5-fluoro-2oxopyridin-1 (2H)-yl}-N-hydroxy2-methyl-2- (m ethylsu Ifonyl) butanam i d e | >64.0 | >64.0 | >64.0 | 0.43 | 440.1 | |
124 | 4-[4-(4-cyanophenyl)-5-fluora-2oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2- (methylsulfonyl)butanamide | 0.0034 | >64.0 | 32 | 8 | 0.53 | 408 |
125 | 4-[5-fluoro-4-(2- methoxyphenyl)-2-oxopyridïn- | 0.0129 | >64.0 | 64 | 8 | 0.57 | 413.1 |
104
1 (2Η) -yl]-N-hydroxy-2-methyl-2(methylsulfonyl)butanamide |
Claims (2)
- What is claimed is:1. A compound of the formula:E-H or a pharmaceutically acceptable sait thereof, in which:R1 is represented by CrC3 alkyl;R2 is represented by hydrogen or C1-C3 alkyl;R3 is represented by hydrogen, halogen, hydroxy, cyano, C^Cgalkyl, C^Cgalkoxy, trifluoromethyl or trifluoromethoxy;T is represented by ethynyl, optionally substituted (C6-C10)aryl or optionally substituted heteroaryl;D is absent, or is represented by -(CHa)r-, -(CH2)n-O-(CH2)p-, or a bond;r is represented by the integer 1,2, or 3;n and p are each independently represented by the integer 0,1, or 2;E is absent, or is represented by a substituent selected from the group consisting of:i) (C3.C1o)cycloalkyl, optionally substituted;ii) (C6-C10)aryl optionally substituted;iii) heteroaryl, optionally substituted; and iv) heterocyclic, optionally substituted;with the proviso that:1) if E is absent, then D is also absent;
- 2) T is not represented by unsubstituted phenyl; when E and D both are absent, R3 is hydrogen and R1 and R2 are each methyl.1062. A compound according to claim 1 in which R1 and R2 are each methyl.3. A compound according to claims 1 or 2 in which R3 is hydrogen.4. A compound according to claims 2 or 3 in which said compound is the Renantiomer, substantially pure.5. A compound according to any of claims 1,2, 3 or 4 in which T is represented by phenyl which may be optionally substituted.6. A compound according to any of claims 1,2, 3, 4 or 5 in which D and E are both absent.7. A compound according to any of claims 1 -5 in which D is a bond.8. A compound according to claim 7 in which E is represented by cyclohexyl, pyrimidinyl, triazolyl, pyridinyl, isoxazolyl, or cyclopropyl, any of which may be optionally substituted.9. A compound of the formula la or a pharmaceutically acceptable sait thereof, in which;R3 is represented by hydrogen, halogen, hydroxy, cyano, C^Cgalkyl, Cy C3alkoxy, trifluoromethyl or trifluoromethoxy;Ra is represented by one or more substituents selected from the group consisting of CrC3alkyl, Ci-C3 alkoxy, fluorine, chlorine, hydroxy, trifluoromethyl and trifluoromethoxy.x/10710. (2R)-4-(5-Fluoro-2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)pheny l]pyridin-1 (2H)-yl}-Nhydroxy-2-methyl-2-(methylsulfonyl)butanamide, or a pharmaceutically acceptable sait thereof.11. (2R)-4-[5-Fluoro-4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1 (2H)-yl]-N-hydroxy2-methyl-2-(methylsulfonyl)butanamide, or a pharmaceutically acceptable sait thereof.10 12. A pharmaceutical composition comprising a compound according to any of daims 1-11 in admixture with at least one pharmaceutically acceptable excipient.13. Use of a compound according to any of clairns 1-11 in the manufacture of a médicament for bacterial infections.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/449,825 | 2011-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16551A true OA16551A (en) | 2015-10-22 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012226473B8 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
DK2512474T3 (en) | N-linked hydroxamic acid derivatives which can be used as antibacterial agents | |
KR20170042687A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
JP2000515133A (en) | Hypoglycemic and hypolipidemic compounds | |
MXPA05002886A (en) | Cox-2 inhibiting pyridine derivatives. | |
JP2004517870A (en) | Cyclooxygenase inhibitor | |
JP2007522181A (en) | Substituted azetidine compounds as cyclooxygenase-1 and cyclooxygenase-2 inhibitors, and their preparation and use as pharmaceuticals | |
OA16551A (en) | Fluoro-pyridinone derivatives useful as antibacterial agents. | |
AU2015215883A1 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
NZ614205B2 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
AU2007202607B2 (en) | Substituted Pyridinones as Modulators of p38 MAP Kinase |